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ABSTRACT 
 
In the mammalian genome, 5‟-CpG-3‟ dinucleotides are frequently methylated, 
correlating with transcriptional silencing. Genome-wide waves of demethylation are 
thought to occur only twice during development, in primordial germ cells and in the pre-
implantation embryo. They are followed by de novo methylation, setting up a pattern that 
is inherited throughout development. No global methylation changes are thought to occur 
during further somatic development, although methylation does alter at gene-specific 
loci, contributing to tissue-specific patterns of gene expression. Here we studied DNA 
methylation in differentiating mouse erythroblasts in vivo using several approaches 
including genomic-scale, reduced representation bisulfite sequencing (RRBS). 
Surprisingly, demethylation at the erythroid-specific β-globin locus was coincident with a 
wave of global DNA demethylation at most genomic elements, including repetitive 
elements and genes silenced in erythropoiesis. Over 30% of total methylation is 
irreversibly lost during erythroid differentiation. Demethylation occurred through a 
passive mechanism, requiring the rapid DNA replication triggered with the onset of 
erythroid terminal differentiation. Global loss of DNA methylation was not associated 
with a global increase in transcription, as determined by GeneChip analysis. We propose 
that global demethylation is a consequence of cellular mechanisms required for the rapid 
demethylation and induction of β-globin and other erythroid genes. Our findings 
demonstrate that, contrary to previously held dogma, DNA demethylation can occur 
globally during somatic cell differentiation, providing a new experimental model for the 
study of global demethylation in development and disease. 
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PREFACE 
 
The work presented in Chapter II was a collaboration with Ramona Pop, a post-
doctoral fellow in the Socolovsky laboratory at University of Massachusetts Medical 
School. My primary contributions to her work are the DNA methylation studies presented 
in Figure 2.6 and described in the results section “The Transition from S0 to S1 
Coincides with S-Phase-Dependent DNA Demethylation at the β-Globin LCR”. I also 
contributed to Figure 2.5A and Figure 2.S3A-B. This work was published in the journal 
PLoS Biology in September of 2010: Ramona Pop, Jeffrey R. Shearstone, Qichang Shen, 
Ying Liu, Kelly Hallstrom, Miroslav Koulnis, Joost Gribnau, and Merav Socolovsky. “A 
Key Commitment Step in Erythropoiesis is Synchronized with the Cell Cycle Clock 
through Mutual Inhibition between PU.1 and S-Phase Progression”. PLoS Biol (2010) 
8(9) e1000484. 
The work presented in Chapter III constitutes the major portion of my thesis 
research. Ramona Pop performed the work in Figure 3.11 and contributed to Figure 
3.12A and 3.13A. Alexander Meissner and Christoph Bock of Harvard University and the 
Broad Institute performed the reduced representation bisulfite sequencing and analysis 
presented in Figure 3.5, 3.6A-C, 3.14, and 3.16C. This chapter is an extended version of 
work that is currently under review with the following title and authors: Jeffrey R. 
Shearstone, Ramona Pop, Christoph Bock, Alexander Meissner, and Merav Socolovsky. 
“Global DNA Demethylation during Erythropoiesis In Vivo”. 
The CD71/Ter119 flow cytometric method for identifying erythroid progenitors 
and erythroblasts, as presented in Figure 1.1, Figure 2.1, and Figure 3.1 is currently in 
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press at the Journal of Visualized Experiments and will be published in August 2011 with 
the following title and authors: Miroslav Koulnis*, Ramona Pop*, Ermelinda Porpiglia*, 
Jeffrey R. Shearstone*, Daniel Hidalgo, and Merav Socolovsky. “Identification and 
analysis of mouse erythroid progenitors using the CD71/Ter119 flow-cytometric assay.” 
J Vis Exp (2011) *Contributed equally. 
I have also performed experiments of general relevance to our laboratory that are 
not discussed in this thesis. These experiments will provide a basis for future lines of 
research, as well as support current projects in the lab. For example, I have conducted 
Affymetrix GeneChip genome-wide mRNA profiling on S0, S1, S3, EpoR knockout, S0 
„mid‟ wild type, and S0 „mid‟ EpoR knockout cell populations. This work has been done 
for triplicate biological replicates allowing statistical analysis of gene expression changes 
within key erythroid differentiation subsets. I have also analyzed and consolidated this 
data into a spreadsheet from which lab members can query the expression level of their 
gene(s) of interest. 
Also not presented in this thesis are microRNA profiling experiments that I 
conducted on sorted S0 and S1 subsets. By combining microRNA expression, predicted 
mRNA targets from the TargetScan database, and differentially regulated mRNA from 
the GeneChip data described above, I computationally identified groups of miRNAs that 
synergize to suppress gene expression during erythropoiesis. This work was not pursued 
further in the wet lab because other projects took priority, but the data and resulting 
analysis should provide a starting point for new lines of research in the future. 
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CHAPTER I 
Introduction 
  
2 
 
DNA Methylation and Gene Regulation 
The basic building block of chromatin is comprised of genomic DNA spooled 
around a histone protein octamer. Histones or DNA can be modified by the enzymatic 
addition of various chemical groups, resulting in recruitment or exclusion of associated 
proteins that have profound effects on local chromatin structure and gene expression. 
Because these modifications fundamentally do not alter the DNA sequence and because 
they have the potential to be mitotically and/or meiotically heritable, they have been 
termed „epigenetic‟ modifications. One such epigenetic mark, DNA methylation (5mC), 
is simply the presence of a methyl group on the 5‟-carbon ring of cytosine. In mammals, 
the vast majority (>99%) of methylation is found to occur symmetrically at the 
dinucleotide palindrome cytosine-guanine (CpG), although asymmetrical CpHpG and 
CpHpH (H=A, T, or C) methylation has been detected in embryonic stem (ES) cells [1, 
2]. DNA methylation has long been correlated with transcriptional inactivity and 
heterochromatin formation. The repressive effect of DNA methylation on gene 
transcription has been directly tested using transient transfections and stable integration at 
defined genomic loci [3-7]. Furthermore, DNA methylation is essential for X-
chromosome inactivation, parental-specific silencing of imprinted genes, suppression of 
transposable elements, and silencing of gene-specific loci [8-15]. 
 Proper establishment and maintenance of 5mC patterns are required for 
mammalian development and normal functioning of somatic cells. These processes are 
mediated through the DNA methyltransferase (Dnmt) family of proteins; the de novo 
methyltransferases Dnmt3a and Dnmt3b establish 5mC patterns, while the maintenance 
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methyltransferase Dnmt1 and accessory factors act to preserve existing patterns during 
DNA replication and subsequent cell division [16-25]. Knockout studies in mice show 
that DNA methyltransferases are essential genes, with death of Dnmt1-/- or Dnmt3a-/-3b-/- 
embryos before day 11, Dnmt3b-/- embryos before birth, and Dnmt3a-/- mice at 4 weeks 
of age [13, 26-28]. The requirement for methylation in somatic cells has been well 
documented. For example, absence of Dnmt1 prevents differentiation of ES cells into 
embryoid bodies, teratomas, cardiomyocytes, or hematopoietic progenitors [26, 29, 30]. 
Inactivation of Dnmt1 in embryonic fibroblasts results in demethylation and p53-
dependent apoptosis [31]. Similarly, maintenance of methylation by Dnmt1 is required 
for proliferation and survival of the T-cell lineage, survival of postnatal central nervous 
system neurons, and self-renewal of somatic stem cells of the epidermal and 
hematopoietic lineages [32-35]. 
Methylation generally occurs at 70-80% of all CpG sites, a consistent finding 
across a wide-range of somatic cell types [1, 36]. Somatic genomes are not methylated 
uniformly but contain methylated regions interspersed with unmethylated domains. For 
example, CpG islands, the CpG-dense (about 1 CpG per 10 bp) regions found at 70% of 
promoters [37], are almost always unmethylated regardless of developmental stage, tissue 
type, or transcriptional activity [12, 38-42]. In contrast, CpGs that are found infrequently 
(about 1 CpG per 100 bp) are highly methylated. Sites of low CpG frequency occur 
predominantly in repetitive genomic regions, including satellite DNA and retroelements, 
but are also common at 30% of promoters, exons, introns, 3‟ untranslated regions, and at 
the less CpG-rich regions flanking CpG-islands called „island shores‟ [1, 42, 43]. 
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Importantly, despite these broad similarities in the overall 5mC abundance and 
distribution, the detailed DNA methylation pattern of each somatic cell type is distinct [1, 
38-40, 42, 44].  
Differentially methylated regions (DMRs) are short stretches of DNA (about 250 
bp) that distinguish one somatic cell type from another on the basis of 5mC. The 
combination of genome-wide methylation analysis and transcriptional profiling has led to 
the characterization of DMRs that correlate with tissue-specific gene expression in vivo. 
DMRs are found infrequently at high CpG density promoters (about 5% of all DMRs), 
suggesting these regions are not major targets for developmental regulation [38, 40, 42-
45]. Surprisingly, DMRs occurred most frequently at intermediate CpG density 
promoters and showed a high inverse relationship with gene expression [40, 46]. 
Consistent with this result, more detailed studies found the majority of DMRs reside at 
island shores, within 2 kb of a CpG island [43, 47]. Furthermore, these DMRs were 
tightly conserved between human and mouse tissues [38, 43, 47]. Collectively, these 
results show that intermediate CpG density promoters and island shores are regions of 
dynamic methylation that contribute significantly to gene expression and somatic cell 
identity. 
DNA methylation exerts its repressive effects directly and indirectly. Many 
studies have demonstrated that 5mC is able to directly prevent the binding of 
transcription factors to DNA, as is the case for E2f, Creb, Usf1, Ap-2, and Myc/Max [48-
56]. Similarly, DNA methylation at Ctcf-binding sites directly prevents Ctcf from 
binding, thereby altering Igf2 expression at the imprinted H19/Igf2 locus [48, 57]. 
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Notably, Mll1 (mixed lineage leukemia 1), a histone H3 lysine 4 (H3K4)-specific 
methyltransferase, can only bind its target CpGs when they are unmethylated, suggesting 
how DNA methylation might inhibit the addition of a histone modification associated 
with active chromatin [51]. 
DNA methylation indirectly silences transcription by recruiting methyl-CpG 
binding proteins which associate with various chromatin modifiers. These proteins 
include members of the methyl binding domain (Mbd) family, such as MeCP2, Mbd1, 
Mbd2, and Mbd4; and the Kaiso family, which use a three-zinc-finger motif to 
specifically bind methylated DNA [58-61]. MeCP2 is found complexed with histone 3 
lysine 9 (H3K9) methyltransferase activity and also binds the Sin3a, NCoR, and Ski co-
repressor complexes which contain histone deacetylase activity [62-65]. Mbd1 associates 
with the H3K9-specific methyltransferases Setdb1 and Suv39h1 [66, 67]. Mbd2 interacts 
with the NuRD co-repressor complex that has both histone deacetylation and chromatin 
remodeling ATPase activity [68-71]. Additionally, Sin3A and NCoR co-repressor 
binding has been implicated in Mbd4 and Kaiso-dependent transcriptional repression [72, 
73]. Interestingly, methyl-CpG binding proteins have distinct sequence preferences, 
providing a means to target 5mC-facilitated repression to specific genomic regions [60, 
73-75]. Taken together, methyl-CpG binding proteins link DNA methylation to 
heterochromatin-associated histone modifications. 
Conversely, histone methylation or the enzymes which modify histones are able 
to coordinate DNA methylation. For example, Dnmt3L-mediated recruitment of Dnmt3a 
and Dnmt3b to DNA is blocked by H3K4 methylation [76]. Methylation of histone 4 
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arginine 3 (H4R3) serves as a direct binding target of Dnmt3a, an interaction leading to 
5mC addition at the γ-globin promoter [77]. Additionally, the H3K9 methyltransferases 
G9a, Suv39h1 and Setdb1, and the H3K27 methyltransferase EZH2, can mediate DNA 
methylation by direct interaction with Dnmt3a and Dnmt3b [65, 78-82].  
The close connection between histone modification and DNA methylation is 
illustrated by the finding that the presence of H3K4 methylation and absence of H3K9 
methylation are better predictors of unmethylated CpGs than CpG-density alone [39, 42]. 
Clearly, these epigenetic marks play an important and interrelated role in gene expression 
regulation. A model has been proposed where histone modifications act as flexible 
repressors, while DNA methylation results in highly stable inactivation [83]. As 
discussed in the following sections, it is less clear as to how DNA methylation is 
removed to permit gene activation. 
β-globin Expression and Definitive Erythropoiesis 
β-globin is an essential subunit of the oxygen-transporting hemoglobin complex 
found in erythrocytes. The β-globin locus contains an ordered cluster of 5 human genes 
(ɛ, Gγ, Aγ, δ, β) or 4 mouse genes (ɛy, βh1, βmaj, βmin) that are sequentially switched 
on/off during development [84]. In mouse, primitive erythropoiesis occurs in the yolk sac 
at embryonic day 7.5 (E7.5) and is defined by expression of the embryonic β-globins ɛy 
and βh1 [85]. Primitive erythropoiesis is transient, lasting only a few days, and results in 
nucleated erythrocytes. Definitive erythropoiesis begins at E11.5 in the fetal liver and is 
marked by expression of the adult globins βmaj and βmin [86]. Near the time of birth, the 
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site of definitive erythropoiesis moves to the bone marrow, where it persists throughout 
life. Primitive and definitive erythroblasts are considered two distinct cell lineages [84].  
Full transcriptional activation of β-globin is dependent on the locus control region 
(LCR), a segment of DNA found 6 kb to 20 kb upstream of the embryonic y gene [87, 
88]. The LCR is distinguished by five, 200-300 bp DNase I hypersensitivity sites (HS1-
5), which acquire a relaxed chromatin state during β-globin activation [84, 89, 90]. This 
chromatin change exposes transcription factor binding motifs within the hypersensitivity 
sites and, in one proposed model, facilitates the looping of the LCR into regions proximal 
to β-globin promoters [91].  
Epigenetic modifications play a key role in the lineage-specific regulation of the 
β-globin gene cluster [92-94]. For example, differences in the CpG methylation profile of 
the LCR or at 5‟ regions of β-globin genes have been observed in primitive and definitive 
erythroid lineages [95]. Additionally, in a large number of studies, gene activating 
histone marks are enriched at the LCR and β-globin loci of primitive [85, 96, 97] and 
definitive precursors [92, 94, 96-99], as well as in erythroid cell lines [96, 98, 100-103]. 
Unfortunately, the current understanding of epigenetic changes at the β-globin LCR is 
based on the differences between heterogeneous, late-stage erythroblasts of the primitive 
and definitive lineages, rather than the progressive changes that occur during the 
maturation of a single lineage. Moreover, the mechanism by which LCR demethylation 
occurs is completely unknown.  
The developmental stage of definitive erythroid progenitors is traditionally 
defined morphologically or by colony formation in soft agar. Differentiation of these 
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progenitors is accompanied by temporally regulated changes in cell surface protein 
expression, decreasing cell size, increasing hemoglobin expression, nuclear condensation, 
and ultimately, enucleation. Recently, a flow cytometry method, based on the cell surface 
markers CD71 and Ter119, has been developed to identify subsets within the fetal liver 
that form an erythroid developmental sequence [104, 105]. Fetal liver cells may be 
classified into 6 such subsets, each at an increasing stage of differentiation (S0-S5) 
(Figure 1.1). S0 is the earliest developmental subset, composed largely of early erythroid 
progenitors, while S5 cells contain nucleated, hemoglobinized erythroblasts and 
enucleated erythrocytes. Therefore, flow cytometric sorting of CD71/Ter119-staged fetal 
liver cells has the potential to address the timing of epigenetic alterations, such as CpG 
methylation, at the β-globin gene cluster during erythropoiesis. 
Passive DNA Demethylation 
Demethylation that requires DNA replication is termed „passive‟, while 
replication-independent demethylation is classified as „active‟. Each mode of 
demethylation has been implicated in both gene-specific and global demethylation 
processes. Active demethylation is well established in plants, but some have questioned 
its prominence in mammals [106]. Conversely, some are doubtful that passive 
demethylation plays a major role in gene-specific demethylation [107]. In the remainder 
of this chapter, evidence for both mechanisms will be presented with an emphasis on the 
events that drive global demethylation in the early embryo, primordial germ cells, and 
cancer. 
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During semi-conservative DNA replication, unmethylated deoxycytidine is 
incorporated into the nascent strand, creating hemi-methylated DNA at CpG sites where 
the parent strand is methylated. Dnmt1, which is targeted to replication foci and has a 20 
to 40-fold preference for hemi-methylated DNA, is able to restore methylation symmetry 
by catalyzing the transfer of a methyl group from an S-adenosylmethionine (SAM) donor 
[17, 18, 22, 108]. Inhibition of this „maintenance‟ methylation leads to a passive loss of 
up to 50% of 5mC per round of DNA replication (Figure 1.2A). 
Targeting of Dnmt1 to replication foci is promoted by an interaction with 
proliferating cell nuclear antigen (Pcna) [17]. In Dnmt1 mutants deficient for Pcna 
binding, the efficiency of methylation was reduced by 2-fold [109, 110]. Another critical 
co-factor is Uhrf1 (ubiquitin-like, containing PHD and RING finger domains 1), which 
binds specifically to hemi-methylated DNA and recruits Dnmt1 to these sites by a direct 
association [111, 112]. Loss of maintenance methylation observed during gliomagenesis 
is associated with a loss of Dnmt1-Uhrf-Pcna interactions and a decline in recruitment of 
Dnmt1 to DNA. Loss of these interactions was mediated by phosphorylation of Dnmt1 at 
serine 127, which prevented binding to Uhrf1, and additional phosphorylation at serine 
143, further abrogated Pcna binding [113]. Similarly, a peptide of the Pcna binding 
domain from cyclin dependent kinase inhibitor 1A can disrupt the Dnmt1-Pcna 
interaction [17]. Therefore, the combined action of Pcna, Uhrf1, and Dnmt1 is critical to 
the high fidelity of 5mC maintenance and disruption of any of these interactions could 
lead to passive demethylation. 
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Maintenance methylation also depends on the level and activity of Dnmt1, which 
increases during S-phase, decreases after S-phase, and reaches its lowest level during G1 
[114-116]. Dnmt1 protein stability is regulated by a complex system of post-translational 
modifications; Usp7 and Uhrf1 deubiquitnate and ubiquitnate Dnmt1, respectively [114, 
117]; Tip60 promotes Dnmt1 degradation through acetylation, while stability is induced 
by Hdac1-mediated deacetylation [114]; and methylation of Dnmt1 by Set7 at Lys-142 
leads to its degradation, while Lsd1 demethylates and stabilizes Dnmt1 [118, 119]. 
Additional post-translational modifications, such as phosphorylation and SUMOylation, 
seem to positively affect Dnmt1 activity [120, 121]. Dnmt1 activity is also controlled by 
its localization, as is the case in the early embryo where the maternal specific splice 
variant of Dnmt1 is excluded from the nucleus during early cleavage divisions [122, 
123]. In human embryonic kidney (HEK)-293 cells phosphorylation near the nuclear 
localization signal motif of Dnmt1 enhances its localization in the nucleus [124]. Finally, 
patients with neurodegenerative disorders exhibit a mislocalization of Dnmt1 in the 
cytoplasm and a significant loss of global DNA methylation [125]. 
 Maintenance methylation can also be inhibited by the binding of protein factors to 
DNA. For example, Sp1 binding sites induced localized promoter demethylation of an in 
vitro methylated plasmid injected into Xenopus embryos, and Gal4 binding sites could be 
demethylated in the presence of exogenous transcription factors designed to target those 
sites [126]. Importantly, in both cases DNA replication was required. Similarly, DNA 
replication and EBNA-1 binding was required for demethylation of an episomal oriP 
sequence in PC-3 prostate cancer cells [127]. Furthermore, episomal lacO sites become 
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demethylated upon binding of LacI in the human embryonic kidney 293 cell line [128]. A 
decrease in LacI binding affinity, caused by increasing amounts of IPTG, resulted in a 
slower loss of methylation. Collectively, these studies suggest that binding of 
transcription factors can protect hemi-methylated CpGs from the maintenance activity of 
Dnmt1, a mechanism recently proposed in neural precursor cell differentiation [129]. 
 Recently it was discovered that the Tet family of proteins are 5mC hydroxylases 
that catalyze the conversion of 5mC to 5-hydroxymethycytosine (5hmC) [130]. 5hmC 
accumulates during global DNA demethylation of the paternal genome in the early 
embryo, discussed later in more detail, and is found at relatively high frequency in ES 
cells [131-133]. Interestingly, DNA sequences containing 5hmC are not substrates for the 
maintenance methyltransferase Dnmt1 [134]. Therefore, a defect in maintenance 
methylation could result from a mechanism where 5mC is first converted to 5hmC, 
followed by dilution through DNA replication, but this has yet to be shown to occur in 
vivo. 
Although Dnmt1 is responsible for the majority of maintenance methylation, 
some have suggested that the de novo methyltransferases Dnmt3a and Dnmt3b participate 
in this process [135]. Unlike Dnmt1, Dnmt3a and 3b have equal affinity for both hemi- 
and un-methylated CpGs [21]. In ES cells lacking Dnmt3, global methylation was slowly 
but progressively lost with continued passage, even though Dnmt1 remained stably 
expressed [16, 136]. These cells also exhibit an increase in the frequency of hemi-
methylated sites as compared to their wild-type ES cell counterparts [136]. Similarly, 
inactivation of Dnmt3b leads to retroelement and minor satellite repeat hypomethylation 
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in murine embryonic fibroblasts [137]. Furthermore, combined knockdown of Dnmt1 and 
Dnmt3b enhanced the methylation loss observed by Dnmt1 knockdown alone [138]. 
These results are consistent with a model where, soon after DNA replication, Dnmt3a and 
Dnmt3b correct errors that result from Dnmt1 infidelity [135]. Therefore, a reduction in 
Dnmt3a or 3b activity might contribute to inhibited maintenance methylation. 
Maintenance methylation activity is also modulated by the cellular steady state 
concentration of SAM, the methyl donor utilized by DNA methyltransferases in a 
reaction that forms 5mC and S-adenosyl homocysteine (SAH). SAM is also 
decarboxylated (dcSAM) and then used as an aminopropyl group donor for the synthesis 
of polyamines. Both SAH [139, 140] and dcSAM [141] act as competitive inhibitors of 
DNA methyltransferases and disruption in the balance of SAM relative to these by-
products is linked to hypomethylation [142-147]. SAM is derived from methionine, 
whose formation is in turn dependent on the levels of methyl group donors such as 
choline, folate, and vitamin B-12. Folate is also required for the de novo synthesis of 
deoxynucleotides, thereby linking the metabolic pathways involved in DNA synthesis 
and DNA methylation [148]. Diets deficient in methionine, folate, choline and B-12 lead 
to reduced levels of SAM and genomic hypomethylation in rat hepatocytes [149-151]. 
Conversely, maternal dietary supplementation with these factors can permanently alter 
offspring coat color by increased methylation at the agouti gene promoter [152].  
Active DNA Demethylation 
Erasure of DNA methylation in a manner that does not require DNA replication 
is, by default, called active. Active demethylation has been extensively documented in 
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plants and animals, with the majority of examples acting locally, at gene-specific regions 
[107, 153]. In contrast, active genome-wide demethylation has only been documented in 
a handful of physiological situations; in plants during endosperm development and in 
mammals during pre-implantation embryo development and primordial germ cell 
specification, as will be discussed in later sections (Figure 1.3) [154-157]. In some of 
these cases, such as the promoter regions of interleukin-2 and interferon- genes in T-
cells, the authors have formally excluded DNA replication as a contributing factor to 
demethylation using rapamycin and mitomycin C, respectively, to block cell cycle 
progression [158, 159]. Many other examples rely on fast kinetics and non-dividing/post-
mitotic nature of the model system as proof of active demethylation. The exact 
mechanism of active demethylation in mammals is still unknown and this area of 
research continues to be contentious [106]. Five potential mechanisms have been 
proposed, each with varying amounts of supportive evidence (Figure 1.2B) 
In one proposed mechanism the methyl group is directly cleaved from cytosine. 
Mbd2 (methyl binding domain 2) was identified as having this ability [160]. However, 
this finding could not be repeated when attempted by two independent groups and Mbd2 
knockout mice are viable with no alteration in 5mC levels [69, 71, 161].  
The nucleotide excision repair (NER) pathway has also been implicated in 
demethylation. In two independent reports, Gadd45a (growth arrest and DNA-damage-
inducible gene 45 alpha) overexpression promoted gene specific and/or global 
demethylation [162, 163]. Conversely, knockdown of Gadd45a induced 
hypermethylation. Gadd45a associated with Ercc5 and other members of the NER 
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pathway and knockdown of Ercc5 led to hypermethylation or inhibited demethylation. 
However, attempts to repeat many of these results have proved unsuccessful and 
biochemical evidence is lacking, leaving the role of the NER pathway in active 
demethylation in question [164]. 
More recently, Elp3 and other Elp family members were identified as necessary 
for genome demethylation in the paternal pronucleus of the murine zygote [165]. Elp 
proteins are components of the RNA polymerase elongator complex, suggesting a link 
between transcription and DNA demethylation. Demethylation required the Fe-S radical 
SAM domain of Elp3, but otherwise the mechanism by which Elp proteins act is entirely 
unknown.  
Methyl groups are known to be removed through a base excision repair (BER) 
pathway. This has been well documented in plants, where direct excision of methyl-
cytosine is performed by the DME/ROS1 family of bifunctional glycosylases [166-168]. 
These enzymes first remove the 5mC base to form an apurinic/apyrimidinic (AP) site. 
Next, using their AP lyase activity, they cleave the abasic site. AP endonucleases remove 
the sugar group and the resulting single nucleotide gap is then filled with unmethylated 
cytosine. In mammals, no such 5mC glycosylase orthologues have been identified. 
However, the T/G glycosylases Mbd4 (methyl binding domain 4) and Tdg (thymine-
DNA glycosylase) are able to act as a 5mC glycosylases in vitro, albeit with a 30-fold 
reduced activity compared to their T/G mismatch activity [169, 170]. Furthermore, recent 
work suggests a 5mC glycosylase activity for Mbd4 that is dramatically improved upon 
its phosphorylation [171]. 
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A more likely BER-based mechanism in mammals begins by deamination of 5mC 
to form a thymine, followed by T/G mismatch repair via the T/G glycosylase activity of 
Mbd4 or Tdg. The Aicda (activation-induced cytidine deaminase) and Apobec 
(apolipoprotein B mRNA editing enzyme, catalytic polypeptide) protein families are 
cytidine deaminases that act on 5mC in vitro [172]. Aidca and Apobec2 are required for 
demethylation of genomic and exogenous DNA in zebrafish embryos and co-expression 
of Mbd4 enhanced this effect [173]. Importantly, T/G mismatch intermediates were 
detected, supporting deamination as one step in the demethylation process. Other 
evidence linking Aidca to demethylation comes from Aidca-/- primordial germ cells, 
where global methylation levels were found to be slightly elevated, and nuclear 
reprogramming in interspecies heterokaryons, where siRNA knockdown of Aidca 
prevented Nanog and Oct4 promoter demethylation [174, 175]. In addition to Aidca and 
Apobec, the catalytic domains of Dnmt3a and Dnmt3b have deaminase activity in vitro 
when SAM availability is limited [176]. Evidence that active demethylation is mediated 
by Tdg comes from studies in Tdg-/- MEFs where Tdg was required for gene-specific 
hypomethylation and recruitment of the DNA repair enzymes Xrcc1 and Apex1 [177]. 
Furthermore, Tdg knockdown attenuated pS2 promoter methylation loss in vivo [176]. 
The ten-eleven translocation (Tet) family of proteins is capable of oxidizing hemi- 
or fully-methylated 5mC to produce 5hmC [130, 131]. A variety of active demethylation 
mechanisms that utilize a 5hmC intermediate have been proposed [153]. For example, 
direct removal of 5hmC by a 5hmC glycosylase could induce BER-mediated replacement 
with cytosine [178]. Alternatively, deamination of 5hmC to form hydroxymethyluracil 
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(5hmU) followed by 5hmU removal by a 5hmU glycosylase could invoke the BER 
pathway. This mechanism is strongly supported by a very recent study that found Tet1, 
when introduced into HEK-293 cells, could induce 5mC loss of exogenous template and 
gene-specific loci [179]. Template DNA containing 5hmC, but not 5mC, was 
demethylated, an effect that could be prevented by chemical inhibition of the BER 
pathway [179]. Furthermore, Aidca and Apobec family members significantly increased 
5hmC demethylation [179]. Finally, expression of Tet1, introduction of 5hmC template 
DNA, or overexpression of Apobec in HEK293 cells each led to an increase in cellular 
5hmU [179].  
Global DNA Demethylation in the Early Embryo 
Prior to fertilization, the overall DNA methylation level of sperm is equal to 
somatic cells [180], while the egg shows a lower initial level of methylation [156, 157, 
181-185]. The zygote that results from fertilization undertakes several cell divisions in 
the formation of the blastocyst, during which the parental DNA undergoes genome-wide 
methylation loss that affects single copy genes, long interspersed repeated elements 
(LINE), intracisternal A particle elements (IAP), early retrotransposons (Etn), and 
centromeric satellites (Figure 1.3) [156, 157, 181-186].  
Immunofluorescence microscopy (IF) using an anti-5-methylcytosine antibody 
(5mC-IF) has been the primary tool for measuring DNA methylation loss in the early 
embryo. In these studies, virtually all methylation appears to be lost during blastocyst 
formation. In contrast, about 50% of methylation is lost when measured by non-5mC-IF 
assays, such as those that utilize bisulfite conversion of genomic DNA [187]. Only 
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imprinted regions appear to be spared from demethylation [123, 188-190]. Genome-wide 
DNA methylation profiling of egg, sperm, and blastocyst has yet to be done, but is 
necessary for a comprehensive understanding of the magnitude and sequence specificity 
of methylation loss during blastocyst formation.  
It is noteworthy that the timing and mechanism of paternal and maternal DNA 
demethylation during blastocyst formation are considerably different. Maternal 5mC loss 
occurs gradually over several post-zygotic cell divisions [186, 191]. During this time, the 
highly abundant, maternally derived isoform of Dnmt1 (Dnmt1o) is localized to the 
cytoplasm [122, 123]. Therefore, maternal 5mC loss is thought to occur through a passive 
mechanism, i.e. DNA replication in the absence of nuclear Dnmt1. Yet 50% of global 
5mC is maintained in non-5mC-IF assays and imprinted regions are protected from 
demethylation, suggesting that some maintenance methylation activity is still present. 
Consistent with this idea, recent studies have shown that the somatic Dnmt1 isoform 
(Dnmt1s) is present in the nucleus of the early embryo, albeit at a far lower level than 
cytoplasmic Dnmt1o [123, 192, 193]. Antibody neutralization or siRNA knockdown of 
Dnmt1s resulted in a loss of 5mC at IAP repeats and a H19 imprinted region at the 
morula stage [193]. Furthermore, conditional knockout experiments demonstrated that 
Dnmt1s and Dnmt1o, but not Dnmt3, is required to maintain imprints in the 
preimplantation embryo [123]. These results also show that the extent of methylation loss 
in a passive mechanism is critically sensitive to Dnmt1 abundance. 
In contrast to the maternal pronucleus, the paternal pronucleus begins to 
demethylate in the one-cell embryo, shortly after fertilization [191]. In vitro fertilization 
18 
 
experiments established that 5mC loss was initiated 4 hours post-fertilization and was 
completed by 8 hours post-fertilization, just prior to fusion of parental pronuclei [186]. 
Similar demethylation timing has been observed in rat, pig, bovine, and human [194, 
195]. These 5mC-IF results are supported by bisulfite sequencing at several endogenous 
genes, including Igf2, a foreign transgene TKZ751, and LINE and Etn regions [165, 182]. 
There are several lines of evidence supporting the idea that paternal pronuclear 
5mC loss is via an active mechanism. First, methylation loss is observed before S-phase 
of the first cell cycle [182, 191]. Second, the demethylation observed by IF and at the 
Igf2 and TKZ751 loci is so severe that it could not simply result from a lack of 
maintenance methylation [182]. Finally, demethylation still occurred in the presence of 
the DNA replication inhibitor aphidicolin [191, 196]. Active demethylation of the 
paternal pronucleus is thought to proceed through the BER pathway, since 5mC loss is 
correlated with the appearance of repair markers H2A.X, Parp, Apex1, and DNA-bound 
Xrcc1 by IF [184, 197]. Additionally, Parp or Apex1 inhibitors were able to prevent 5mC 
loss [197]. Elp3 is also required for demethylation, but the molecular mechanism by 
which it acts is unknown [165]. 
However, the evidence for active paternal DNA demethylation is far from 
conclusive. For example, the exact timing of DNA replication in the mouse zygote varies 
across laboratory and methodology [184, 198, 199], which has raised the possibility that 
paternal DNA may have at least partially replicated in previous studies [133]. 
Importantly, emerging research using fluorescent antibodies against 5hmC calls 
conclusions from previous 5mC-IF data into question. 5mC reduction coincides with 
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5hmC accumulation specifically in the paternal, and not maternal, pronucleus prior to S-
phase of the first cell cycle [133, 200]. Accumulation of 5hmC occurred in the presence 
of aphidicolin, which is consistent with the 5mC loss observed in aphidicolin. Finally, 
knockdown of the Tet3, which oxidizes 5mC to form 5hmC, diminished the loss of 5mC 
and prevented 5hmC accumulation. These data strongly suggest that loss of 5mC staining 
in previous 5mC-IF studies is simply a reflection of its conversion into 5hmC, rather than 
a bona fide active demethylation event. 5hmC has been speculated to act as a substrate or 
as an intermediate in an active, repair-coupled demethylation process [201]. Even more 
provocative is the finding DNA sequences containing 5hmC are not substrates for the 
maintenance methyltransferases Dnmt1 [134]. Therefore, 5mC loss in the paternal 
pronucleus could be the result of a passive mechanism, whereby 5mC is first converted to 
5hmC, followed by dilution through DNA replication [133].  
The significance of global methylation loss in the early embryo is still under 
investigation. One theory is that genome-wide reprogramming might play an important 
role in preventing the transgenerational accumulation of potentially detrimental 
epialleles, which could cause chronic disease and limit life span [202, 203]. Instead, 
current evidence suggests that global methylation loss is required for the activation of 
genes leading to pluripotency. For example, Nanog is a known pluripotency regulator that 
is completely methylated in sperm, but lacks any 5mC in the blastocyst or embryonic 
stem (ES) cells [204]. Targeted methylation of an exogenous Nanog promoter was 
sufficient to silence its expression in ES cells, emphasizing the importance of 
demethylation in Nanog gene activation.  
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The majority of supporting evidence for global demethylation-induced activation 
of pluripotency-specific genes is derived from work investigating reprogramming of 
somatic cells to an ES or ES cell-like state [205]. While methylation of Oct4 and Nanog 
promoters silences gene expression in somatic cells [206-208], their demethylation is 
associated with gene activation in ES cells derived from nuclear transfer [42, 209]. 
Failure to demethylate Oct4, Nanog, and other pluripotency genes is associated with an 
intermediate reprogramming state in induced pluripotent stem (iPS) cells [210-212]. 
Importantly, in these partially reprogrammed cells, 5-aza-2-deoxycytidine inhibition or 
siRNA knockdown of Dnmt1 led to global 5mC loss and induced a rapid and stable 
transition to a fully reprogrammed iPS state [212]. Similarly, by using a hypomorphic 
allele of Dnmt1 in donor fibroblasts, the rate of ES cell generation after nuclear transfer 
to the oocyte was improved [209]. Finally, initiation of reprogramming towards 
pluripotency in heterokaryons, generated by fusion of human fibroblasts to mouse ES 
cells, required 5mC loss at the Nanog and Oct4 promoters and their subsequent activation 
[174]. These examples show that somatic cell reprogramming is dependent on activation 
of key pluripotency genes through DNA methylation loss. Therefore, it is likely that 
global demethylation acts similarly in the pre-implantation embryo; reprogramming 
sperm and egg-derived genomes to allow for pluripotent gene activation. 
Global DNA Demethylation in Primordial Germ Cells 
At embryonic day E3.5, just prior to implantation, the blastocyst undergoes a 
wave of global methylation that is mediated by the de novo DNA methyltransferases 
Dnmt3a and Dnmt3b [27]. The majority of pluripotent epiblast cells originating in the 
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inner cell mass develop high levels of global methylation prior to E7.25, which is then 
maintained during lineage specification into embryonic and adult somatic cells, with only 
the pattern at specific loci being altered depending on the particular cell type. However, 
at E7.25 a subset of <50 epiblast cells become committed to the primordial germ cell 
(PGC) lineage, i.e. cells that can only differentiate into eggs or sperm [213, 214]. The 
PGCs proliferate and migrate into the genital ridges between E10.5 and E11.5, then 
continue to proliferate until E13.5, making approximately 10 cell divisions in total. PGCs 
will erase the vast majority of their DNA methylation marks, a process that begins as 
early as E8.5 and continues through E13.5 (Figure 1.3) [214-218]. 
Using several complementary assays, early work established that PGC lose 
methylation at a variety of sequence types, including single copy genes, retroviral 
repetitive elements, and the CCpGG motif recognized by the isoschizomers MspI and 
HpaII [156, 157, 185]. Importantly, and in contrast to the early embryo, PGCs completely 
lose DNA methylation within imprinted regions [214, 215, 219]. Additionally, the 
magnitude of global methylation loss is greater than that seen in the early embryo. For 
example, PGCs lost 74% and 55% of initial methylation at LINE and IAP regions, 
respectively, compared to only 57% and 36% in the early embryo [185]. Recently, these 
observations have been extended using whole-genome bisulfite sequencing of male and 
female PGCs [175]. Both male and female PGCs were drastically hypomethylated, 
showing a median methylation level of 16.3% and 7.8%, respectively, compared to 70-
75% for the entire embryo or ES cells. Methylation loss was observed within introns, 
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intergenic regions, repeats, exons, and promoters, confirming that PGC demethylation is 
truly global.  
The mechanism of 5mC loss in PGCs is largely unknown, but evidence exists to 
support both a passive and/or active mechanism. In support of the passive mechanism, IF 
suggests Dnmt1 is briefly down-regulated at E7.25, but then re-expressed at E8.5 [218]. 
In addition, mRNA for the Dnmt1 co-factor Uhrf1 is also transiently down-regulated 
during this period [220]. However, other studies show Dnmt1 mRNA level is constant 
throughout early PGC specification and found at equal or greater levels than in 
surrounding somatic cells [220, 221]. Furthermore, IF demonstrates Dnmt1 protein is 
highly expressed from E8.5 to 12.5 [214, 218]. Given the brevity and timing of Dnmt1 
and Uhrf1 down-regulation, these events cannot account for the majority of 
demethylation. Experiments utilizing aphidicolin or other cell cycle inhibiting drug to 
prevent DNA replication during PGC development are yet to be performed. Therefore, 
5mC loss through a passive, DNA replication-dependent mechanism cannot be formally 
ruled out. 
  Several lines of evidence suggest active demethylation in PGCs. First, 
methylation is lost despite the presence of Dnmt1 [153]. Second, BrdU incorporation and 
5mC-IF has shown that from E7.75 to E9.0 the majority of PGCs (>85%) are in G1 or 
G2/M phases of the cycle, yet 5mC IF staining decreases during this time [218, 222]. 
Third, bisulfite sequencing of E12.5 and E13.5 PGCs showed an almost complete loss of 
5mC at imprinted and single-copy genes [214]. Since the doubling time of cells at this 
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stage is about 14-16 hours, the extent of methylation loss cannot be accounted for by a 
passive mechanism alone [213, 223].  
The mechanism for active demethylation in PGCs is not known. However, 
activation of the BER pathway correlates with the dramatic loss in methylation occurring 
between E11.5 and E13.5 [197]. One possible trigger for BER is deamination of 5mC by 
Aidca or Apobec resulting in a T/G mismatch. In a genome-wide bisulfite sequencing 
experiment, knockout of Aicda resulted in only a minor effect on global methylation 
levels in E13.5 PGCs [175]. While 5mC deamination by Aidca does not appear to play a 
major role in PGC demethylation, other deaminases such as the Apobec family might be 
acting redundantly. The detection of Tet1 and Tet2 in E11.5 PGCs raises the possibility 
that 5mC might be first modified to 5hmC prior to removal by an active repair-coupled, 
or even passive DNA replication-dependent, pathway that requires a 5hmC intermediate 
[197]. Whether demethylation occurs by an active or passive mechanism, re-methylation 
is thought to be prevented by the down-regulation of Dnmt3a and the down-regulation 
and nuclear exclusion of Dnmt3b, in the early stages of PGC specification [214, 218, 220, 
221]. 
A critical function of methylation loss in PGCs is the removal of parental 
imprints, so that new imprints can be established according to the sex of the developing 
embryo [213-215, 219, 224]. DNA methylation, when located at DMRs near or within 
imprinted genes, regulates expression of the imprinted gene from either the paternal or 
maternal allele. This parental-origin-specific monoallelic expression makes the presence 
of both paternal and maternal genomes a requirement for development. In the female 
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germline, imprints are re-established in the postnatal ovary during the growth phase of 
meiotic prophase I, while male germline imprints are progressively re-established in 
PGCs after E14.5 and are complete in the newborn [225]. Imprinting is coincident with 
global methylation and both of these events are dependent on Dnmt3a, Dnmt3b, and 
Dnmt3L [225-227]. 
While lacking supporting evidence, global methylation loss in the PGCs, like that 
of the early embryo, could be a way to limit aberrant epiallele inheritance [203]. Another 
proposed role is the activation of germ-line specific genes. In support of this function, 
induction of Ddx4, Sycp3, Ant4, and Dazl occurs in PGC at E11.5-E13.5 and is 
coincident with DNA hypomethylation of flanking DNA, while in somatic cells these 
genes are hypermethylated and not expressed [228-230]. Ddx4, Sycp3 and Dazl are 
prematurely expressed in E9.5 embryos derived from Dnmt1 knockouts or hypomorphs 
[229]. 5-aza-2-deoxycytidine treatment of fibroblasts induces Dazl expression [228]. 
Furthermore, in vitro reporter assays show that methylation of Ant4 and Dazl promoter 
regions suppresses their transcription [228, 230]. DNA demethylation has been linked to 
germ-line specific activation of other genes as well [231-233].  
Global DNA Demethylation in Cancer 
Cancer-related global loss of 5mC was first observed in chemically induced 
hepatocellular carcinomas in rats [234]. Shortly thereafter, two seminal studies 
established global demethylation as a common occurrence in primary human tumors; the 
first compared 5mC in colon and lung cancers to matched adjacent tissue at three gene 
loci unrelated to cancer [235]; the second measured total 5mC by liquid chromatography 
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in a wide variety of benign, malignant and metastatic cancers and normal tissues [236]. 
Over the last 28 years, an abundance of studies have established that global 
hypomethylation is a hallmark of many cancers (Figure 1.4) [237, 238].  
The magnitude of 5mC loss during oncogenesis differs by the type of cancer, 
ranging between 20-50% [237]. For example, relative to matched controls, breast and 
hepatocellular carcinomas lose up to 50% of methylation [239, 240], while colorectal 
neoplasias only lose 10-20% of total 5mC [241-243]. Therefore, the overall 5mC loss in 
cancer is similar to that of the early embryo, but not as severe as in PGC development. 
Similar to the early embryo and PGCs, hypomethylation in cancer is observed at an 
extensive variety of sequence elements including cancer-linked and non-cancer related 
gene loci, centromeric satellite DNA, and retroelements such as LINEs, short interspersed 
repetitive elements (SINEs), and long-terminal repeats (LTRs) [237, 238, 244]. Unbiased, 
genome-wide DNA methylation profiling of cancer show results consistent with these 
earlier findings [43, 245, 246].  
DNA methylation loss appears to play a causal role in cancer development. 
Reduction of methylation in Dnmt1 hypomorphic mice led to development of T-cell 
lymphomas at 4 to 8 months of age that harbored centromeric hypomethylation and a 
single-copy gain in chromosome 15 [247]. Similarly, DNA demethylation resulting from 
the introduction of a hypomorphic Dnmt1 allele into ApcMin/+ mice increased the 
formation of intestinal microadenomas and hepatocellular carcinoma, which correlated 
with an elevated loss of the wild-type Apc allele [248]. When the Dnmt1 hypomorph was 
introduced into Nf1+/- p53+/- mice, soft tissue sarcomas occurred at an earlier age by 
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promoting the loss of heterozygosity (LOH) required for tumor development [249]. 
Finally, Dnmt1-/- ES cells showed an increase in Hprt and tk viral transgene mutation rate 
due to genomic rearrangements or deletion. These observations suggest that 
hypomethylation promotes carcinogenesis by decreasing genomic stability and is 
consistent with a model where DNA methylation suppresses the potentially destabilizing 
effect of recombination at repetitive and transposable elements [8, 250-252].  
Hypomethylation of retroelements also leads to their activation and transposition, 
which could result in perturbed gene expression at the site of insertion [8, 253, 254]. For 
example, disruption of gene expression by LINE transposition to the Myc and Apc loci is 
found in breast and colon cancer, respectively [255, 256]. Furthermore, demethylation 
and activation of retroelements are correlated events in cancer [257-260]. Direct evidence 
of this mechanism has been demonstrated in the Dnmt1 hypomorph-induced lymphomas 
described above, where many were found to contain an IAP somatic insertion in the 
middle of the Notch1 genomic locus, leading to an oncogenic form of Notch1 [261]. 
In addition to repetitive elements, single copy gene loci also exhibit 
hypomethylation-linked expression of genes that contribute to malignant progression 
[237, 238]. For example, activation of synuclein-, which is highly expressed in breast 
carcinomas and can induce breast cancer cells to proliferate and metastasize, is correlated 
to methylation loss at a CpG island within exon 1 in a variety of cancers [262, 263]. 
Furthermore, treatment of synuclein- negative ovarian and breast cancer cells with 5-
aza-2-deoxycytidine resulted in removal of exon 1 methylation and gene activation [262]. 
Imprinted gene expression is also altered by hypomethylation. By genetically eliminating, 
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then re-establishing Dnmt1 expression, ES cells were generated that had normal global 
DNA methylation but lacked 5mC associated with imprinting [264]. Significantly, adult 
chimeric mice derived from these cells developed tumors in multiple tissues and injected 
embryonic fibroblasts formed tumors in recipient mice. In colorectal cancer, loss of 
imprinting of Igf2, an important autocrine growth factor in cancer, was linked to 
hypomethylation of a differentially methylated region on the normally silent allele [265].  
It is notable that global DNA methylation loss occurs despite coincident CpG 
island hypermethylation, and subsequent silencing, of tumor-suppressor genes. 
Hypermethylation has been shown to affect genes involved in cell cycle control, invasion, 
DNA repair, cell signaling, and apoptosis [266]. For example, abnormal CpG island 
methylation in the promoter region of the VHL tumor-suppressor was associated with its 
silencing in renal carcinomas [267]. Similarly, E-cadherin and BRCA1 gene silencing has 
been linked to aberrant DNA methylation in sporadic breast carcinomas [268-271]. The 
cause of CpG island hypermethylation, and whether CpG island hypermethylation and 
global hypomethylation are mechanistically linked, remains unknown. 
Despite a causal role in disease, the mechanism of demethylation in any cancer, 
whether passive or active, is largely unknown. A role for putative active demethylation 
genes such as Gadd45a, Mbd4, Tdg, Aicda, Apobec and Tet family members has not 
been reported. Another proposed mechanism would act through a cellular deficiency in 
the methyl donor SAM, which could induce Dnmt3-mediated active demethylation or 
simply reduce maintenance methylation activity [176, 272]. DNA demethylation is 
known to be an early event during carcinogenesis that often escalates with disease 
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progression [113, 239, 240, 248, 273-275]. This slow progression, and incomplete loss of 
methylation, suggests a passive mechanism requiring many rounds of cell division. Yet, 
there is no evidence of a link between DNA methyltransferase abundance and genome 
hypomethylation in cancer [238]. In fact, in many cancers the level of Dnmt1 and Dnmt3 
increase [237, 240, 243, 276-279], likely due to an increase in cellular proliferation [243, 
276].  
Only very recently has evidence of a mechanism for global DNA methylation loss 
in cancer been presented. In glioma, decreased methyltransferase activity resulted from 
decreased recruitment of Dnmt1 to DNA, even though Dnmt1 protein levels remained 
constant [113]. This defect was mediated by Dnmt1 phosphorylation which prevented its 
interaction with Pcna and Uhrf1. Clearly, the role of DNA methyltransferases, replication 
machinery components, and their post-translational modifications, as well as the 
involvement of cell proliferation in cancer-linked global hypomethylation is an important 
area of future study. 
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Figure 1.1. Definitive erythropoiesis in the fetal liver. 
Flow cytometric profile of freshly isolated E14.5 fetal liver stained with 
fluorescent antibodies against CD71 and Ter119 then detected by flow cytometry (left 
panel). Fetal liver cells may be classified into 6 subsets, each at an increasingly mature 
stage of differentiation (S0-S5). Examples of cells from each of subsets S0 to S4/5 (right 
panel). Erythroid maturation is associated with decreasing cell size, nuclear condensation 
and positive staining for hemoglobin with diaminobenzidine (brown). Cell density in the 
flow-cytometric profile is represented by color, from highest (red) to lowest (blue).  
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Figure 1.2. General mechanisms of DNA demethylation. 
A. Passive demethylation. Following DNA replication, the nascent strand is 
methylated to maintain the pattern of the parental strand. Inhibition of this „maintenance‟ 
methylation leads to a passive loss of up to 50% of 5mC per round of DNA replication. 
 
B. Active demethylation. Methylation loss can occur in the absence of DNA 
replication through a variety of proposed mechanisms. Proteins implicated in each 
mechanism are listed. 
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Figure 1.3. Genome-wide demethylation in mammalian development. 
Global DNA demethylation has been documented at only two specific times 
during the mammalian lifespan. The first wave of demethylation occurs in the pre-
implantation embryo following fertilization. The male and female pronuclei demethylate 
via an active and passive mechanism, respectively. The second wave of demethylation 
occurs during primordial germ cell specification, potentially through an active 
mechanism. Sex-specific genomes (♂= male, ♀= female) undergo demethylation and 
methylation at different times. While DNA methylation is known to be altered at gene-
specific loci within somatic lineages, global methylation levels are thought to remain 
stable (black line). Adapted by permission from Macmillan Publishers Ltd: Nature, May 
24;447(7143):425-32, copyright 2007. 
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Figure 1.4. Genome-wide demethylation is observed in many cancers. 
A multistage model of carcinogenesis in skin is shown [274]. In conjunction with 
phenotypic cellular changes and the accumulation of genetic defects, there is a 
progressive loss of total DNA methylation content in the development of the disease. The 
mechanism(s) of methylation loss is cancer is unknown. Used by permission from New 
England Journal of Medicine, Mar 13;358(11):1148-59, copyright 2008. 
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CHAPTER II 
A Key Commitment Step in Erythropoiesis is Synchronized with the Cell Cycle Clock 
through Mutual Inhibition between PU.1 and S-Phase Progression 
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Abstract 
Hematopoietic progenitors undergo differentiation while navigating several cell 
division cycles, but it is unknown whether these two processes are coupled. We 
addressed this question by studying erythropoiesis in mouse fetal liver in vivo. We found 
that the initial up-regulation of cell surface CD71 identifies developmentally matched 
erythroblasts that are tightly synchronized in S-phase. We show that DNA replication 
within this but not subsequent cycles is required for a differentiation switch comprising 
rapid and simultaneous committal transitions whose precise timing was previously 
unknown. These include the onset of erythropoietin dependence, activation of the 
erythroid master transcriptional regulator GATA-1, and a switch to an active chromatin 
conformation at the β-globin locus. Specifically, S-phase progression is required for the 
formation of DNase I hypersensitive sites and for DNA demethylation at this locus. 
Mechanistically, we show that S-phase progression during this key committal step is 
dependent on down-regulation of the cyclin-dependent kinase p57KIP2 and in turn causes 
the down-regulation of PU.1, an antagonist of GATA-1 function. These findings 
therefore highlight a novel role for a cyclin-dependent kinase inhibitor in differentiation, 
distinct to their known function in cell cycle exit. Furthermore, we show that a novel, 
mutual inhibition between PU.1 expression and S-phase progression provides a 
„„synchromesh‟‟ mechanism that „„locks‟‟ the erythroid differentiation program to the 
cell cycle clock, ensuring precise coordination of critical differentiation events. 
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Introduction 
Hematopoietic progenitors execute a cell division program in parallel with a 
differentiation program in which lineage choice is followed by lineage-specific gene 
expression. In many differentiation models, cell cycle exit, driven by cyclin-dependent 
kinase inhibitors (CDKI), is a prerequisite for terminal differentiation, establishing a key 
interaction between the cell cycle and differentiation programs [280-282]. However, it is 
unclear how the cell cycle and differentiation programs might be linked prior to cell cycle 
exit. Such links are presumably required to ensure the correct number of differentiated 
progeny. In addition, it has been speculated that the reconfiguration of chromatin at sites 
of lineage-specific genes, a necessary step preceding lineage-specific gene expression, 
may be innately dependent on DNA replication [283, 284]. An intriguing possibility is 
that the clockwork-like mechanisms regulating orderly cell cycle transitions may also be 
used, in the context of differentiating cells, to coordinate key steps in differentiation.  
Here we studied differentiation of the enucleated red blood cell lineage, which 
first arises from hematopoietic stem cells in the fetal liver on embryonic day 11 (E11). It 
replaces a transient, nucleated yolk-sac erythrocyte lineage and persists throughout life. 
Although many of the committal events that lead to the erythroid phenotype are known, 
their precise timing in erythroid differentiation, and the manner in which they are 
coordinated with each other and/or with the cell cycle machinery, is poorly understood. 
Thus, survival of erythroid progenitors requires both the hormone erythropoietin (Epo), 
and its receptor, EpoR, a class I cytokine receptor expressed by erythroid progenitors 
[285]. However, the precise time in erythroid differentiation when progenitors become 
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dependent on Epo had not been defined. The master transcriptional regulator GATA-1 is 
responsible for the erythroid gene expression profile, in combination with a number of 
additional transcriptional regulators, including FOG-1, EKLF, SCL/Tal-1, LMO2, Ldb1, 
E2A, and Zbtb7a [286-289]. Though GATA-1 functional activation must precede 
erythroid gene induction, its precise timing in primary differentiating progenitors is not 
known. GATA-1 functions are antagonized by PU.1, an Ets transcription factor that acts 
as a master regulator in the myeloid and B-cell lineages. The mutual inhibition between 
PU.1 and GATA-1 is thought to underlie cell fate choice in multipotential progenitors 
[290-293]. PU.1 has been implicated in erythroleukemia [292, 294], but its physiological 
function in erythropoiesis is not known.  
Erythroid gene induction by GATA-1 requires an „„open chromatin‟‟ 
conformation in the vicinity of erythroid-specific genes. The erythroid-specific β-globin 
locus is one of the best studied models of lineage-specific gene expression [295, 296]. 
The active locus is characterized by early replication during S-phase, higher sensitivity to 
DNase I digestion, low levels of DNA methylation, and post-translational histone tail 
modifications associated with actively transcribed genes. Conversely, the same locus in 
non-erythroid cells is DNase I resistant, replicates late in S-phase, and contains histone 
tail modifications characteristic of silent chromatin.  
In spite of the detailed knowledge contrasting chromatin states in erythroid cells 
with non-erythroid cells, the precise time during erythroid differentiation when chromatin 
reconfiguration occurs is not known. Furthermore, it is not known whether this 
reconfiguration involves a number of sequential stepwise alterations occurring over a 
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number of cell cycles/differentiation stages or whether the many changes entailed in 
chromatin activation occur simultaneously. 
Here we studied erythroid differentiation using a flow-cytometric assay that 
identifies sequential stages in erythroid differentiation directly within primary 
hematopoietic tissue. We found that in mouse fetal liver in vivo, up-regulation of CD71 
marks cells that are synchronized in S-phase of a single cell cycle, corresponding to the 
last generation of erythroid colony-forming cells, approximately three cell cycles prior to 
terminal cell cycle exit. A number of differentiation milestones, whose precise timing in 
erythroid development was previously unknown, occur during early S-phase of this cycle. 
These include the onset of Epo dependence, activation of GATA-1 function, and the 
opening up of chromatin at the β-globin locus. We show that S-phase progression during 
this specific cell cycle is dependent on down-regulation of p57KIP2 and is required for 
execution of these differentiation milestones, including the reconfiguration of chromatin 
at the β-globin locus. Further, this S-phase dependent rapid differentiation transition is 
regulated by PU.1 through a newly identified, mutual antagonism between S-phase 
progression and PU.1 expression that coordinates the precise locking of the 
differentiation program to the cell cycle clock as cells enter a terminal differentiation 
phase.   
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Results 
Up-regulation of cell-Surface CD71 marks the onset of EpoR dependence in 
erythroid progenitors 
Mouse fetal liver between E11 and E15 is primarily an erythropoietic tissue. Cell 
surface markers CD71 and Ter119 may be used to identify differentiation-stage specific 
subsets, directly in primary tissue [104, 297, 298]. Here we divided freshly harvested 
fetal liver cells into six CD71/Ter119 subsets that we termed S0 to S5 and that form a 
developmental sequence (Figure 2.1A). Cells isolated from subsets S1 to S5 show 
morphological features characteristic of erythroid maturation, including decreasing cell 
and nuclear size, nuclear condensation, and hemoglobin expression (Figure 2.1A, right 
panel). The precise proportion of fetal liver cells within each of the CD71/Ter119 subsets 
is a function of embryonic age, with the majority of cells being in the early, S0 and S1 
subsets in E12. The more mature, S3 to S5 subsets are gradually populated with cells 
during subsequent embryonic days (E13 to E15) [104]. 
The EpoR-/- fetal liver is small and lacks morphologically identifiable 
hemoglobinized erythroblasts of the enucleated (definitive) lineage [285]. Here we found 
that EpoR-/- fetal liver does not contain subsets S1 to S5 (Figure 2.1B). This suggested 
that in the definitive erythropoietic lineage that gives rise to adult-type enucleated red 
cells, EpoR becomes essential on or prior to the transition from S0 to S1; subsets S1 to S5 
are composed almost entirely of Epo-dependent erythroblasts. Of note, the small number 
(<5%) of Ter119+ cells in the EpoR-/- fetal liver are all nucleated erythrocytes of the 
transient yolk-sac (primitive) lineage ( Figure 2.S1A). 
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The majority of S0 cells are erythroid progenitors at the CFU-e stage 
Erythroid progenitors have traditionally been identified by their in vitro colony-
forming potential. “Colony forming unit-erythroid” (CFU-e) are defined as cells that give 
rise to colonies containing 8 to 32 hemoglobinized cells after 2–3 days of in vitro culture 
in Epo [299]. We investigated the colony-forming potential of cells sorted from each of 
the S0 to S3 subsets (Figure 2.1C). CFU-e potential was exclusive to S0 and S1 and was 
lost with the transition to S2. Cells in S2 and S3 gave rise to small, 2 to 4 cell clusters 
(Figure 2.1C, right panel). 
The frequency of CFU-e obtained from sorted S0 cells was 65%–70% of the 
frequency from sorted S1 (Figure 2.1C). S1 consists entirely of Epo-dependent cells of 
similar maturation, with CFU-e potential (Figure 2.1A–C). Assuming similar plating 
efficiency for sorted S0 and S1 (of <30%, Figure 2.1C), this suggested that CFU-e make 
up 65%–70% of the S0 subset. This is in agreement with our finding that fetal liver cells 
expressing non-erythroid lineage markers, which were limited to S0, formed up to 30% 
of this subset (Figure 2.1D, Figure 2.S1B). Non-erythroid colony-forming progenitors 
were also restricted to S0, where they formed less than 5% of all colony-forming cells 
(Figure 2.1C). Our conclusion that 65%–70% of S0 cells are CFU-e was further 
supported by single cell RT-PCR, which showed that 68% of S0 cells expressed EpoR 
mRNA (Figure 2.S1C). In all the experiments that follow, “S0” refers to S0 cells from 
which cells expressing non-erythroid markers were excluded by flow-cytometric gating 
or sorting. 
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S1 cells are synchronized in S-phase of a single cell cycle  
To examine the cell cycle status of erythroid subsets S0 to S5 in vivo, we injected 
pregnant female mice with the nucleotide analogue bromodeoxyuridine (BrdU) and 
harvested fetal livers 30 min post-injection. We sorted cells from each of S0 to S5 and 
stained them with antibodies directed at BrdU (Figure 2.1E, F). Cells that incorporated 
BrdU were in S-phase of the cell cycle at the time of harvesting. Subsets S4 to S5 showed 
a rapid decline in the number of S-phase cells, consistent with cell cycle exit of 
terminally differentiating cells. Unexpectedly, we noted that <90% of S1 cells were in S 
phase, as compared with <50% of cells in S0 (Figure 2.1E, F). In addition, the intensity 
of the BrdU fluorescence within S1 cells was approximately 50% higher than in S0, 
suggesting a higher rate of DNA synthesis (Figure 2.S1D). Similar experiments with 
EpoR-/- fetal liver showed that EpoR appears to have no effect on progenitor cell cycle 
status (Figure 2.S1E). 
Consistent with the higher number of S-phase cells in S1, we found a 
corresponding increase in the E cyclins in S1 compared with S0 (Figure 2.1G). 
Strikingly, we noted >30-fold decrease in the CDKI p57KIP2 mRNA, but no significant 
change in the mRNA of other members of the CIP/KIP CDKI family; there was induction 
in p27KIP1 later in differentiation, in subsets S2 and S3 (Figure 2.1G and Figure 2.S1F). 
[300, 301]. The p57KIP2 protein also decreased at the S0 to S1 transition (Figure 2.1G 
lower panel). 
The finding that nearly all S1 cells were in S-phase could be due to an unusual 
cell division cycle with short or no gap phases. Alternatively, S1 cells may be 
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synchronized in S-phase of the cycle. The latter explanation would require that cells 
spend only a brief period of a few hours in S1, lasting through part or all of a single S-
phase. The preceding G1 phase of this same cell cycle would have occurred prior to the 
transition from S0 to S1. The G2 and M-phases of this same cycle would occur as cells 
upregulate Ter119 and transition into S2. 
To investigate these possibilities, we isolated S0 cells by flow cytometry, labeled 
them with the cell-tracking dye carboxyfluorescein diacetate succinimidyl ester (CFSE), 
and followed their Epo dependent differentiation into S1 in vitro (Figure 2.1H). By 10 h, 
53% of S0 cells transitioned into S1 in the absence of cell division, as indicated by a 
single CFSE peak for S1 (solid red histogram, t=10 h) that was identical in intensity to 
that of the CFSE peak for S0 (blue histogram, t=10 h; median CFSE fluorescence for 
both S1 and S0 peaks=4,400). This suggested that the transition from S0 to S1 occurred 
in the absence of cell division, within a single cell cycle. Four hours later, at t=14 h, 
essentially all S1 cells had divided once, as indicated by the halving of the CFSE signal 
(red histogram at t=14 h, CFSE fluorescence=2,100). The simultaneous division of S1 
cells suggested they were synchronized in their cell cycle phase. By contrast, only a 
portion of S0 cells, which were presumably asynchronous in their cell cycle phase, had 
divided at this time, resulting in a biphasic CFSE peak (blue histogram, t=14 h). 
Taken together, these results suggest that the most mature CFU-e progenitor 
(“CFU-e.2”, Figure 2.1I), capable of giving rise to an eight-cell colony, traverses S0, S1, 
and enters S2 within a single cell cycle. This progenitor arises in S0, becomes Epo 
dependent, and upregulates CD71, transitioning into S1 during S-phase of its cell cycle. 
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Up-regulation of Ter119 occurs at approximately the same time that it completes its cycle 
and divides, giving rise to progeny that lack CFU-e activity in S2 (Figure 2.1C). These 
conclusions are consistent with essentially all S1 cells being in S-phase (Figure 2.1E, F), 
and with our finding that nearly all S1 cells are sensitive to hydroxyurea, a drug that 
specifically targets S-phase cells (Figure 2.S2A). These conclusions are consistent with a 
number of other observations: the loss of CFU-e activity with Ter119 expression (Figure 
2.1C, [302]), the short time span (<15 h) that freshly sorted S0 cells require to transition 
through S1 and into S2 (compare with an estimated cell cycle length of 16 h for a CFU-e 
cell that will undergo three cell divisions in 48 h, giving rise to an eight cell colony), and 
with early work suggesting that Epo dependence first occurs in early S-phase of a specific 
CFU-e cell generation [303]. These conclusions are also consistent with the finding that 
EpoR-/- embryos have normal numbers of CFU-e [285]: though EpoR-/- embryos lack S1 
cells, all the CFU-e in S1 first arise as Epo-independent cells in S0, where they are 
presumably retained in the EpoR-/- fetal liver.  
S-Phase progression is required for the transition from S0 to S1 
There are two ways to explain how up-regulation of CD71, a differentiation event, 
might coincide with S-phase, a cell cycle event. These events may have each been 
initiated in parallel by a common upstream regulator, such as the EpoR, since both occur 
at the time that cells become EpoR dependent. Alternatively, there may be a direct 
mechanistic link between the differentiation and cell cycle programs. To distinguish these 
possibilities, we examined whether a block to S-phase progression would interfere with 
CD71 up-regulation (Figure 2.2). We incubated sorted S0 cells in vitro for 10 h in the 
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presence of Epo, and either in the presence or absence of aphidicolin, an inhibitor of 
DNA polymerase that arrests S-phase progression [304]. At t=10 h, cells were washed 
free of aphidicolin and incubated in Epo alone for an additional 10 h (Figure 2.2A). In the 
initial 10 h of incubation, there was an Epo-dependent transition of cells from S0 to S1 
(Figure 2.2C, rows 1 and 5). However, the presence of aphidicolin blocked this transition 
(Figure 2.2C, rows 2 & 3, t=10 h). Both S-phase and the transition into S1 resumed once 
the cells were washed free of aphidicolin (Figure 2.2C, rows 2 & 3, t=20 h). These 
observations suggested that the transition from S0 to S1 occurred during S-phase and 
required both Epo and S-phase progression.  
We also examined the effect of mimosine, a plant amino acid that blocks cell 
cycle progression in late G1 [305]. We incubated sorted S0 cells in Epo and in the 
presence or absence of mimosine. By 4 h of incubation, the majority of cells were 
arrested in G1. However, a small fraction of cells (12%) could be seen in S-phase at t=4 h 
(Figure 2.2C, row 4, BrdU/7AAD at t =4 h). Presumably, at the time mimosine was 
added, these cells were advanced in their cell cycle beyond the point at which mimosine 
exerts its block. BrdU/7AAD analysis showed that these cells were in the early half of S-
phase and expressed the highest CD71 levels within the S0 subset (Figure 2.2D, cells 
marked in red). By t=10 h, no S-phase cells were seen in S0, presumably because they 
have now transitioned into S1, where a similar number of cells (15%) had newly 
appeared (Figure 2.2C, row 4, BrdU/7AAD for S0 at t=10 h, and CD71/Ter119 for S1 at 
t=10 h). These observations were consistent with the onset of CD71 up-regulation 
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occurring in early S-phase in S0, culminating in the transition to S1 later within that same 
S-phase.  
CD71, the transferrin receptor, is required during erythroid differentiation in order 
to facilitate cellular uptake of iron for hemoglobin synthesis. CD71 is also expressed, 
albeit at lower levels, on all cycling cells. We therefore examined whether, in the context 
of S1 cells, CD71 might be required specifically for S-phase progression. We used RNAi 
to prevent CD71 up-regulation in S0 cells during their incubation in Epo (Figure 
2.S2B,C). The failure of these cells to upregulate CD71 did not interfere with the number 
of cells in S-phase (Figure 2.S2B). Therefore, the link between S-phase progression and 
CD71 up-regulation in S1 cells is not due to a cell cycle function for this gene.  
The S0 to S1 transition is marked by down-regulation of PU.1 and GATA-2 and 
precedes induction of erythroid-specific genes  
To investigate the link between S-phase and the erythroid differentiation program, 
we examined expression of erythroid transcriptional regulators and erythroid-specific 
genes in freshly sorted fetal liver subsets and in fetal brain (Figure 2.3A). We found that 
the GATA-1 mRNA was present in S0 cells, at 200-fold higher levels than in fetal brain 
(Figure 2.3A) and 40-fold higher level than in Mac-1+ cells ( Figure 2.S3A). It increased 
a further 2-fold with the transition from S0 into S1 and continued to increase in S2 and 
S3. Of note, total RNA per cell decreased 4-fold over the course of differentiation from 
S2 to S4 (Figure 2.S3B), suggesting an overall modest increase in GATA-1 mRNA per 
cell over this period. Other erythroid transcriptional activators and GATA-1 associated 
factors, including EKLF, NF-E2 [306], SCL/Tal-1, and Lmo2, showed a similar 
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expression pattern to that of GATA-1 (Figure 2.3A). Therefore, expression of GATA-1 
and of other activators of the erythroid transcriptional program precedes the transition 
from S0 to S1. By contrast, we found that PU.1, a repressor of GATA-1 function, and 
GATA-2, a target of GATA-1-mediated repression [307], were both down-regulated 
approximately 30-fold and 20-fold, respectively, at the S0 to S1 transition, becoming 
undetectable with further differentiation (Figure 2.3A). Prior to its down-regulation, the 
level of PU.1 in S0 cells was comparable to that of myeloid Mac-1+ cells (Figure 2.S3A). 
PU.1 protein levels also declined with the transition from S0 to S1 (Figure 2.S3C).  
EpoR-/- fetal liver cells, though apparently arrested at the S0 stage (Figure 2.1B), 
have a similar expression pattern of transcriptional regulators to wild-type S1 (Figure 
2.3A). Therefore, down-regulation of PU.1 and GATA-2 at the S0 to S1 transition, as 
well as the preceding induction of GATA-1, are independent of EpoR signaling.  
We examined expression of several erythroid-specific GATA-1 target genes: β-
globin (Hbb-b1); the first enzyme of heme synthesis, aminolevulinic acid synthase 2 
(ALAS2); and the anion exchanger Band 3 (Slc4a1), a major erythrocyte membrane 
protein [308]. There was a modest increase in their expression at the S0 to S1 transition, 
followed by a 30- to 100-fold induction during subsequent differentiation in S2 and S3 
(Figure 2.3A). Expression of the EpoR gene, itself a GATA-1 target, increased 10-fold 
above its S0 level with the transition to S1 (Figure 2.S3D). Taken together, induction of 
erythroid GATA-1 target genes and repression of GATA-2 suggest that GATA-1 
function is activated at the S0 to S1 transition. The modest increase in GATA-1 mRNA at 
this time suggests that its activation may be principally a result of PU.1 down-regulation. 
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S-Phase arrest at the S0 to S1 transition blocks induction of erythroid-specific genes 
We had found that S-phase progression at the transition from S0 to S1 was 
required for CD71 up-regulation (Figure 2.2). We therefore examined whether S-phase 
progression at this time was also required for induction of erythroid-specific genes. We 
cultured sorted S0 cells in Epo for 10 h, a period sufficient for 25%–50% of cells to 
transition into S1 (Figures 1H, 2C), and examined the effect of adding aphidicolin to the 
culture. Cells were then washed free of aphidicolin, continuing incubation in Epo alone. 
Cells incubated in Epo alone for the entire period showed 50- to 100-fold induction in the 
mRNAs for β-globin, Band 3, and ALAS2 ( Figure 2.3B, red curves). By contrast, cells 
that were subject to aphidicolin treatment during the initial 10 h showed reduced mRNA 
induction by the end of the culture period (Figure 2.3B, blue curves). The reduced mRNA 
levels corresponded closely to the levels predicted had there been a 10 h delay in the time 
course of induction for each of the genes (Figure 2.3B, black curves). Therefore, 
induction of erythroid-specific genes was likely blocked during the incubation period in 
aphidicolin.  
We also examined whether S-phase arrest interferes with erythroid gene induction 
if applied at the S1 stage of differentiation. We sorted S1 cells and incubated them in 
Epo, either in the presence or absence of aphidicolin. Unlike S0 cells, aphidicolin 
mediated S-phase arrest of S1 did not interfere substantially with their induction of 
erythroid specific genes, as shown by the unperturbed induction of β-globin, Alas2, and 
Band 3 (Figure 2.3C, Figure 2.S3E) or with the up-regulation of Ter119 (Figure 2.S3F). 
Therefore, S-phase progression is required for activation of erythroid-specific genes, 
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specifically at the S0 to S1 transition, but not a few hours later when the cells have 
traversed into S1. The lack of effect of aphidicolin on mRNA induction in S1 suggests its 
effects in S0 are not due to non-specific suppression of transcription.  
S-Phase arrest at the S0 to S1 transition blocks down-regulation of PU.1 and 
GATA-2 and arrests erythroid morphological maturation 
Transcripts for PU.1 and GATA-2 are markedly down-regulated at the transition 
from S0 to S1 (Figure 2.3A). We examined whether S-phase arrest interferes with their 
down-regulation. Sorted S0 cells were incubated in Epo for 4 h, at which time, just prior 
to their transition into S1 (Figure 2.2C), aphidicolin was added to the cultures for a period 
of 10 h. Cells were then washed free of aphidicolin and incubated in Epo for a further 10 
h. Aphidicolin halted the down-regulation of both PU.1 and GATA-2, which resumed 
once the cells were washed free of the drug (Figure 2.3D,E). Similar results were 
obtained in cells treated with mimosine (Figure 2.S3G). Therefore, S-phase progression is 
required for down-regulation of PU.1 and GATA-2 at the S0 to S1 transition. Of note, 
GATA-1, Nfe2, and Lmo2 mRNAs, which did not change significantly during the 
transition from S0 to S1 (Figure 2.3A), were not altered significantly by the aphidicolin 
treatment (Figure 2.3E, Figure 2.S3H).  
We also examined the effects of aphidicolin or mimosine treatment on 
morphological maturation of S0 cells cultured in Epo. Following 10 h in Epo in the 
presence of aphidicolin or mimosine, cells appeared larger than cells incubated in Epo 
alone. This suggested that, while S-phase progression and the erythroid differentiation 
program had both arrested, cell growth was not perturbed (Figure 2.3F). Cells were then 
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washed free of aphidicolin or mimosine and cultured in Epo alone. By 20 h, erythroid 
maturation had resumed in cells that were initially incubated in cell cycle blocking drugs, 
as judged by decreasing cell size, nuclear condensation, and decreased nuclear to 
cytoplasmic ratio, but was nevertheless delayed when compared with control cells. These 
results are consistent with the effect of S-phase arrest on gene expression (Figure 2.3B, 
D, E) and suggest that S-phase progression at the S0 to S1 transition is a key requirement 
for activation of the erythroid differentiation program. 
Preventing p57KIP2 down-regulation blocks S-phase progression at the S0 to S1 
transition and arrests erythroid differentiation  
Expression of p57KIP2 mRNA decreases over 30-fold at the S0 to S1 transition, 
and this is associated with down-regulation of the p57KIP2 protein (Figure 2.1G). To 
examine the effect of preventing p57KIP2 down-regulation, we generated a point mutant of 
p57KIP2, p57T329A, analogous to a proteolysis-resistant human p57KIP2 mutant [309]. 
Sorted S0 cells were infected with bicistronic retroviral vectors expressing either wild-
type p57KIP2 or p57T329A, linked through an internal ribosomal entry site (IRES) to a 
human CD4 (hCD4) reporter; control cells were infected with retroviral vector expressing 
the IRES-hCD4 construct only (MICD4). To allow expression of the transduced p57KIP2, 
infected cells were cultured for 15 h in stem-cell factor (SCF) and interleukin 3 (IL-3), 
cytokines that sustain viability of progenitors but, unlike Epo, do not support 
differentiation from S0 to S1. Infected S0 cells were then transferred to Epo for 14 h 
(Figure 2.3G). Expression of either wild-type (unpublished data) or mutant p57KIP2, but 
not expression of MICD4, resulted in a block to S-phase progression and inhibited the 
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transition from S0 to S1 (Figure 2.3G). Further, PU.1 mRNA was >3-fold higher in cells 
expressing p57KIP2 compared with control cells expressing vector only (Figure 2.3H), 
suggesting that, as in the case of aphidicolin-mediated S-phase arrest, p57KIP2-mediated 
S-phase arrest prevents down-regulation of PU.1 at the transition from S0 to S1. 
Erythroid morphological maturation, but not cell growth, of p57T329A-transduced cells 
was also arrested (Figure 2.S3I).  
Taken together, up-regulation of CD71, which defines the transition from S0 to 
S1, identifies a key differentiation transition within the last generation of CFU-e (“CFU-
e.2”, Figure 2.3I). It marks the onset of EpoR dependence and occurs exclusively during 
S-phase of the cell cycle. Induction of GATA-1 and other activators of the erythroid 
transcriptional program precede this transition, whereas induction of erythroid-specific 
genes such as β-globin and Ter119 follows it. The S0 to S1 transition coincides with 
rapid down-regulation of p57KIP2, PU.1, and GATA-2. Both Epo and S-phase progression 
are required for up-regulation of CD71. S-phase progression at the S0 to S1 transition 
requires the down-regulation of p57KIP2 and is in turn required for the down-regulation of 
PU.1 and GATA-2 and the subsequent activation of erythroid-specific genes. By contrast, 
S-phase arrest in S1 cells does not affect erythroid gene activation (Figures 2.3C, 2.S3E–
F). 
Persistently elevated PU.1 arrests S-phase progression and blocks erythroid 
differentiation  
Both PU.1 and GATA-2 were rapidly and dramatically down-regulated at the 
transition from S0 to S1 (Figure 2.3A, Figure 2.S3A). We examined the effect of 
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preventing this down-regulation by expressing either PU.1 (Figure 2.4A–D) or GATA-2 
(Figures 2.4E, 2.S4C, D) in S0 cells using retroviral constructs and a similar strategy to 
that described above for p57KIP2. Following infection, S0 cells were cultured for 15 h in 
IL-3 and SCF and then transferred to Epo for 24 h, when CD71/Ter119 and cell cycle 
profiles were examined (Figure 2.4A–C). We divided the PU.1 expression profile at t=24 
h into 7 sequential hCD4 gates labeled (i) to (vii) (Figure 2.4A), each containing cells 
with increasing levels of the hCD4 reporter and, therefore, increasing levels of PU.1. By 
measuring PU.1 protein directly in fixed and permeabilized cells using a PU.1-specific 
antibody and flow-cytometry, we found that hCD4 protein expression was a reliable 
reporter of exogenous PU.1 protein expression in our system (Figures 2.4D, 2.S4A–B); 
expression of transduced PU.1 was also measured by qPCR (Figure 2.S4D). Sequential 
hCD4 gates were also obtained for control cells expressing the empty MICD4 vector. 
PU.1 expression blocked transition from S0 to S1, with the number of cells transitioning 
into S1 declining as PU.1 expression increased (Figure 2.4B, upper panels). PU.1 
expression also resulted in a decrease in the number of S-phase cells, with cells arresting 
principally at the transition from G1 to S-phase, though there was also an increase in the 
number of cells within G2 or M (Figure 2.4B, lower panels). The decrease in the number 
of cells in S1 was paralleled by decreased S-phase cell number, suggesting a direct 
correlation between the PU.1-mediated block of the transition from S0 to S1, and its 
inhibitory effect on S-phase (Figure 2.4C). Therefore, PU.1 inhibits both S-phase and 
erythroid differentiation at the S0 to S1 transition.  
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Since the down-regulation of both PU.1 and p57KIP2 are required for S-phase 
progression and for the transition from S0 to S1 (Figure 2.3G, Figure 2.4B, C), we 
examined whether PU.1 may be a regulator of p57KIP2. However, we found that 
exogenous expression of PU.1 did not prevent down-regulation of p57KIP2 (Figure 
2.S4E). Therefore, PU.1‟s inhibitory effect on S-phase is not mediated via p57KIP2.  
In contrast to PU.1, expression of GATA-2 in S0 cells did not prevent transition 
into S1, though it somewhat reduced the subsequent transition from S1 to S2 (Figure 
2.4E). GATA-1 overexpression in S0 cells had the opposite effect, of promoting the 
transition from S1 to S2. There was no significant effect of either GATA-1 or GATA-2 
on the cell cycle profile (Figure 2.4E).  
The S0 to S1 transition coincides with a switch in the timing of replication of the β-
globin locus 
A long-standing hypothesis suggests that DNA replication may provide an 
opportunity for the restructuring of chromatin at tissue specific gene loci [283, 284]. 
Given the requirement for DNA replication for the transition from S0 to S1, we asked 
whether chromatin change may be taking place at this time. The β-globin gene locus 
(Figure 2.5A) is a well-studied model of tissue-specific gene expression. The features that 
characterize the open chromatin conformation at the actively transcribed locus in 
erythroid cells have been established, but the time during development when the active 
chromatin conformation is acquired is not known. We therefore set out to examine 
whether the S0 to S1 transition might coincide with an alteration in the structure or 
function of chromatin at this locus.  
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The timing of replication of the β-globin locus is correlated with its chromatin 
state. In higher eukaryotes the timing of replication of genes correlates with their 
transcriptional activity [310]. Housekeeping genes replicate early in S-phase, whereas 
silent chromatin and heterochromatin replicate late. The β-globin locus replicates in mid 
to late S-phase in non-erythroid cells and early in S-phase in erythroid cells [311]. We 
examined the timing of replication of the β-globin locus in S0 and S1 cells sorted from 
fresh fetal liver. Individual alleles were identified using fluorescence in situ hybridization 
(FISH) with a probe directed at the -major gene. Cells in S-phase were identified by 
positive staining for BrdU incorporation. Nuclei from at least 100 S-phase cells from 
either S0 or S1 were examined in each of two experiments (Figure 2.5B). Using this 
approach, two single dots (“SS”) suggest that neither of the β-globin alleles had yet 
replicated. Nuclei in which both alleles have replicated contain a pattern of two double 
dots (“DD”). Replication of only one allele results in one single and one double dot (SD) 
[311]. We found that the number of cells with a DD pattern increased from only 15% in 
S0 to over 50% in S1 (Figure 2.5B), suggesting a switch in the timing of replication from 
late to early S-phase. In addition, an average of 36% of S0 cells, but only 21% of S1, had 
an SD pattern, consistent with a switch from late, asynchronous replication in S0 to early, 
synchronous replication in S1 [311].  
The S0 to S1 transition coincides with the onset of DNase I hypersensitivity at the β-
globin locus control region (LCR)  
A key indicator of open chromatin at the β-globin LCR is the presence of 
hypersensitivity (HS) sites (Figure 2.5A). We prepared nuclei from freshly sorted S0 or 
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S1 cells and tested their sensitivity to DNase I digestion. Following digestion, we 
measured remaining DNA using quantitative PCR, with amplicons within HS2, HS3, and 
HS4 [312]. Results were expressed as a ratio to the DNase I resistant, non-expressing 
neural gene, Nfm. We found that S0 cells were relatively resistant to DNase I, while S1 
cells were hypersensitive at all tested HS sites (Figure 2.5C). Therefore, the S0 to S1 
transition coincides with the onset of DNase I hypersensitivity at the β-globin LCR.  
We also examined E12.5 EpoR-/- whole fetal livers, which do not contain S1 cells 
(Figure 2.1B). We found that EpoR-/- fetal livers were resistant to DNase I, whereas 
whole fetal livers from wild-type or heterozygous littermates showed the expected 
hypersensitive sites (Figure 2.5D). We therefore concluded that DNase I hypersensitivity 
develops at the S0 to S1 transition, synchronously with the onset of EpoR dependence.  
S-phase progression is required for the onset of DNase I hypersensitivity at the β-
globin LCR 
Since the transition from S0 to S1 coincides with, and requires, S-phase 
progression, we examined whether development of DNase I hypersensitivity at the β-
globin LCR also requires S-phase progression. We incubated sorted S0 cells in Epo, in 
the presence or absence of aphidicolin, for 10 h. Over this period 25%–50% of S0 cells 
transition into S1, a process arrested by aphidicolin (Figures 1H, 2C). At the end of a 10-
h incubation period, nuclei were prepared and digested with varying concentrations of 
DNase I. There was a clear increase in DNase I sensitivity in cells incubated in Epo 
alone, relative to cells incubated in Epo and aphidicolin (Figure 2.5E). Therefore, the 
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development of DNase I hypersensitivity at the S0 to S1 transition is dependent on S-
phase progression.  
Changes in post-translational histone tail modifications associated with the 
transition from S0 to S1 
 The switch in timing of replication and in DNase I hypersensitivity at the S0 to 
S1 boundary suggested the β-globin LCR was undergoing structural changes. To 
investigate these, we used chromatin immunoprecipitation (ChIP) to determine specific 
histone tail modifications at the β-globin LCR in freshly sorted S0, S1, and in fetal brain. 
We used ChIP-qPCR for amplicons at the β-globin LCR HS sites, or at a control, neural 
gene, Nfm. Changes in histone modifications were expressed as a ratio, between S0 and 
either S1 or fetal brain (Figure 2.5F, G). Figure 2.5F summarizes data pooled from seven 
experiments with various immunoprecipitating antibodies as indicated. A comparison of 
S1 with S0 shows a 7-fold decrease in trimethylation of histone 3 lysine 27 (H3K27me3, 
p = 0.019, paired t test), a mark associated with silent chromatin, and a 2.5-fold increase 
in histone 3 lysine 4 dimethylation, a mark associated with active chromatin (H3K4me2, 
p = 0.032), at the HS2 site of the β-globin LCR. A similar trend for these two 
modifications was also found at other HS sites (p = 0.0006 and p = 0.011 for H3K4me2 
and H3K27me3, respectively, pooling all HS sites). An increase in acetyl marks in 
histones H3 and H4 associated with active chromatin was also seen consistently across 
the HS sites tested, though it did not reach statistical significance. Of note, no significant 
changes in histone marks were found between S0 and S1 at the Nfm gene. Further, there 
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was no significant change in total histone occupancy of the HS sites between S0 and S1, 
as determined by ChIP with antibodies directed against total H3 and H4 (Figure 2.5F).  
We noted that H3K27me3, associated with silent chromatin, and H3K4me2, 
associated with active chromatin, were both enriched in S0 compared with fetal brain 
(Figure 2.5G, lower panel). These results were suggestive of bivalent chromatin at the β-
globin LCR in S0, and loss of the repressive H3K27me3 mark with transition into S1 
(Figure 2.5G, upper panel, 2.5F).  
The transition from S0 to S1 coincides with S-phase-dependent DNA demethylation 
at the β-globin LCR  
We examined DNA methylation of six CpG dinucleotides, three each at the HS1 
and HS2 sites of the β-globin LCR (Figures 5A, 6A). Genomic DNA was prepared from 
sorted hematopoietic cell subsets from fresh fetal liver, including S0, S1, megakaryocytic 
CD41+ , myeloid Mac-1+, and Lin-Sca1+Kit+ (LSK) cells, enriched for hematopoietic 
stem-cells. We also examined EpoR-/- fetal livers depleted of cells expressing lineage 
markers, and fetal brain. DNA methylation at each of the six CpGs was obtained 
following bisufite conversion of genomic DNA, PCR amplification at HS1 and HS2, and 
pyrosequencing. In fetal brain methylation levels were high, at <60%–80%, for all six 
CpG dinucleotides. Methylation levels were lower in all hematopoietic cell subsets 
(Figure 2.6A). Methylation levels were largely similar in all hematopoietic, Epo-
independent cell subsets examined: LSK, Mac-1+, CD41+, S0, and EpoR-/- cells. The 
onset of Epo dependence in S1 was associated with a marked reduction in DNA 
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methylation in all six CpG dinucleotides, with the level of methylation dropping to 
virtually undetectable levels in S1 for four of the six CpGs.  
We found that DNA demethylation also took place in freshly sorted S0 cells 
allowed to differentiate in vitro (Figure 2.6B, C). Demethylation in vitro occurred earlier 
at the HS1A, B, C, and HS2C than at HS2A, B (Figure 2.6B, C, red lines), in agreement 
with results in vivo (Figure 2.6A). Demethylation in vitro was arrested at all CpGs if 
either aphidicolin or mimosine were added to the incubation medium, and resumed when 
these drugs were removed (Figure 2.6B, C). Therefore, DNA demethylation, initiated at 
the transition from S0 to S1, is dependent on S-phase progression. These results are 
suggestive of a passive demethylation process, due to loss of maintenance methylation at 
nascent DNA.  
PU.1 down-regulation is required for the onset of DNA demethylation at the 
transition from S0 to S1. 
We examined HS1 and HS2 DNA methylation levels in S0 cells transduced with 
PU.1 (as in Figure 2.4A) and incubated in Epo for 24 h. DNA methylation was 
significantly higher at 3 of the 6 CpGs in S0 cells transduced with PU.1-ICD4, compared 
with control cells transduced with MICD4 (Figure 2.6D). Therefore, PU.1 expression, 
along with its inhibitory effect on erythroid differentiation, also impaired DNA 
demethylation, possibly due to its inhibitory effect on S-phase in these cells (Figure 
2.4C).  
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Discussion 
We have identified a committal step in erythropoiesis in which the cell cycle 
clock is precisely synchronized with and coordinates an erythroid differentiation switch. 
It takes place during S-phase of the last CFU-e generation, at the transition from S0 to S1, 
when S-phase progression is required for several distinct committal differentiation 
events, including the onset of Epo dependence, a switch in chromatin at the β-globin 
locus into an open conformation, and activation of GATA-1 function with consequent 
transcription of GATA-1 target genes (Figure 2.7A). The transition from S0 to S1 can be 
replicated in vitro, where sorted S0 cells develop into a differentiation state characteristic 
of S1 within 10 to 12 h.  
S-phase progression at the S0 to S1 transition and the ensuing differentiation 
switch are dependent on the down-regulation of p57KIP2 (Figures 2.3G, 2.7B), a novel 
finding since, to date, the principal known role of CDKIs in differentiating cells had been 
to mediate terminal differentiation secondary to cell cycle exit [280-282]. Unlike other 
CDKIs, p57KIP2 is required for the development of multiple tissues [313], suggesting that 
its novel role in erythropoiesis, triggering S-phase progression during a committal 
differentiation event, may be replicated in other systems. Of note, p57KIP2 is the only 
CDKI of the CIP/KIP family to be down-regulated at the S0/S1 transition.  
The synchronization of S-phase progression with several rapid and committal 
differentiation transitions suggests they are coregulated. A key mediator of this co-
regulation is PU.1, whose expression declines at the transition from S0 to S1. We have 
identified a novel cross-antagonism between S-phase progression and PU.1 expression. 
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We show that S-phase arrest, caused by high levels of p57KIP2 or by cell cycle blocking 
drugs, prevents down-regulation of PU.1 (Figure 2.3E, H); conversely, failure to 
downregulate PU.1 arrests S-phase progression (Figure 2.4B, C). Either maneuver blocks 
erythroid differentiation, including a block of chromatin reconfiguration at the β-globin 
locus and blocked expression of erythroid-specific genes (Figures 2.3B, 2.3D–H, 2.S3G, 
2.S3I, 2.4B, 2.5E, 2.6C–D).  
We propose that the mutual inhibition between PU.1 and S-phase progression at 
the S0 to S1 transition (Figure 2.7B) simultaneously controls the transition in both 
differentiation and cell cycle states. Its function is analogous to a synchromesh 
mechanism in an automotive transmission, matching the speeds of two rotating gears 
before allowing them to lock together during a gear-shift. The mutual antagonism 
between S-phase progression and PU.1 expression ensures that PU.1 down-regulation 
does not occur prior to the cell‟s entry into S-phase; conversely, S-phase entry cannot 
occur before conditions for PU.1 down-regulation are in place. In this manner the cell 
cycle and differentiation programs can only proceed when precisely synchronized.  
Once cells have transitioned from S0 into S1, S-phase progression is no longer 
required for expression of erythroid genes (Figure 2.3C, 2.S3E–F). Therefore, the 
synchromesh mechanism is specific to the transition from S0 to S1, when committal 
decisions bring about an irreversible terminal differentiation phase. Our findings reveal a 
key organizational feature in erythroid differentiation and have implications for 
differentiation of other lineages, where similar synchronization events may occur. 
Further, the synchromesh mechanism we describe may be a target in leukemogenesis, 
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consistent with reports that high levels of PU.1 promote erythroleukemia [294]. 
Similarly, although no reports at present implicate p57KIP2 specifically in erythropoiesis, 
mutations in p57KIP2 are implicated in the familial Beckwith-Weidemann syndrome, 
which predisposes to pediatric tumors [301].  
The cross-antagonism between PU.1 and S-phase progression is lineage and 
differentiation stage-specific 
PU.1, whose physiological function in erythropoiesis had not been clear, plays a 
pivotal role at the S0 to S1 transition, through its cross-antagonism with S-phase 
progression. This cross-antagonism is lineage and differentiation stage-specific, since it 
presumably does not operate in myeloid and B-cell lineages where PU.1 is an essential 
transcriptional activator. Similarly, within the erythroid lineage, this mutual antagonism 
must be activated specifically in the last generation of CFU-e. Its premature activation at 
an earlier CFU-e cycle may be predicted to result in premature transition into S1 and 
consequently, in a reduced number of differentiated progeny. This prediction helps 
explain previous observations, where erythroid cells from PU.1-null embryos were found 
to differentiate prematurely and to have reduced self-renewal capacity [314]. These 
observations are consistent with the PU.1-null phenotype mimicking premature down-
regulation of PU.1. The mutual inhibition between PU.1 and S-phase may also explain 
findings in the T-cell lineage, where exogenous expression of PU.1 at the pro-T cell stage 
was found to block both thymocyte expansion and differentiation [315].  
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The cross-antagonism between PU.1 and GATA-1  
Previous work documented cross-antagonism between PU.1 and GATA-1, 
showing them to interfere with each other‟s transcriptional functions through a variety of 
mechanisms including direct physical binding [290-293]. We propose that the activation 
of erythroid terminal differentiation at the S0/S1 boundary is due to functional activation 
of GATA-1 (Figure 2.7B). Though present in S0 cells prior to the transition into S1 
(Figure 2.3A), GATA-1 function is inhibited by PU.1. Down-regulation of PU.1 at the S0 
to S1 transition alleviates this inhibition, allowing GATA-1-mediated activation of 
erythroid gene induction. Among its known targets, GATA-1-mediated transcriptional 
repression of GATA-2 [307] would account for our observation that GATA-2 is down-
regulated at the S0 to S1 transition (Figure 2.3A). This scheme places the decrease in 
GATA-2 downstream of the cross-antagonism between PU.1 and GATA-1 (Figure 2.7B) 
and explains why exogenous high levels of GATA-2, unlike PU.1, do not block the 
transition from S0 to S1 (Figure 2.4).  
Based largely on immortalized progenitor-like cells, the antagonism between 
GATA-1 and PU.1 was proposed to underlie a binary cell fate choice in cells expressing 
both GATA factors and PU.1. An increase in GATA-1 would result in PU.1 suppression 
and the erythro-megakaryocytic cell fates, whereas an increase in PU.1 would suppress 
GATA-1 and give rise to the myelo-lymphocytic lineages [290-293]. However, our data 
show that CFU-e cells, considered committed erythroid progenitors, express PU.1 at 
levels equivalent with those found in cells of the myeloid lineage (Figure 2.S3A). Our 
results are consistent with previous reports of PU.1 expression in early erythroid 
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progenitors, including the expression of a GFP reporter “knocked in” to the PU.1 gene 
locus in S0 (CD71lowTer119negative) fetal liver cells [314, 316].  
The biochemical nature of commitment to the erythroid lineage is unknown at 
present. It is possible that CFU-e cells prior to PU.1 down-regulation, which are also 
expressing GATA-1 and GATA-2, are in fact multipotential cells that may give rise to 
either myeloid or erythro-megakaryocytic lineages. In this case, the cross-antagonism 
between PU.1 and GATA-1 would simultaneously be responsible for a lineage choice, as 
well as facilitate activation of the erythroid gene expression program at the S0 to S1 
transition should this choice be in favor of the erythroid lineage. Our ability to isolate 
CFU-e cells expressing high levels of PU.1 prior to their transition into S1 should 
facilitate further study of this issue.  
The role of S-phase  
Why is S-phase progression coupled to the erythroid differentiation program at 
the S0 to S1 boundary? Linking developmental transitions to cell cycle phases may serve 
as a strategy for their correct developmental timing [317] and may ensure the correct 
number of differentiated progeny. Another possibility is that S-phase progression plays a 
direct role in the re-configuration of chromatin at erythroid-specific gene loci. DNA 
replication was proposed to provide an opportunity for structural changes in chromatin, 
since the passage of the replication fork transiently disrupts nucleosomes [283, 284]. 
Indeed, S-phase is essential for activation or silencing of some genes in yeast [318, 319] 
and metazoa [317, 320-323], though it is not known that this is due to a requirement in 
the reconfiguration of chromatin. However, S-phase is not required for activation of other 
63 
 
developmental genes [324-328]. Further, in recent years the structure of chromatin was 
found to be much more dynamic outside S-phase than originally suspected [329]. It is 
therefore unclear whether there is an innate requirement for DNA replication in the 
reconfiguration of chromatin during activation of lineage-specific genes, or what specific 
aspects of chromatin restructuring might require S-phase.  
Here we found that S-phase is required for DNA demethylation and for formation 
of DNase I hypersensitive sites. The requirement for DNA replication suggests that DNA 
demethylation is passive, due to a decrease in maintenance methylation of the nascent 
DNA strand [330]. This raises the possibility that formation of DNase I hypersensitive 
sites may require DNA replication because it might be contingent on DNA 
demethylation. Alternatively, DNase I hypersensitivity may require S-phase progression 
in order to lift a direct repressive effect of PU.1 on chromatin [292].  
The role of EpoR  
Our examination of EpoR-/- fetal liver shows that the EpoR becomes essential for 
erythroid differentiation at the S0/S1 boundary. The principal function of EpoR at this 
time is its pro-survival signaling: EpoR-/- erythroid progenitors undergo apoptosis but 
their cell cycle status is unaltered, suggesting that EpoR signaling is not required for S-
phase progression (Figure 2.S1E). These findings are consistent with the established role 
of EpoR as a survival factor that does not affect the erythroid cell cycle [331]. EpoR 
signaling is probably also dispensable for down-regulation of PU.1 at the S0 to S1 
transition, since both PU.1 and GATA-2 are low in EpoR-/- cells (Figure 2.3A). In spite of 
both S-phase progression and PU.1 down-regulation being apparently unimpaired,   
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EpoR-/- cells fail to develop DNase I HS sites and fail to undergo DNA demethylation at 
the β-globin LCR (Figures 2.5D, 6A). It has been reported that exogenous expression of 
Bcl-xL facilitates Epo-independent differentiation of erythroblasts [332] arguing against 
a direct requirement for EpoR signaling in chromatin reconfiguration. Therefore, EpoR-/- 
cells may be undergoing rapid apoptosis prior to the time when the chromatin change 
would have otherwise taken place.  
Other than its survival function, EpoR is probably directly required for CD71 up-
regulation, via Stat5 [333, 334]. However, EpoR signaling results in CD71 up-regulation 
only if S-phase is allowed to proceed (Figure 2.2).  
Thus, while the onset of Epo dependence occurs synchronously with committal 
chromatin and transcriptional events in erythroid differentiation, there is apparently no 
direct requirement for EpoR signaling in these events, other than ensuring cell survival. 
The principal function of Epo in erythropoiesis is to determine the number of 
differentiated erythrocytes, via Epo concentration [104]. The S0 to S1 transition may 
have evolved as the time of onset of Epo dependence as it represents a biochemical 
commitment to erythroid differentiation, setting in motion chromatin and transcriptional 
transformations that lead to expression of erythroid- specific genes. This therefore 
represents the earliest time in erythroid differentiation when Epo may regulate cell 
number specifically within the erythroid lineage, with minimal lateral effects on other 
hematopoietic cells.  
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An all-or-none switch in chromatin state at the β-globin LCR  
The β-globin LCR had long been studied as a model of chromatin at sites of 
lineage-specific genes. However, the time in erythroid differentiation when the locus 
switches from a “closed” to an “open” conformation had not been clearly defined. 
Further, it was not known whether activation of the locus develops in a step-wise fashion 
over several cell cycles and differentiation stages or whether it occurs rapidly in a single 
step.  
Our findings show that, strikingly, the locus transitions to an active conformation 
rapidly, within S-phase of a single cell cycle. Further, several distinct functional and 
biochemical changes that characterize the active chromatin conformation appear to 
develop simultaneously. We found marked differences between S0 and S1 cells in DNA 
methylation and in DNase I hypersensitivity at the LCR. These transformations could be 
reproduced when purified S0 cells transitioned into S1 in vitro (Figures 2.5, 6). Both 
DNA demethylation and DNase I hypersensitivity required S-phase progression for their 
development. Further, we also found that development of histone-tail modifications 
characteristic of active chromatin, as well as the switch in the timing of replication of the 
locus from late to early S-phase, both coincide with the transition from S0 to S1 (Figure 
2.5). Therefore, our findings support an „„all or none‟‟ model for the state of chromatin, 
previously hypothesized based on the probabilistic nature of developing DNase I 
hypersensitivity in a range of mutated chicken β-globin enhancer constructs [335].  
Previous work showed that while the highest levels of DNase I accessibility at the 
β-globin LCR are attained in mature erythroid progenitors, the β-globin LCR is already 
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poised for expression in earlier multipotential progenitors, contributing to low-level β-
globin transcription (“priming”) [336, 337]. The β-globin LCR was found to already 
contain DNase I hypersensitive sites in cell lines resembling early hematopoietic 
progenitors [338]. Here we find that the β-globin LCR appears poised for change prior to 
the transition from S0 to S1. Thus, LSK and S0 cells have similar DNA methylation 
levels that are substantially lower than in fetal brain, suggesting chromatin already 
primed for expression at the LSK stage (Figure 2.6A). Histone tail modifications in the 
LCR similarly suggest that chromatin in S0 is poised for change, as it is enriched with 
both H3K4me2, a mark associated with active chromatin, and with H3K27me3, a mark 
found in silent chromatin (Figure 2.5G). The LCR is therefore marked as a bivalent 
domain, which may denote chromatin that is silent but primed for activation [339, 340]. 
Regardless of the precise state of chromatin readiness in earlier hematopoietic 
progenitors, however, our results show a clear switch in chromatin conformation at the 
S0 to S1 transition.  
The clear switch we identified at the β-globin LCR occurs in synchrony with 
other switch-like transformations at the transition from S0 to S1, including the onset of 
Epo dependence and activation of GATA-1 function. Our ability to identify this transition 
with precision in vivo and manipulate it genetically in vitro should facilitate further study 
of the pivotal link between the cell cycle clock and the committal chromatin decisions 
that bring about the erythroid phenotype.  
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Materials and Methods  
Flow cytometry  
Fetal livers (E12.5–E14) were mechanically dissociated and immunostained as 
described [341]. Immunofluorescence was measured on an LSRII (BD Biosciences, CA) 
and data analyzed using FloJo (Tree Star, CA). Cells were sorted on a FACSAria, 
FACSVantage (BD Biosciences), or MoFlo (Beckman Coulter) cell sorters. In a small 
number of experiments StemSep columns (StemCell Technologies) were used.  
Fetal liver cells were simultaneously stained for CD71, Ter119 and a Lineage-
cocktail with anti-CD3, Gr-1, B220, CD41 and Mac-1 antibodies (BD Biosciences). 
Background fluorescence in each channel (“fluorescence minus one” - FMO) was 
determined with isotype-matched antibodies substituting for each specific antibody, one 
channel at a time. Cells were sorted on a FACSAria, FACSVantage (BD Biosciences) or 
MoFlo (Beckman Coulter) cell sorters. Dead cells were excluded using 7-
aminoactynomycin (7-AAD, Viaprobe, BD Biosciences) or DAPI (Roche). Alternatively, 
fetal liver cells were labeled with biotin-conjugated antibodies against CD71, Ter119, Gr-
1, Mac-1 and CD41, and S0 cells were purified through a StemSep magnetic column as 
per manufacturer‟s instructions (StemCell Technologies, Vancouver, BC, Canada).  
For detection of PU.1 protein, fetal liver cells freshly sorted, or after retroviral 
infection were fixed and permeabilized using the BD Cytofix/Cytoperm kit (BD 
Pharmigen), stained for PU.1 with anti-PU.1 Alexa Fluor® 647 (#2240, Cell Signaling) 
and analyzed by flow cytometry. FMO control with Rabbit (DA1E) mAb IgG Isotype 
Control Alexa Fluor® 647 (#2985, Cell Signaling) was used. The following antibodies 
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were used: Rat Anti-Mouse Gr1-biotin monoclonal RB6-8C5, BD Pharmingen; Rat Anti-
Mouse CD71-biotin monoclonal C2F2, BD Pharmingen; Rat Anti-Mouse Ter119-biotin 
monoclonal Ter119, BD Pharmingen; PE Anti-human CD4 monoclonal RPA-T4, BD 
Pharmingen; FITC Rat Anti-Mouse CD41 MWReg30, BD Pharmingen; FITC Rat Anti-
Mouse CD45R/B220 RA3-6B2, BD Pharmingen; FITC Hamster Anti-Mouse CD3e 145-
2C11, BD Pharmingen; FITC Rat Anti-Mouse CD411b/Mac-1 M1/70, BD Pharmingen; 
FITC Rat Anti-Mouse Ly-6G and Ly-6C (Gr-1) RB6-8C5, BD Pharmingen; Rat Anti-
Mouse CD41-biotin monoclonal MWReg30, GenWay Biotech,Inc; PU.1 (9G7) Rabbit 
mAb Alexa Fluor® 647 (#2240, Cell Signaling). 
In vitro culture  
Freshly harvested fetal liver cells were sorted and cultured in medium containing 
20% fetal calf serum and 2 U/ml Epo (Amgen) for up to 48 h.  
Cell cycle analysis  
BrdU (100 l of 10 mg/ml) was injected intra-peritonealy to pregnant mice and 
embryos were harvested 30–50 min later. In vitro, cells were pulsed with BrdU for 30 
min. BrdU incorporation was detected using BrdU flow kit (BD Biosciences). Cell 
tracking with CFSE (carboxyfluorescein diacetate succinimidyl ester) was performed on 
sorted S0, incubated with 2.5 M CFSE (Invitrogen) for 10 min at 37C.  
Retroviral transduction  
Retroviral transduction was by spin infection of sorted S0 cells at 2,000 rpm, 
37C on fibronectin coated dishes in 5 g/ml polybrene (Sigma). Transduced cells were 
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incubated overnight in the presence of 100 ng/ml SCF and 10 ng/ml IL3 (Peprotech, 
Rocky Hill, NJ) and were then transferred to Epo-containing medium for the indicated 
times.  
cDNA for PU.1 (provided by D. Tennen, Beth Israel Deaconess Medical Center), 
GATA-1 and GATA-2 (Open Biosystems) were subcloned into MSCV-IRES-hCD4 
retroviral vector. p57T329A has a 1 bp mutation at position T329A (based on the human 
mutant p57 T310A,[309]) which was created by PCR with the following primers: wild-
type forward: 5‟-ATGTCAGAATTCACAGCGATGGAACG-3‟ and mutant reverse: 5‟-
ATGTCAGCGGCCGCTCATCTCAGACGTTTGCGCGGGGC-CTGCTCC-3‟. The 
mutation was verified by sequencing. CD71 shRNA (source ID V2MM_13414) was 
obtained through the UMass Medical School shRNA core facility and subcloned into the 
LMP-IRES-GFP retroviral vector (Open Biosystems). High-titer viral supernatants were 
prepared by co-transfecting the desired plasmid and the pCL-Eco packaging vector into 
Phoenix cells. 
Quantitative RT-PCR  
Quantitative RT-PCR was performed as described [341]. RNA was prepared 
using the All Prep DNA/ RNA Micro Kit (Qiagen), and measured with RiboGreen RNA 
reagent kit (Thermo Scientific) on the 3300 NanoDrop Fluoro-spectrometer. Reverse-
transcription was done using the SuperScript II/III (Invitrogen) with random hexamer 
primers. The ABI 7300 sequence detection system, TaqMan reagents and TagMan MGB 
probes (Applied Biosystems, San Diego, CA) were used following the manufacturer‟s 
instruction. The Ct method was used to estimate mRNA using β-actin as a control. The 
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following TagMan MGB probes were used: β-actin (actin, beta) Mm02619580_g1; 
BAND 3 (solute carrier family 4 anion exchanger) Mm01245920_g1; ALAS2 
(aminolevulinic acid synthase 2, erythroid) Mm01260713_m1; PU.1 (SFFV proviral 
integration1) Mm00488140_m1; GATA-2 (GATA binding protein 2) Mm00492300_m1; 
GATA-1 (GATA binding protein 1) Mm01352636_m1; NF-E2 (nuclear factor, erythroid 
derived 2) Mm00801891_m1; Tal1 (T-cell acute lymphocytic leukemia 1) 
Mm00441665_m1; LMO2 (LIM domain only 2) Mm00493153_m1; EKLF1 (Kruppel-
like factor 1, erythroid) Mm00516096_m1; P57 (cyclin-dependent kinase inhibitor 1C) 
Mm00438170_m1; P21 (cyclin-dependent kinase inhibitor 1A) Mm00432448_m1; P27 
(cyclin-dependent kinase inhibitor 1B) Mm00438168_m1; EpoR (erythropoietin 
receptor) Mm01175894_m1. 
DNase I hypersensitivity assays  
DNase I hypersensitivity assays were performed as described [312] with 
modifications to amplicons. Nuclei were prepared by incubating cells for 5 minutes in 
hypotonic buffer (=“RSB”, 10 mM Tris pH 7.5, 10 mM NaCl, 3 mM MgCl2), then 
adding 0.2% NP40 and briefly vortexing. Nuclei were visually inspected, washed in 
DNase I digestion buffer (= “DDB”, 15 mM Tris pH 7.5, 15 mM NaCl, 60 mM KCl, 0.2 
mM EDTA, 0.2 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine with added 1mM 
DTT and 1 mM PMSF). DNase I digestion with increasing doses of DNase I (Sigma or 
Roche) was then carried out in DDB supplemented with 1mM CaCl2, at 37ºC for 10 
minutes, and stopped by the addition of an equal volume of cold stop buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 15 mM EDTA, 0.3% SDS). Samples were treated with proteinase 
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K overnight and DNA was extracted with the DNeasy Tissue kit (Qiagen) or 
phenol/chloroform extraction.  
The following primers were used for real-time quantitative PCR, in both DNase I 
hypersensitivity and ChIP-qPCR assays, in conjunction with SYBR Green PCR Master 
Mix (Applied Biosystems): β-actin Forward, GTTGGGTGACCCCCAGAAT; β-actin 
Reverse, TTGTGGACACTGCCCCATT; HS1 Forward, TTATCTACTCATGAAGG-
AGCAATGATG; HS1 Reverse, GTCAGCTGGGTGGAGTCACA; HS2 Forward, 
GGGTGTGTTCAGCCTTGTGA; HS2 Reverse, TCCCTGTGGACTTCCTCCTAGA; 
HS3 Forward, GATGTGTCTATCAGAGGTCCCATATG; HS3 Reverse, TCTCCCCA-
CCCTTTGTCCTA; HS4 Forward, TGAACAATTTGCCCTCTCTTACATC; HS4 
Reverse, GGCTTCCTGGTCCAGTAGATAGTATT; Nfm Forward, TGCAGGA-
TGAGGTGGCTTTC; Nfm Reverse, TGGTGCATGTTCTGGTCTGAGT 
ChIP-qPCR  
Sorted S0, sorted S1, or fetal brain cells (at least 106 cells per sample) were cross-
linked in 1% formaldehyde for 10 min at room temperature and stopped by adding 150 
mM glycine (pH 7). Cells were lysed in immunoprecipitation (IP) buffer (150 mM NaCl, 
50 mM Tris-HCl, pH7.5, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100), supplemented 
with 20 mM sodium butyrate and protease inhibitors (Roche). Chromatin was sonicated 
30 times for 10 sec pulses with Misonix Sonicator 3000‟s microprobe. For immuno-
precipitation, samples were diluted to 500 µl with IP buffer and incubated overnight with 
antibodies for specific covalent modifications of histones (see list below), followed by a 
3-4 hour incubation with Dynabeads protein G (Invitrogen) at 4 C. Cross-links were 
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reversed at 65 C overnight in elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 
1% SDS). DNA was purified with Zymo Research mini-spin columns; 2 µg herring 
sperm DNA was used as a carrier. Purified DNA was measured by qPCR using the same 
amplicons as in the DNase I hypersensitivity assay. The following antibodies were used: 
Anti H3 acetyl K9, K14, Upstate 06-599; Anti H4 acetyl K5, 8, 12, 16, Upstate 06-866; 
Anti H3 acetyl K9, Abcam ab4441; Anti H3 dimethyl K4, Abcam ab7766; Anti H3 
trimethyl K4, Abcam ab8580; Anti H3 dimethyl K9, Abcam ab1220; Anti H3 trimethyl 
K27, Active Motif 39535; Anti H3, Abcam ab1791; Anti H4, Abcam ab31827 
DNA methylation 
Genomic DNA (gDNA) was isolated using the DNA/RNA Micro Kit (Qiagen). 
Between 50 and 150 ng of gDNA were treated with sodium bisulfite using the EZ DNA 
Methylation-Direct Kit (Zymo Research, Orange, CA) to generate bisulfite-converted 
DNA (bcDNA). Specific primers were designed to the sense strand of the bcDNA 
sequence, within the HS1 and HS2 sites (see primer sequences below), and used for PCR 
amplification, with 2 µl of bcDNA as template, in a 30 µl reaction containing 3 µl of 10x 
PCR buffer (Qiagen), 1.8 µl of 25 mM MgCl2, 0.6 µl of 10 mM (each) dNTP, 0.6 µl of 
10 µM forward primer, 0.6 µl of 10 µM reverse primer, and 0.15 µl HotStarTaq Plus 
DNA Polymerase (Qiagen). One of the PCR primers was biotinylated to convert the PCR 
product to single-stranded DNA templates. For the HS1 amplicon, PCR cycling 
conditions were as follows: 95ºC for 15 min, 45 x (95ºC for 30 sec, 56ºC for 30 sec, 72ºC 
for 30 sec), then 72ºC for 5 min.  The HS2 amplicon used 61ºC for annealing.  
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Calculation of CpG methylation and verification of complete bisulfite conversion 
of template DNA was performed on the PCR product by EpigenDx (Worcester, MA) 
using the Pyrosequencing PSQ96 HS System (Qiagen) as per manufacturer‟s instructions. 
Pyrosequencing for allele quantification is a real-time, sequencing-based DNA analysis 
that quantifies multiple, and consecutive CpG sites individually. HS1 primers: Forward, 
GGTATATTTGAAAATTTTGGTAATAGT; Reverse, CAACAAATAAAAACCAAA-
ACTACACA. HS2 primers: Forward, GGTTTTTTGGTAGATAGGTTATATGTG; 
Reverse, AAAACTAAACACACCCACAAAATA. 
Cytospin preparation 
Fetal liver cells (freshly sorted, or after retroviral infection and incubation in Epo 
for 24-48 hours) were cytospun onto coated glass slides at 800 rpm for 5 minutes (Single 
Cytofunnel, Fisher Brand). The slides were air-dried, methanol fixed, stained with 
diaminobenzidine hydrochloride followed by Wright-Giemsa stain (Sigma). Digital 
images were taken with a Zeiss microscope using a SPOT Flex Camera (Diagnostic 
Instruments, Inc) and analyzed with version 4.5 Spot imaging software. 
Single cell PCR analysis 
S0 cells were individually sorted from fresh fetal liver directly into 96 well plates 
containing lysis buffer (0.4% NP-40, 25 µM DTT, 0.5 U RNase Out and 65 µM dNTPs). 
Reverse transcription was performed directly on cell lysates according to the 
manufacturer‟s instructions (Qiagen Sensiscript RT kit or Invitrogen SuperScript III First 
Strand Synthesis System kit). EpoR and β-actin were amplified from 2 µL of cDNA via 
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nested PCR. Each experiment included spleen cDNA (positive control), thigh muscle 
cDNA and no template (negative controls). The following primers were used: β-actin 
Forward, CTAGGCACCAGGGTGTGATGG; β-actin Reverse: TCTCTTTGATGTCAC-
GCACGA; EpoR Forward, AACTTCCAGCTGTGGCTGCTG; EpoR Reverse, CCTTG-
TCCCAGACTCAGAG; Nested PCR β-actin Forward, CGAGGCCCAGAGCAAGA-
GAG; Nested PCR β-actin Reverse, CGGTTGGCCTTAGGGTTCAG; Nested PCR 
EpoR Forward: CCTACTTGGTATTGG; Nested PCR EpoR Reverse: 
CCTCACCTTCCAGCTTTGAG 
Fluorescent in situ hybridization 
Cell preparation: BrdU pulse labeling was done in vivo by injecting pregnant 
females with BrdU intraperitoneally. Sorted S0 and S1 (0.5 to 1 x 106 cells for each) were 
washed twice in 5 ml cold PBS/2% sucrose, and fixed by adding 5 ml of cold 
Methanol/Acetic acid mixture (3:1) drop-wise, while vortexing. Cells were fixed for 10 
min at 4ºC, washed x3 in Methanol/ Acetic acid and stored at -20ºC until used for FISH. 
Alternatively, sorted S0 and S1 cells were suspended at 50,000 cells in 200 ml PBS/2% 
sucrose and cytospins prepared by spinning 5 min at 800 rpm, allowed to dry briefly (10-
20 seconds), and fixed in a 50 ml Falcon containing 20 ml Methanol/Acetic acid at 4ºC 
for 10 min; slides were poly-L lysine coated.  
Prior to FISH, fixed cells on slides were treated in 70% ethanol, subjected to 
pepsin digestion (0.01%) and post-fixed in 3.7% paraformaldehyde. Cells were 
dehydrated in successive 3 min washes of 70%, 90% and 100% ethanol and air-dried and 
used for probe hybridization on the same day.  
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Probe to the β-globin major gene was labeled with digoxigenin and resuspended 
in hybridization mix in the presence of tRNA and mouse COT DNA, used at 20 ng/l, 50 
l per slide. Hybridization was carried out in a humidified chamber at 37% overnight in 
hybridization mix containing 10 mg/ml sonicated Salmon Sperm DNA, 50% formamide, 
2X SSC, 50 mM sodium phosphate buffer and 10% dextran sulphate. Immunostaining 
was performed by labeling slides with sheep anti-digoxigenin (Roche, 1 333 089) 
followed by fluorescein-conjugated rabbit anti-sheep IgG (402104, EMD Bioscience, NJ, 
USA) and then FITC-conjugated goat anti-rabbit IgG together with mouse anti-BrdU IgG 
(M0744, Dako, CA, USA) followed by Texas Red-conjugated donkey anti-mouse IgG 
(Jackson immunoresearch). Nuclei were counterstained in DAPI and visualized using 
fluorescence microscopy.  
Quantitative western blot analysis 
Sorted cells from each fetal liver subset were lysed by rocking for 15 min at 4°C 
in lysis buffer (1% NP40, 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% 
glycerol supplemented with protease inhibitors); following centrifugation for 15 min at 
4°C, supernatant was quantified by the BCA Protein Assay Kit (Pierce). Lysates were 
analyzed on a 4-12% gradient polyacrylamide gel (Invitrogen), transferred to a 
nitrocellulose membrane, and probed with Rabbit polyclonal to beta actin (ab8227, 
Abcam), and with Mouse monoclonal to p57KIP2 (sc-56341, Santa Cruz) overnight at 4ºC. 
Membranes were probed simultaneously with anti-Rabbit IRDye 680 (red channel) and 
anti-Mouse-IRDye 800CW (green channel) and analyzed for both β-actin and p57KIP2 
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using the Odyssey infrared imaging system (LI-COR Biosciences). Target protein bands 
were quantified using the Odyssey software v3 (LI-COR). 
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Figure 2.1. Up-regulation of CD71 coincides with the onset of EpoR dependence and 
with S-phase of the last generation of CFU-e. 
A. Fetal liver subsets S0 to S5 form an erythroid developmental sequence. Freshly 
isolated E14.5 fetal liver was mechanically dissociated and labeled for cell-surface CD71 
and Ter119. Cytospin preparations from each subset (right panel) were stained with 
Giemsa and diaminobenzidine. Scale bar = 20 m  
 
B. CD71/Ter119 profiles for E12.5 EpoR-/- and wild-type littermate fetal livers. 
Erythroid differentiation of EpoR-/- cells is blocked at the transition from S0 to S1. 
Ter119+ cells in EpoR-/- liver are nucleated yolk-sac erythrocytes (Figure 2.S1A). 
Representative of more than four experiments.  
 
C. Erythroid and non-erythroid colony forming potential of fetal liver subsets. 
100,000 cells sorted from each of S0 to S3 were plated in methylcellulose in the presence 
of Epo, IL-3, SCF, and IL-6. Colonies were scored on days 3 (CFU-e) and 10 (CFU-
GM). Data are mean ± SE of three independent experiments. Pictures of colonies on day 
2 are shown (right panel, lens magnification x20 for all subsets). There was no 
statistically significant difference between S0 and S1 (p = 0.2, paired t test).  
 
D. Non-erythroid lineage-marker expression in S0 to S5. Wild-type or EpoR-/- 
fetal livers were labeled with CD71 and Ter119 to identify subsets S0 to S5, and with a 
cocktail of non erythroid lineage markers containing Mac-1, Gr-1, CD41, B220, and 
CD3, or with isotype control antibody. See also Figure 2.S1B.  
 
E. Representative cell cycle analysis for S0 to S5. Pregnant mice were injected 
with a pulse of BrdU, and fetal livers were harvested 30 to 50 min post-injection. Cells 
from each of subsets S0 to S5 were sorted by flow-cytometry and labeled for BrdU 
incorporation and DNA content (7AAD).  
 
F. Summary of six independent cell cycle analysis experiments as described in 
(E). Data are mean ± SE. The difference between the number of S-phase cells in S0 and 
S1 is significant at p<0.0001 (paired t test).  
 
G. Upper panel: Quantitative RT-PCR analysis of mRNA expression for cyclins 
A2, B1, E1, E2, D2, and for p57KIP2. Data (mean ± SE of three experiments) were 
normalized to β-actin mRNA in each sample and expressed as S1/S0 fold change (no 
change = 0). Fold changes are indicated. Lower panel: p57KIP2 protein in sorted S0, S1, 
and S2+3 subsets. Quantitative western blotting with antibodies directed at p57KIP2 and β-
actin; Near infra-red (NIR) fluorescence–conjugated secondary antibodies. S0 cell 
transduced with retroviral vector encoding either p57T329A-ICD4 or empty vector 
(MICD4) were harvested 24 h post-infection and used as positive and negative controls, 
respectively. 
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H. CFSE cell tracking of S0 cells as they transition into S1 and S2 in vitro. Sorted 
S0 cells were pulsed with CFSE and incubated in Epo for 18 h. The time points examined 
during in vitro incubation are indicated. Upper panel: CD71/Ter119 profiles. The S0 
(blue), S1 (red), and S2 (green) gates are indicated with the percentage of cells in each 
gate. Middle panel: Corresponding CFSE histograms for cells in each of the S0 (blue), S1 
(red), and S2 (green) subsets. Lower panel: Median fluorescence intensity of CSFE for 
the corresponding histograms and colors shown in the middle panel. Representative of 4 
similar experiments.  
 
I. Representation of the transition from S0 to S1. S0 contains several CFU-e 
generations. The last generation of CFU-e, noted as “CFU-e.2”, arises in S0 as an EpoR-
independent cell. The onset of EpoR dependence and up-regulation of CD71 ( = 
transition to S1) occur during S-phase of this cell generation. Up-regulation of Ter119 ( = 
transition into S2) occurs as the CFU-e.2 cell divides, giving rise to non-CFU-e progeny 
in S2. Other than the cell cycle corresponding to CFU-e.2, the timing of other cell cycles 
with respect to differentiation events is not known. See also Figure 2.S1.  
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Figure 2.2. The S0 to S1 transition requires S-phase progression.  
A. Design of experiments illustrated in sections (B–D). Flow-cytometrically 
sorted S0 cells were incubated in Epo for 20 h. In the first 10 h, cells were also in the 
presence or absence of a cell cycle blocking drug, either aphidicolin (Aphi) or mimosine 
(Mim). DMSO was added to control cells in the Aphi experiments. Aphi or Mim were 
removed by washing at t = 10 h. Cell cycle status and CD71/Ter119 expression were 
examined at 4, 10, and 20 h.  
 
B. CD71/Ter119 expression and BrdU/7AAD cell cycle profile of freshly sorted 
S0 cells at t = 0. Cells were incubated in the presence of BrdU for 30 min prior to 
fixation, permeabilization, and staining with antibodies for CD71, Ter119, and BrdU.  
 
C. CD71/Ter119 expression (left columns) and corresponding cell cycle profile of 
S0 and S1 cells (right columns) at the indicated time points. The presence or absence of 
Epo, Aphi, or Mim is indicated above each row of histograms. The indicated percentages 
correspond to the fraction of cells in S1 (left columns) or in S-phase of the cycle (right 
columns). Note that Ter119 signal is reduced in fixed and permeabilized cells compared 
with equivalent non-fixed cells (e.g., Figure 2.1H and Figure 2.S2A), since the Ter119 
epitope is partially detergent soluble. Data representative of five experiments.  
 
D. “Back-gating” analysis for CD71 expression of S0 cells that are either in G1 
(blue) or in S-phase (red), at t = 4 h in the presence of Epo+Mim. The same BrdU/7AAD 
profile as in section (C), row 4, t = 4 h. See also Figure 2.S2.  
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Figure 2.3. Block of S-phase progression at the S0 to S1 transition arrests the 
erythroid differentiation program.  
A. Expression of transcriptional regulators (upper panel) and erythroid-specific 
genes (lower panel) in sorted fetal liver subsets S0 to S3, in fetal brain, and in lineage 
marker-depleted EpoR-/- fetal liver. mRNA measured by quantitative RT-PCR, 
normalized to the β-actin mRNA, and expressed as a ratio to the S0 subset. Data are mean 
± SD of 2 (for EpoR-/- and brain) or 3 (for S0 to S3) independent experiments. 
 
 B, C. Effect of aphidicolin-mediated S-phase arrest on erythroid-specific gene 
expression. Sorted S0 (in B) or S1 (in C) cells were incubated in Epo, and in either 
aphidicolin (3 M) or DMSO, for the first 10 h. Aphidicolin and DMSO were removed 
by washing at t = 10 h. mRNA was measured by qRT-PCR, normalized to β-actin, and 
expressed as a ratio to mRNA at t = 10 h in Epo+DMSO. Duplicate independent 
experiments shown, fitted with exponential curves. Black curves are the calculated time 
course for a 10 h delay in induction for each gene, obtained by shifting the respective red 
curves (describing time course for Epo+DMSO) by 10 h.  
 
D. Effect of aphidicolin-mediated S-phase arrest on PU.1 and GATA-2. 
Experiment and mRNA measurement as described for (B), except that aphidicolin and/or 
DMSO were applied at t = 4 h and removed at t = 14 h. Data from two independent 
experiments. 
 
E. mRNA expression of transcriptional regulators GATA-1, GATA-2, and PU.1 
at the end of a 10 h incubation in Epo aphidicolin, compared with cells incubated in 
Epo+DMSO. Experimental design and mRNA measurement as described in section (D), 
with data pooled from nine independent experiments (each with a distinct symbol). Bar 
indicates position of mean. Differences between Epo+aphidicolin and Epo control 
samples are significant (paired two-tailed t test) for GATA-2 (p = 0.004) and for PU.1 (p 
= 0.002).  
 
F. Effect of aphidicolin or mimosine-mediated S-phase arrest on erythroblast 
morphology during differentiation of S0 cells in vitro. Sorted S0 were incubated in Epo, 
and for the first 10 h of incubation, also in the presence of either aphidicolin or mimosine. 
Control cells were incubated in Epo alone throughout. Cytospin preparations of cells at 
10 and 20 h of incubation are shown, stained with Giemsa. Morphological maturation 
(decreasing cell and nuclear size), compared with control cells, was arrested at t = 10 h, 
and remained delayed when the block to cell cycle progression was removed (t = 20 h).  
 
G. S-phase arrest by overexpression of a non-degradable mutant of p57KIP2 
(p57T329A). Sorted S0 cells were transduced with retroviral vector expressing 
p57T329A linked to IRES-hCD4 reporter, or with control vector (MICD4). Cells were 
cultured for 15 h in IL-3 and SCF and transferred to an Epo containing medium at t = 0, 
to allow their transition from S0 to S1. CD71/Ter119 profiles of infected, hCD4 positive 
S0 at t = 0 and t = 14 h (upper panels) and BrdU/7AAD cell cycle profiles (lower panels) 
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at t = 14 h are shown. Representative of 4 experiments. Transduction efficiency of 
p57KIP2 exceeded 90% in all experiments.  
 
H. Transcriptional regulators GATA-1, GATA-2, and PU.1 in cells expressing 
p57T329A. Experiment as described in (G). mRNAs measured by qRT-PCR following 
24 h of incubation in Epo, and expressed relative to cells transduced with control vector 
(MICD4) after normalization to β-actin. Duplicate independent experiments are shown.  
 
I. Representation of erythroid gene expression at the transition from S0 to S1. 
GATA-1 and other activators of the erythroid transcriptional program are induced at an 
unknown time preceding the S0/S1 boundary, and increase modestly with further 
differentiation. P57KIP2, PU.1, and GATA-2 are expressed in S0 and are markedly down-
regulated at the S0 to S1 transition. Erythroid specific Ter119, β-globin, ALAS2, and 
Band3 are induced subsequent to the S0/S1 boundary. S-phase arrest at this stage (dashed 
black line) results in arrest of all subsequent events, including PU.1 and GATA- 2 down-
regulation, CD71 and Ter119 expression, erythroid-specific gene induction, and 
morphological maturation. See also Figure 2.S3.  
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Figure 2.4. PU.1, but not GATA-2, inhibits the transition from S0 to S1.  
A–C. Effect of exogenous PU.1 on the transition from S0 to S1. Sorted S0 cells 
were transduced with retroviral vector expressing PU.1-IRES-hCD4 (PU.1-ICD4) or 
control vector (MICD4) and were incubated in IL-3 and SCF for 15 h before being 
transferred to Epo for 24 h.  
 
A. Expression profiles of the hCD4 reporter in cells transduced with either PU.1-
ICD4 or with control MICD4, at 24 h of Epo culture. Vertical, narrow gates each 
containing cells of relatively uniform hCD4 expression are shown and numbered (i to vii) 
and are used in the analysis shown in sections (B) and (C) below.  
 
B. CD71/Ter119 (upper panels) and cell cycle (lower panels) analysis of cells in 
individual hCD4 gates (ii) to (v), at t = 24 h. Higher hCD4 indicates higher PU.1 
expression in cells transduced with PU.1-ICD4.  
 
C. Summary of histogram data in (B), correlating cell cycle and differentiation 
data to hCD4 expression. Each data point corresponds to one of the hCD4 vertical gates 
marked in (A). Data are representative of five independent experiments.  
 
D. Linear correlation between PU.1 expression levels as measured by flow-
cytometry using a PU.1-specific antibody, and hCD4 levels, in cells transduced either 
with PU.1-ICD4 or with control MICD4. Summary of data shown in Figure 2.S4A, B. 
Data are representative of 2 independent experiments.  
 
E. Effect of exogenous GATA-1 or GATA-2 on S0 cell differentiation and cell 
cycle. Experimental design as in section (A–C). CD71/Ter119 and cell cycle profiles are 
shown for hCD4+ cells transduced with the indicated retrovirus. Flow-cytometric 
expression of retroviral constructs is shown in Figure 2.S4C.  
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Figure 2.5. The S0 to S1 transition coincides with an S-phase dependent switch in 
the state of chromatin at the β-globin locus. 
A. A map of the mouse β-globin locus. β-globin genes are indicated with 
horizontal arrowheads. Vertical arrows indicate DNase I hypersensitivity sites (HSs). 
Solid arrows for HS1 to HS4 indicate sites examined in experiments below. Expanded 
HS1 and HS2 sites show locations of CpG dinucleotides (labeled HS1A, B, C, and 
HS2A, B, C).  
 
B. FISH analysis of the timing of replication at the β-globin locus. Pregnant 
female mice were injected with BrdU 30 min prior to harvesting of fetal livers. Sorted S0 
and S1 cells were fixed and stained for BrdU (red) to identify S-phase cells. Cells were 
hybridized with a probe to the -major gene (green), and the number of hybridization 
spots in 100 BrdU-positive cells in consecutive fields for each of S0 or S1 were counted 
by fluorescence microscopy, in two independent experiments. Cells were scored as DD 
(two double dots, indicating both alleles have replicated), SD (one single and one double 
dot, indicating only one allele has replicated), or SS (two single dots, indicating neither 
allele has replicated). Examples of nuclei with each of the patterns are shown. 
  
C. DNase I sensitivity in S0 or S1 cells. Nuclei were prepared from sorted S0 and 
S1 cells and digested with increasing concentrations of DNase I for 10 min. DNA was 
extracted and quantitative PCR used to measure remaining DNA at each of HS2, HS3, 
and HS4 using 150 bp amplicons. DNA measurements were normalized to DNA 
amplified at the neuronal gene Nfm. Representative of three independent experiments. 
 
D. DNase I sensitivity of whole fetal liver from E12.5 EpoR-/- and littermate wild-
type controls. Method as in (C). Representative of three independent experiments.  
 
E. Effect of S-phase arrest on development of DNase I hypersensitivity. Sorted S0 
cells were incubated in Epo for 10 h to allow transition to S1, in the presence of 
aphidicolin (Aphi) or DMSO (control). Nuclei were prepared and DNase I sensitivity 
measured as described in (C). DNA in each sample was normalized to Nfm and 
expressed as a ratio of DNA in cells incubated in Epo+aphidicolin to DNA in cells 
incubated in Epo+DMSO. Individual data points are pooled from 3 independent sorting 
and digestion experiments; curves are fitted second order polynomials.  
 
F, G. ChIP-qPCR in sorted S0 and S1 cells and in fetal brain. ChIP was 
performed with the indicated antibodies and with control, isotype-matched antibody. 
qPCR was of 150 bp amplicons at the LCR HSs and at the β-actin and Nfm genes. Data 
are expressed as enrichment over input DNA in S1 relative to S0 (in F and in G, upper 
panel) or S0 relative to fetal brain (in G, lower panel). Each sample was normalized to β-
actin after subtraction of background (ChIP background was the signal with isotype 
control antibodies, which was, 10% of the signal obtained with specific antibodies).  
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F. Summary of seven independent ChIP-qPCR experiments. Data are means of at 
least 2 to 4 experiments for each antibody/amplicon combination (SE is provided when at 
least 3 experiments are averaged for a given antibody/amplicon). * indicates statistically 
significant difference between S0 and S1 at the HS2 site (p = 0.019 and 0.032 for 
H3K27me3 and H3K4me2, respectively). Changes in H3K27me3 and H3K4me2 over all 
HSs tested were significant at p = 0.011 and p = 0.0006, respectively (paired t test used 
for all significance tests). 
 
 G. Representative ChIP-qPCR experiment that included sorted S0, S1, and fetal 
brain. Data are mean ± SE of three replicates, expressed as a ratio of S1 to S0 (upper 
panel) and S0 to fetal brain (lower panel).  
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Figure 2.6. The transition from S0 to S1 is marked by the onset of S-phase 
dependent, DNA demethylation at HS1 and HS2.  
A. Methylation levels at each of the 6 CpG dinucleotides in HS1 (HS1A, B, C) 
and HS2 (HS2A, B, C; Figure 2.5A), in each of the indicated cell populations. 
Hematopoietic cells were sorted flow-cytometrically from freshly isolated fetal liver. 
Brain = fetal brain; LSK = Lin-Sca1+Kit+; Mac-1 = CD71lowTer119-Mac-1+; CD41 = 
CD71lowTer119-CD41+; EpoR-/- = Lin- cells from EpoR-/- fetal liver. Methylation levels 
were assessed following PCR-amplification of bisufite-converted genomic DNA at each 
of the HS1 and HS2 loci followed by pyrosequencing. Each data point is the mean ± SE 
of 2 to 4 independent sorting and pyrosequencing experiments.  
 
B. Arrest of S-phase progression by aphidicolin prevents DNA demethylation. 
Aphidicolin was added for 10 h at t = 0 (HS1A, B, C, and HS2C, left panel) or at t = 4 h 
(HS2A, B, right panel) to sorted S0 cells incubated in Epo for 48 (left panel) or 24 h 
(right panel). Control cells were incubated in Epo only. CpG methylation was measured 
at the indicated time points as described in (A). Data are from two independent 
experiments.  
 
C. Arrest of S-phase entry by mimosine prevents DNA demethylation. Sorted S0 
cells were incubated in Epo for 24 h, in the presence or absence of mimosine between t = 
4 and t = 14 h. CpG methylation was measured as described in (A). Data are mean ± SE 
of three independent sorting and pyrosequencing experiments.  
 
D. Preventing PU.1 down-regulation prevents DNA demethylation of HS1 and 
HS2 at the S0 to S1 transition. S0 cells were transduced with retroviral vectors expressing 
either PU.1-ICD4 or MICD4 as described in Figure 2.4A–C. CpG methylation levels 
were measured as described in (A) following 24 h incubation in Epo. Data are mean ± SE 
of three independent experiments (cells were transduced with PU.1-ICD4 at >90% 
efficiency in one experiment, and in two additional experiments hCD4+ cells were sorted 
before the start of Epo incubation).  
 
88 
 
 
 
  
89 
 
Figure 2.7. Regulatory events at the transition from S0 to S1.  
A. Multiple differentiation milestones coincide with early S-phase in the last 
CFU-e generation. Up-regulation of CD71 marks the transition from S0 to S1 in early S-
phase of this cell cycle. It coincides with the onset of Epo dependence, down-regulation 
of transcriptional suppressor PU.1 and CDKI p57KIP2, and reconfiguration of chromatin 
at the β-globin locus, including a switch in the timing of replication from late to early S-
phase and, within the LCR, the formation of DNase I hypersensitivity sites, the onset of 
DNA demethylation, and a loss of repressive histone marks from bivalent chromatin. The 
dashed black line marks the time at which inhibition of S-phase arrests PU.1 down-
regulation, CD71 up-regulation, and the switch in chromatin. Induction of erythroid 
transcriptional activators, including GATA-1, precedes this step. Erythroid specific genes 
including β-globin, Band3, and ALAS2 are induced subsequently. Up-regulation of 
Ter119 occurs approximately with entry into the next cell cycle.  
 
B. Causal relationships at the transition from S0 to S1. Red arrows mark novel 
causal relationships implicated in the transition from S0 to S1. Down-regulation of 
p57KIP2 is required for S-phase progression during the last CFU-e generation. Mutual 
antagonism between PU.1 and S-phase results in PU.1 down-regulation as cells progress 
into S-phase. Decreasing PU.1 allows for functional activation of GATA-1, which in turn 
represses GATA-2 and induces erythroid-specific genes such as β-globin. S-phase 
progression is also required for the formation of DNase I hypersensitive sites and for 
DNA demethylation bringing about a switch in chromatin conformation at the β-globin 
LCR and, together with Epo, for CD71 up-regulation.  
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Figure 2.S1. Supplemental data to Figure 2.1.  
A. Ter119+ cells in EpoR-/- fetal livers are nucleated erythrocytes of the yolk-sac 
(primitive) lineage. Cytospin preparations of sorted Ter119 + cells from fetal livers of 
EpoR-/- (E12.5) and wild-type littermate. Yolk-sac erythrocytes are fully hemoglobinized, 
large nucleated cells (arrow; see brown coloration of hemoglobinized cells stained with 
diaminobenzidine). Basophilic (blue cytoplasm) erythroblast precursors of the definitive 
lineage form the majority of Ter119+ cells in the wild type fetal liver but are absent from 
EpoR-/- fetal liver. Scale bar =20 .  
 
B. Distribution of cells expressing non-erythroid lineage markers within fetal 
liver. The fraction of cells expressing each indicated marker is shown for embryonic ages 
E12.5 to E14.5 in wild-type embryos, and for EpoR-/- embryos on E12.5. The same data 
are represented for each lineage marker either as a fraction of whole fetal liver (left 
panel) or as a fraction of S0 (right panel).  
 
C. The fraction of S0 cells expressing EpoR mRNA assessed by single cell RT-
PCR. Single cell RT-PCR was carried out on 324 individual S0 cells. An mRNA signal 
(either EpoR or β-actin or both) was obtained for 159 cells (49%). 68% of cells with a 
positive mRNA signal were positive for the EpoR mRNA. Single S0 cells were sorted by 
flow-cytometry into single wells of a 96-well plate. Following reverse transcription, two 
rounds of PCR amplification were used to detect EpoR and β-actin expression in 
individual cells. Shown are representative examples of RT-PCR for EpoR (top gel) and β-
actin (lower gel) for four individual cells (lanes 1 to 4). The cells in lanes 1 and 4 
expressed both EpoR and β-actin. Neither EpoR nor β-actin signals were obtained for the 
cell in lane 3. The cell in lane 2 expressed only β-actin. Control lanes are RT-PCR on 
spleen cells (positive control, “c1”), thigh muscle (negative control, “c2”), and no 
template (negative control, “c3”).  
 
D. BrdU incorporation rate (measured as median fluorescence intensity, MFI) in 
wild-type S1 is higher than in other fetal liver subsets, and higher than in EpoR-/- fetal 
liver (latter computed for the few cells within the S1 gate). Difference between wild-type 
S0 and S1 is significant at p<0.0001 (paired t test). Data are mean ± SE of 7 independent 
experiments.  
 
E. Left panels: EpoR does not regulate cell cycle status of erythroid progenitors. 
Representative CD71/Ter119 profiles (upper panels) and BrdU/7AAD (lower panel) for 
the S0 subset in EpoR-/- fetal liver and in wild-type littermates. The fractions (%) of S-
phase cells (lower panels) is indicated. Right panel: EpoR regulates survival of erythroid 
progenitors. “LIVE/ DEAD” profiles of the same EpoR-/- and wild-type littermate 
embryos. The LIVE/DEAD dye (Molecular Probes) stains apoptotic cells with impaired 
membrane permeability prior to fixation and permeabilization assays. The fractions (%) 
of apoptotic cells are indicated.  
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F. qRT-PCR analysis of mRNA expression for p27KIP1, p21CIP1, and p57KIP2 in 
sorted fetal liver subsets S0 to S3 cells. Data were normalized to the β-actin mRNA in 
each sample and expressed as a ratio to the S0 subset. Data are mean ± SD of three 
independent experiments.  
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Figure 2.S2. Supplemental data to Figure 2.2.  
A. S1 cells are sensitive to hydroxyurea (HU). S0 cells were sorted by 
flowcytometry (t= 0) and incubated in the presence or absence of Epo, and in the 
presence or absence of HU (5 mM), as indicated. Samples incubated in Epo alone up-
regulated CD71 and Ter119 sequentially (see t =15 h, t= 24 h). Up-regulation of CD71, 
but not Ter119, is Epo dependent (see „„no Epo‟‟ sample in which Epo was added at t= 
15 h). Cells incubated in Epo and HU did not upregulate CD71 or Ter119, consistent with 
the transition into S1 (CD71 up-regulation) being S-phase dependent. Cells incubated in 
Epo alone for 15 h had transitioned into S1 and began to transition into S2. If HU was 
added at this point (t= 15 h), nearly all S1 cells are lost (due to HU toxicity, unpublished 
data), but many cells in S0 and S2 persist. This suggests that essentially all S1 cells are in 
S-phase. 
 
B. Preventing CD71 up-regulation at the S0/S1 boundary does not interfere with 
the erythroid cell cycle. Sorted S0 cells were transduced with retroviral vectors 
containing an “IRES-GFP” reporter, expressing short hairpin RNA targeting CD71 
(CD71shRNA) or “empty vector” control (LMPv). Cells were then cultured for 24 h in 
the presence of Epo. Shown are the CD71/Ter119 profiles (top panels) and corresponding 
BrdU/ 7AAD cell cycle profiles of cells at t= 24 h. Only retrovirally infected cells are 
shown, identified by the expression of GFP. The fraction (%) of cells in each gate is 
indicated. Representative of three experiments.  
 
C. Cytospin preparations of cells in the experiment described in (B) at t= 24 h. 
Control cells, but not cells expressing shRNA to CD71, have started to express 
hemoglobin in their cytoplasm (brownish color, see arrow). Stained with Giemsa-
diaminobenzidine; scale bar is 20 .  
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Figure 2.S3. Supplemental data to Figure 2.3.  
A. Quantitative RT-PCR analysis of PU.1, Gata-2, and Gata-1 mRNAs in Mac-1+, 
S0, or S1 cells sorted from fetal liver. mRNAs were normalized to the β-actin mRNA in 
each sample. Data are mean ± SD of 2 independent experiments.  
 
B. Total RNA per cell in sorted fetal liver subsets. Total isolated RNA for each 
subset was measured using spectrophotometric optical density and divided by the number 
of sorted cells. Mean ± SE of five independent sort experiments. 
  
C. Flow-cytometry histograms of PU.1 protein levels in sorted fetal liver subsets 
S0 to S3. Fresh fetal liver cells were fixed, permeabilized, and stained for CD71, Ter119, 
and PU.1. Bar graph indicates the PU.1 median fluorescence intensity of each subset. 
Representative of 2 independent experiments.  
 
D. EpoR mRNA increases at the S0 to S1 transition. Results normalized to β-actin 
and expressed as a ratio to S0.  
 
E, F. Experimental design for (E) and (F): sorted S1 cells (t= 0 h) were incubated 
in Epo and in the presence or absence of aphidicolin, for 10 h. Cells were then washed 
free of aphidicolin and Epo incubation continued for a further 10 h. 
 
 E. Arrest of S-phase progression in S1 does not affect the mRNA expression of 
erythroid-specific genes, β-globin, Alas2, and Band3. mRNA was measured by qRT-
PCR, normalized to β-actin, and expressed as relative to mRNA at t= 0. Data are mean ± 
SE from 3 independent experiments.  
 
F. Arrest of S-phase progression in S1 does not affect expression of Ter119. 
CD71/Ter119 profiles showing that Ter119 was up-regulated between t= 0 and t= 10 h 
regardless of the presence of aphidicolin. The fraction (%) of cells in S1 (left gate) or S2 
(right gate) is indicated. Note that the larger cell size resulting from aphidicolin-mediated 
block of DNA replication (Figure 2.3F, main manuscript) is likely responsible for the 
higher Ter119 signal in the aphidicolin treated cells (cell surface Ter119 would be 
expected to increase in proportion to the square of the cell‟s radius). Ten hours following 
the release of the block, there is no significant difference in Ter119 expression between 
treated and untreated cell samples (t= 20 h).  
 
G. Effect of mimosine-mediated S-phase arrest on down-regulation of PU.1 and 
Gata-2 during the S0 to S1 transition. Experiment and mRNA measurement were as in 
Figure 2.3D, main manuscript, with the exception that mimosine was used in place of 
aphidicolin. Data are mean ± SE of three independent experiments.  
 
H. Effect of aphidicolin-mediated S-phase arrest on Lmo2 and Nfe2 mRNAs 
during the S0 to S1 transition. Experiment and mRNA measurements as in Figure 2.3B, 
main manuscript; mRNA levels are expressed as a ratio to mRNA at t= 10 h in the “Epo 
only” control. Data are from two independent experiments.  
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I. Erythroblast morphology of S0 cells transduced with p57T329A-ICD4 or with 
control vector MICD4 at t= 32 h of incubation in Epo. Experiment as described in Figure 
2.3G, main manuscript. Cytospins were stained with Giemsa-diaminobenzidine; scale 
bar= 20 .  
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Figure 2.S4. Supplemental data to Figure 2.4.  
A–B. PU.1 protein levels in cells transduced with PU.1-IRES-hCD4 is 
proportional to the level of the hCD4 reporter in the same cells. Please see also summary 
of these data in Figure 2.4D.  
 
A. Expression profiles of the hCD4 reporter in cells transduced with either PU.1- 
ICD4, or MICD4 control vector, or uninfected control cells, following 24 h of culture in 
Epo. Vertical, narrow gates each containing cells of relatively uniform hCD4 expression, 
numbered 1 to 4, are shown and are used in the analysis in sections (B) and in Figure 
2.4D.  
 
B. Flow-cytometry histograms of cells transduced with MICD4 control vector 
(top panels) or with PU.1-ICD4 (lower panels) for each individual hCD4 gate (numbered 
1 to 4), showing the percent of PU.1 positive cells. An overlay of the same flow 
cytometry histograms is shown on the right.  
 
C. Expression of GATA-1-IRES-hCD4 (GATA-1-ICD4), GATA-2-ICD4, and 
MICD4 at 24 h of Epo culture. The hCD4 + cell gate is indicated in black. Associated 
with Figure 2.4E in the main text.  
 
D. qRT-PCR analysis of Gata-1, Gata-2, and PU.1 mRNAs in S0 cells transduced 
with MICD4 control vector or gene-ICD4 at 24 h of Epo culture, as compared with 
endogenous levels in freshly sorted S0 and S1 subsets. mRNA was normalized to the β-
actin mRNA and expressed as a ratio to the S0 subset. Data are mean ± SD of 3 
independent experiments (the transduction efficiency was >90% for PU.1-ICD4 and 
>50% for Gata-1-ICD4 and Gata-2-ICD4).  
 
E. Preventing down-regulation of PU.1 does not halt down-regulation of p57KIP2 
mRNA. Quantitative RT-PCR analysis of p57KIP2 mRNA in S0 cells retrovirally 
transduced with PU.1-ICD4 or with control vector MICD4 as described in Figure 2.4A–
C, and incubated for 24 h in Epo. mRNA measurements from two independent 
experiments. In the first experiment, hCD4-positive cells were sorted by flow-cytometry 
at t= 0 (first experiment). In the second experiment transduction efficiency exceeded 
90%, as judged by hCD4 expression. mRNAs were also measured in freshly sorted S0 
and S1 subsets.  
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CHAPTER III 
Global DNA Demethylation During Erythropoiesis 
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Statement of Contribution 
I performed the work presented in Chapter 3 unless otherwise noted. Ramona Pop 
performed the work in Figure 3.11 and contributed to Figure 3.12A and 3.13A. Christoph 
Bock and Alexander Meissner performed the reduced representation bisulfite sequencing 
and analysis presented in Figure 3.5, 3.6A-C, 3.14, and 3.16C. Statistics in Figures 3.1, 
3.2, and 3.3 were performed with assistance from Stephen Baker. This chapter is an 
extended version of work that is currently under review with the following title and 
authors:  
Jeffrey R. Shearstone, Ramona Pop, Christoph Bock, Alexander Meissner, and 
Merav Socolovsky. “Global DNA Demethylation During Erythropoiesis In Vivo” 
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Abstract 
In the mammalian genome, 5‟-CpG-3‟ dinucleotides are frequently methylated, 
correlating with transcriptional silencing. Genome-wide waves of demethylation are 
thought to occur only twice during development, in primordial germ cells and in the pre-
implantation embryo [330]. They are followed by de novo methylation, setting up a 
pattern that is inherited throughout development. No global methylation changes are 
thought to occur during further somatic development, although methylation does alter at 
gene-specific loci, contributing to tissue-specific patterns of gene expression. Here we 
studied DNA methylation in differentiating mouse erythroblasts in vivo using several 
approaches including genomic-scale reduced representation bisulfite sequencing (RRBS). 
Surprisingly, demethylation at the erythroid-specific β-globin locus was coincident with a 
wave of global DNA demethylation at most genomic elements, including repetitive 
elements and genes silenced in erythropoiesis. Over 30% of total methylation is 
irreversibly lost during erythroid differentiation. Demethylation occurred through a 
passive mechanism, requiring the rapid DNA replication triggered with the onset of 
erythroid terminal differentiation. Global loss of DNA methylation was not associated 
with a global increase in transcription, as determined by GeneChip analysis. We propose 
that global demethylation is a consequence of cellular mechanisms required for the rapid 
demethylation and induction of β-globin and other erythroid genes. Our findings 
demonstrate that, contrary to previously held dogma, DNA demethylation can occur 
globally during somatic cell differentiation, providing a new experimental model for the 
study of global demethylation in development and disease. 
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Introduction 
Histones or DNA can be modified by the enzymatic addition of various chemical 
groups, resulting in recruitment or exclusion of associated proteins that have profound 
effects on local chromatin structure. Because these modifications fundamentally do not 
alter the DNA sequence and because they are mitotically and/or meiotically heritable, 
they have been termed „epigenetic‟ modifications. One such epigenetic mark, DNA 
methylation, is simply the presence of a methyl group on the 5‟-carbon ring of cytosine 
(5mC). In mammals, the vast majority of DNA methylation (>99%) is found to occur 
symmetrically at the dinucleotide palindrome cytosine-guanine (CpG) [1, 2]. DNA 
methylation leads to transcriptional inactivity and/or heterochromatin formation and 
plays an important role in X-chromosome inactivation, parental-specific silencing of 
imprinted genes, suppression of transposable elements, and silencing of gene-specific 
loci. 
The formation of enucleated red cells, a process known as definitive 
erythropoiesis, first occurs in the murine fetal liver between embryonic days 11 and 15 
(E11-E15), and is dependent on the hormone erythropoietin (Epo). The cell surface 
markers CD71 and Ter119 can be used to identify differentiation-stage-specific 
erythroblasts directly within freshly harvested mouse fetal liver [104, 105, 342]. With this 
approach the fetal liver can be divided into six subsets, S0 to S5, which form an erythroid 
developmental sequence (Figure 3.1A). Subsets S1 to S5 are composed entirely of 
erythroid cells. When plated in vitro, S1 cells differentiate into S5 cells within 48 hours, 
undergoing three cell divisions [105]. The S0 subset is composed largely (70%) of early 
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erythroid progenitors prior to the onset of Epo dependence, which can be further enriched 
(>95%) by excluding non-erythroid hematopoietic cells with lineage-specific cell surface 
markers [105]. Erythroid maturation is associated with decreasing cell size, nuclear 
condensation and positive staining for hemoglobin with diaminobenzidine.  
Proper establishment and maintenance of 5mC patterns are required for 
mammalian development and normal functioning of somatic cells. Methylation generally 
occurs at 70-80% of all CpG sites, a consistent finding across a wide-range of tissues. 
Importantly, despite tissue-specific alterations in DNA methylation within gene 
regulatory regions, the overall 5mC level has been thought to remain constant in all 
somatic cells. Physiological examples of genome-wide methylation loss have been 
limited to the pre-implantation embryo and primordial germ cells, where demethylation is 
thought to induce pluripotency related genes or reset parental imprints, respectively. 
Global DNA hypomethylation is also a well-documented feature of cancer that is thought 
to lead to genomic instability and aberrant gene activation. The mechanism and 
functional significance of global methylation loss remains largely unknown and is an area 
of intensive study. 
In Chapter II we demonstrated that the transition of erythroid progenitors from S0 
to S1 marks a key step in erythropoiesis that is coordinated with S-phase entry and 
requires DNA replication [105]. This transition comprises several rapid and synchronous 
commitment events that include the onset of Epo dependence, activation of the erythroid 
master transcriptional regulator GATA-1, and a switch in chromatin conformation at the 
locus control region (LCR) of the β-globin gene [105]. In this chapter, we report on a 
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completely unexpected finding that emerged while characterizing the S0 to S1 transition: 
DNA demethylation at the erythroid-specific β-globin locus is coincident with 
progressive and irreversible genome-wide methylation loss. We describe the magnitude, 
timing, and location of global demethylation during erythropoiesis, and provide evidence 
of its mechanism and functional significance. These findings demonstrate that DNA 
demethylation can occur globally during somatic cell differentiation, and establishes fetal 
liver erythropoiesis as a new experimental model for studying genome-wide methylation 
loss in development and in disease.  
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Results 
DNA methylation is lost at the β-globin LCR and at loci of genes silenced in 
erythropoiesis 
We examined DNA methylation at the β-globin LCR in freshly-sorted cells from 
subsets S0 to S4/5. Genomic DNA from each subset was subjected to bisulfite 
conversion, and methylation levels at each of 6 CpG dinucleotides in Hypersensitive 
Sites 1 and 2 (HS1, HS2) were measured by pyrosequencing of PCR products amplified 
from the HS1 and HS2 regions (Figure 2.6A, Figure 3.1B). All CpGs at HS1 and HS2 
were undergoing demethylation, beginning with the transition from S0 to S1 and 
continuing throughout erythroid maturation (Figure 2.6A, Figure 3.1B) [105]. LCR 
demethylation preceded induction of the β-globin gene (Figure 3.1B) and correlated with 
indicators of active chromatin at the LCR, including increased DNaseI hypersensitivity 
(Figure 2.5C), increased H3K4 methylation, and decreased H3K27 methylation (Figure 
2.5F, G) [105]. 
In parallel, we also examined the methylation status of genes whose expression 
declines during erythroid differentiation. We first investigated PU.1, a transcriptional 
repressor that stimulates self-renewal and prevents differentiation in erythroid progenitors 
[293, 314]. PU.1 mRNA declines dramatically (≈30-fold) at the S0 to S1 transition 
(Figure 2.3A) [105] and is undetectable in the S4/5 subset. DNA methylation around the 
PU.1 promoter was previously shown to correlate with silenced PU.1 expression [343, 
344]. Therefore, we hypothesized that methylation at this locus might increase during 
erythropoiesis. Surprisingly, each of the four CpG dinucleotides within the PU.1 
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promoter amplicon underwent significant and continuous demethylation as cells 
transitioned from S0 to S4/5 (Figure 3.1C, p<0.001). Using the average 5mC level of the 
amplicon, the PU.1 region underwent an absolute methylation loss of 24%, representing a 
50% reduction in the initial S0 methylation level. 
We similarly investigated the Fas gene, a pro-apoptotic cell surface receptor and 
known negative regulator of erythropoiesis, whose expression also declines with 
erythroid differentiation [104]. We found significant (p<0.001) and progressive 
demethylation at each of the 7 CpG dinucleotides within a regulatory region whose 
methylation was previously shown to correlate with silencing of Fas expression (Figure 
3.1D) [345]. This region underwent a locus average absolute methylation loss of 12%, 
representing a 19% reduction in the initial S0 methylation level. Data was not obtained 
for the S4/5 subset. 
DNA methylation is lost at differentially methylated regions of imprinted genes 
The unexpected results at the PU.1 and Fas loci suggested that there may be 
global loss of DNA methylation during erythropoiesis. To explore this possibility further, 
we examined the methylation status of a number of imprinted genes. In somatic cells, 
imprinted genes are predominantly expressed from one parental allele as a result of 
parental-allele-specific epigenetic modifications that include stable methylation of 
differentially methylated regions (DMRs) [13]. We assayed the H19 DMR, one of four 
DMRs that coordinate the paternal-specific expression of the Igf2 gene [57, 346]. We 
amplified bisulfite converted genomic DNA from S0 and from S4/5 subsets with gene-
specific primers in a region containing 10 CpG dinucleotides, ligated the PCR products 
107 
 
into a cloning vector and sequenced individual clones (Figure 3.2A, left panel). In the 
case of S0 cells, clones formed a bimodal distribution, with approximately half being 
fully methylated, and the other half almost completely unmethylated, a pattern consistent 
with imprinting. However, in the S4/5 subset all but one clone had at least one or more 
demethylated CpGs (Figure 3.2A, left panel); the average methylation level for all clones 
declined from 61% in S0 to 42% in S4/5 (p=0.007, two-tailed Mann-Whitney test). 
Pyrosequencing of the bulk PCR product for each erythroid subset at the H19 DMR was 
consistent with cloning results, showing a significant (p<0.001) and progressive decrease 
in the average locus methylation from 50% in S0 to 36% in S4/5 (Figure 3.2A, right 
panel), representing a 28% reduction in the initial S0 methylation level.  
The H19 DMR assay includes genomic regions that are binding sites for the 
enhancer-blocking protein CTCF [48, 57].  CTCF prevents expression of Igf2 by binding 
unmethylated DNA within the H19 DMR, thereby insulating the upstream Igf2 gene 
promoter from the effects of the downstream enhancer. Therefore, demethylation of the 
H19 DMR could potentially lead to CTCF binding on the active Igf2 allele and 
subsequent Igf2 repression. Consistent with this hypothesis, we found that Igf2 mRNA is 
down-regulated approximately 10-fold during differentiation from S0 to S3 using 
Affymetrix GeneChips (data not shown). However, the observed Igf2 repression could be 
due to another gene regulatory mechanism besides CTCF binding and this line of 
research was not pursued futher. 
We examined two additional imprinted loci by pyrosequencing and again found a 
significant and progressive loss of average DNA methylation at each locus, as well as at 
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individual CpG dinucleotides within each locus (Figure 3.2B, C) [347-349]. Paternally 
expressed gene 3 (Peg3) average locus methylation decreased from 43% in S0 to 36% in 
S4/5 (p<0.001), a 15% drop in initial S0 methylation level. Similarly, Kcnq1ot1 average 
locus methylation decreased from 44% to 37% (p<0.01). 
Global 5mC content is reduced during erythropoiesis 
Unexpected methylation loss within gene-specific regions is consistent with 
genome-wide demethylation during erythropoiesis. To support and extend these 
observations, we measured DNA methylation levels using three distinct assays of global 
5mC content. First, we examined 5 CpG dinucleotides within the 5‟ tandem repeat region 
of the long interspersed nuclear element (LINE-1) using bisulfite conversion with 
pyrosequencing [350]. LINE-1 are repetitive retrotransposon elements of variable lengths 
that are distributed at approximately 100,000 chromosomal sites in the mouse genome 
[351]. Additionally, LINE-1 regions are expected to be highly and stably methylated in 
order to silence retrotransposon activity [8]. These characteristics have made LINE-1 
regions a widely used surrogate marker for global DNA methylation [352-354]. As 
expected, LINE-1 regions were highly methylated in S0 cells, with a locus average 
methylation of 90% (Figure 3.3A). Following the transition from S0 to S1, methylation 
levels of the LINE-1 CpGs underwent a continuous decline, to a locus average of 70% in 
S4/5 (p<0.001), with a maximal decline for CpG2 from 91% in S0 to 65% in S4/5 
(p<0.001) (Figure 3.3A). On average the LINE-1 regions lost 22% of their initial S0 
methylation levels. 
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Second, we used the LUminometric Methylation Assay (LUMA) [355] (Figure 
3.3B) which compares genome-wide cleavage at CCpGG sites by each of the 
isoschizomers HpaII and MspI, which are methylation sensitive and insensitive, 
respectively [356]. The CCpGG site recurs approximately 2.5 x 106 times throughout the 
diploid mouse genome, making LUMA an appropriate measure of global DNA 
methylation [357]. Using LUMA, 70% of sites in S0 cells were methylated, a result 
consistent with the expected level of global methylation in somatic cells [36]. S0 cells 
underwent a global, progressive and significant (p<0.001) loss of DNA methylation upon 
differentiation, reaching a methylation level 50% in S4/5 cells (Figure 3.3B).  
Finally, we measured binding of a 5-methylcytosine-specific antibody to genomic 
DNA purified from S0, S1 and S3 cells, using an Enzyme-Linked Immunosorbent Assay 
(ELISA) (Figure 3.3C). We found 70% of CpG dinucleotides in S0 cells were methylated 
using the ELISA, a finding consistent with the results from LUMA. This approach also 
showed a global, progressive and significant (p<0.01) loss of DNA methylation with 
erythroid differentiation (Figure 3.3C).  
Global demethylation begins at the S0 to S1 transition, is a general feature of 
erythropoiesis, and persists in extruded nuclei.  
We used LINE-1 regions to assess the global methylation levels of other cell 
types within the fetal liver. We isolated Lin-Sca1+cKit+ (LSK) cells, a population of cells 
that are at an earlier developmental stage than S0 erythroid progenitors. LSK cells 
contain early hematopoietic progenitors (including short and long-term hematopoietic 
stem cells and hematopoietic progenitors) and the common myeloid and lymphoid 
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progenitors (CMP and LMP). We also isolated differentiated cells from other 
hematopoietic lineages; Mac1+ cells, composed of granulocytes and macrophages, and 
CD41+ cells, mostly composed of megakaryocytes. Finally, to determine if global 
methylation loss is dependent on EpoR signaling, we isolated erythroid progenitors from 
EpoR-/- fetal livers. LSK, CD41+, Mac1+ and EpoR-/- cells each contained a high level of 
DNA methylation, equivalent to the level found in S0 cells (Figure 3.4A). These data 
suggest that global demethylation is a unique property of the erythroid lineage that begins 
specifically at the EpoR-dependent transition from S0 to S1.  
Next, we characterized methylation levels in primitive erythroid cells in the 
embryo and definitive erythroid cells of adult bone marrow. In mouse, primitive 
erythropoiesis occurs in the yolk sac at embryonic day 7.5 (E7.5), lasts only a few days, 
and results in nucleated erythrocytes. We isolated nucleated primitive erythrocytes from 
the circulation of E13.5 embryos and found that they possessed methylation levels even 
lower than that of S4/5 cells (Figure 3.4A). Near the time of birth, the site of definitive 
erythropoiesis moves from the fetal liver to the bone marrow, where it persists throughout 
life. We sorted increasingly differentiated erythroblasts from adult bone marrow and 
found progressive hypomethylation (Figure 3.4B). ProE and EryB/C populations had 
methylation levels that were equivalent to their S2 and S4/5 fetal liver counterparts, 
respectively. Together, these findings suggest that global demethylation is a general 
feature of erythropoiesis, neither limited to the definitive lineage nor the fetal liver. 
Definitive erythroblasts enucleate by nuclear extrusion, generating reticulocytes 
and small, nucleated cells with a thin rim of cytoplasm, known as pyrenocytes, which are 
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eventually phagocytosed by macrophages. Pyrenocytes, like S5 cells, have exited the cell 
cycle (Figure 2.1E). We sorted these extruded nuclei by flow cytometry and determined 
LINE-1 methylation levels (Figure 3.4A). We found that pyrenocytes had methylation 
levels equivalent to S4/5 cells. This result suggests that global demethylation in vivo is an 
irreversible process that persists even after cell cycle exit and enucleation.  
Genome-wide reduced representation bisulfite sequencing of erythroid subsets  
To fully characterize DNA methylation changes during erythroid differentiation 
on a genomic scale, we used reduced representation bisulfite sequencing (RRBS) [42]. In 
this method, genomic DNA is digested by MspI, 40-220 bp fragments are selected for 
bisulfite conversion, and converted fragments are sequenced from each end. RRBS 
provides methylation data for approximately 1 million distinct CpGs, or in other words, 
5% of all CpGs in the mouse genome. CpG coverage is not distributed evenly. For 
example, RRBS covers 70% of all promoter regions, 30-80% of CpG islands (depending 
on island definition), 25% of island shores, 25% of enhancers, and 30% of all 5 kb 
sliding, non-overlapping windows [358].  
We performed RRBS for each of the sorted erythroblast subsets S0, S1, S3 and 
S4/5 in biological duplicate (Figure 3.5A). In the shown scatterplots (Figure 3.5A) data 
points represent 5 kb non-overlapping tiles with sufficient sequencing coverage, i.e. at 
least 5 CpGs, each with at least 5 sequencing reads. The coordinates for each data point 
are the mean methylation level for each such tile, in each of subsets S1 to S4/5 in turn, 
plotted against the mean methylation level of the same 5 kb tile in the least mature, S0 
subset. The gradual fall of nearly all data points away from the middle diagonal with 
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increasing erythroid maturation indicates a progressive and orderly loss of DNA 
methylation. Overall, the median methylation level genome-wide in S0 cells is 79%, 
falling to 55% in the most mature, S4/5 subset, just prior to erythroblast enucleation 
(Figure 3.5B). Therefore, erythroblasts lose 30% of their initial S0 methylation during 
differentiation. 
Next, each 5 kb window was classified, using statistical analysis of sample 
replicates and the individual CpGs within each window, as either hyper- or hypo-
methylated in a comparison of S0 to each of S1, S3, and S4/5 subsets. A 5 kb window 
was designated “no change” if the false discovery rate (FDR) >0.1; „hypomethylated‟ if 
FDR <0.1, p <0.001, and methylation change >20%; „hypomethylated (weak)‟ if FDR 
<0.1, methylation change >0% and not „hypomethylated‟ as defined above. 
„Hypermethylation‟ criteria were defined similarly, but with the methylation change in 
the opposite direction. By these criteria, less than 0.05% of the 62,844 unique 5 kb 
windows became hyper or weakly hyper-methylated during erythroid differentiation into 
S4/5 cells (Figure 3.5C, D). In contrast, 67% of 5 kb windows became hypo- or weakly 
hypo-methylated (Figure 3.5C), indicating that the majority of the genome undergoes 
some significant methylation loss. 
Further RRBS analysis revealed that the loss of DNA methylation takes place 
across a broad range of genomic elements. Methylation losses were observed at 
retrotransposable elements, including LINEs, short interspersed nuclear elements 
(SINEs), and long terminal repeats (LTRs) (Figure 3.6A); at CpG islands, defined by the 
Gardiner-Garden criteria [41] (Figure 3.6B); at island shores, defined as 2-kb genomic 
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regions that are directly adjacent to bona fide CpG islands (Figure 3.6B) [359]; at 
enhancers, defined based on histone H3K4 dimethylation peaks (Figure 3.6B) [42, 358]; 
and at imprinted regions manually curated from the literature (Figure 3.6B) [358]. The 
largest losses in DNA methylation are in regions whose initial methylation level in S0 is 
high. This includes promoters with low CpG frequency (<1%) (Figure 3.6C). Conversely, 
promoters with high CpG frequency (>2%), having lower initial methylation levels in S0, 
show a smaller methylation loss (Figure 3.6C).  
The fractional loss across most genomic elements is similar; all elements lose 
25%-30% of their initial S0 methylation level by the time cells have differentiated into 
mature S4/5 erythroblasts (Figure 3.6D). The principal exception to this is imprinted 
regions, where the median loss is 14% of the initial methylation in S0 (Figure 3.6D). All 
of the RRBS data, including genome browser tracks with genomic locations, has been 
placed on a supplementary website, http://erythrocyte-demethylation.computational-
epigenetics.org.  
Genome-wide and β-globin LCR demethylation are linearly correlated but occur at 
different rates 
β-globin LCR and genome-wide demethylation are initiated at the transition from 
S0 to S1 and continue throughout erythroid differentiation (Figure 2.6A and Figure 3.4A, 
respectively). These similarities prompted us to investigate the relationship between 
gene-specific and global demethylation events. We found a linear correlation throughout 
erythroid maturation between DNA methylation levels at the β-globin LCR and 
methylation levels of various genomic regions, including LUMA (R2=0.95), the 
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pyrosequencing assays for LINE-1 (R2=0.97), H19 DMR (R2=0.98), or PU.1 (R2=0.94), 
as well as the RRBS measurements at enhancers (R2=0.98), CpG islands (R2=0.96), 
imprinted genes (R2=0.60), and 5 kb windows (R2=0.98) (Figure 3.7). Therefore, the 
fraction of total methylation loss that occurs at a given differentiation stage is similar for 
all loci. These strong linear correlations suggest that a common mechanism is responsible 
for demethylation at both erythroid-specific genes and genome-wide loci.  
The slopes of the various regression lines suggest that the rate of demethylation at 
nearly all global sites is only 30-50% of the rate at the β-globin LCR (Figure 3.7). This 
result is consistent with the observation that the β-globin LCR loses 65-80% of initial S0 
methylation during differentiation to S4/5, while genome-wide levels are reduced by only 
30% (Figure 3.6D). Therefore, while genome-wide and erythroid-specific demethylation 
might be driven by a single mechanism, methylation loss is significantly enhanced at the 
β-globin LCR.  
Genes implicated in active and passive demethylation are differentially regulated 
during erythropoiesis 
We examined whether regulators of DNA methylation were altered in the course 
of erythroid differentiation. Expression of the maintenance methyltransferase Dnmt1 
appeared unaltered at the mRNA and protein levels throughout differentiation (Figure 
3.8A, B). Its interacting partner Uhrf1, which targets Dnmt1 to hemi-methylated DNA, 
was also unchanged at the mRNA level (Figure 3.8A) [111, 112, 360]. By contrast, the de 
novo methyltransferases Dnmt3a and Dnmt3b, which may also contribute to maintenance 
methylation, were down-regulated 10- and 100-fold at the mRNA level, respectively, 
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with the progression from S0 to S3 (Figure 3.8A) [135]. Dnmt3a and 3b mRNA was 
undetectable in the S4/5 subsets and the mRNA for their interacting co-factor, Dnmt3L, 
was not detected in any erythroid subset. Dnmt3a and 3b protein decreased during the S0 
to S1 transition and became virtually undetectable in the S3 subset (Figure 3.8B).  
We also investigated regulators recently implicated in active demethylation [163, 
173-175]. Transcripts for Apobec1, a cytidine deaminase, and Tdg, a T/G glycosylase, 
were present in erythroid cells, but not significantly up-regulated upon differentiation 
(Figure 3.8A). Aicda, another cytidine deaminase, was not detected in any erythroid 
subset. The T/G glycosylase Mbd4 showed a modest, but significant, 2-fold up-regulation 
during erythroid differentiation. Gadd45a, implicated in NER and BER-mediated 
demethylation, was progressively and significantly up-regulated during differentiation, 
reaching a 15-fold greater mRNA abundance in the S3 subset (Figure 3.8A). 
Sustained expression of Dnmt3a or Dnmt3b does not prevent DNA demethylation 
Down-regulation of Dnmt3a and Dnmt3b during differentiation may have 
contributed to global demethylation. We examined the effect of exogenous expression of 
these enzymes in differentiating erythroblasts in vitro. Erythroid differentiation may be 
reproduced in vitro by culturing freshly sorted S0 cells in the presence of Epo; the cells 
transition into S1 within 10 to 15 hours and continue differentiating for 48-72 hours. 
Dnmt3a, Dnmt3b, or the catalytically inactive mutant Dnmt3b1:PC (courtesy of En Li, 
Novartis) [16] were subcloned into a bicistronic retroviral vector where the gene of 
interest is linked through an internal ribosomal entry site (IRES) to green fluorescent 
protein (GFP). Sorted S0 cells were infected for 16 hours in the presence of interleukin-3 
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(IL3) and stem cell factor (SCF) to allow time for retroviral construct expression. IL3 and 
SCF sustain viability of S0 progenitors, but they do not support erythroid differentiation 
(Figure 3.9A). At 16 hours, cells were shifted to medium containing erythropoietin (Epo) 
and allowed to differentiate for 24 hours, at which point GFP-positive cells were sorted 
and assessed for methylation status of LINE-1 and the β-globin LCR loci. Retroviral 
supernatants of the empty vector or Dnmt3a showed high transduction efficiency relative 
to Dnmt3b1 supernatants. Therefore, sorting experiments were done with supernatant 
dilutions of 1:200 for the empty vector and 1:25 for Dnmt3a in order to obtain equivalent 
levels of GFP expression to cells transduced with Dnmt3b1 (Figure 3.9A). 
Cells infected with exogenous Dnmt3a or Dnmt3b1 expressed the respective 
mRNA in all subsets at a constant level, while in the empty vector control Dnmt3 
expression decreased 10-fold during differentiation (Figure 3.9B). Therefore, retroviral 
transduction prevented differentiation-induced down-regulation of Dnmt3a and Dnmt3b 
transcripts. However, exogenous expression of Dnmt3a or Dnmt3b1 did not prevent 
demethylation at global LINE-1 regions (Figure 3.9C). Similarly, exogenous expression 
of Dnmt3a did not prevent demethylation at the β-globin LCR (Figure 3.9C). Exogenous 
expression of Dnmt3b1 led to small but significant elevation in β-globin LCR 
methylation in the S3 subset (Figure 3.9C). However, this observation is not the result of 
DNA methyltransferase activity, since the catalytically inactive Dnmt3b1:PC mutant had 
the same effect (Figure 3.9C).  
Unexpectedly, we noted that ectopic expression of Dnmt3b1, but not DNMT3a, 
had an inhibitory effect on erythroid differentiation. After 24 hours in Epo, approximately 
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50% of empty vector control or Dnmt3a-expressing cells had differentiated into S3 cells. 
In contrast, only 30% of Dnmt3b1 expressing cells had become S3 cells (Figure 3.9D). 
This effect was not dependent on DNA methylation activity as it was also observed in 
cultures expressing Dnmt3b1:PC (Figure 3.9D). Back-gating analysis demonstrates that 
GFP positive S3 cells from Dnmt3b1-tranduced cultures have a significantly higher 
number of DAPI (4',6-diamidino-2-phenylindole) positive cells as compared to Dnmt3a-
expressing or empty vector control cells (Figure 3.9E). This finding suggests that 
sustained expression of Dnmt3b1 in differentiating erythroblasts leads to cell death.  
Suppression of Gadd45a or Mbd4 does not prevent DNA demethylation 
Up-regulation of Gadd45a or Mbd4 during differentiation may have contributed 
to global demethylation. We therefore examined the effect of blocking expression of 
these transcripts using retroviral short hairpin RNAs (shRNA) using an experimental 
design similar to that used for the Dnmt3 exogenous expression experiments described 
above. We transduced fresh S0 cells with a non-silencing control shRNA or shRNAs 
directed at Gadd45a or Mbd4 for 16 hours in the presence of SCF and IL-3. Cells were 
then cultured for 24 hours in the presence of Epo, followed by sorting of the GFP 
positive, Ter119+ population (Ter119+ =combined S1, S2, and S3 sorting gate). The 
infection rate using shRNA retrovirus was nearly 100% at 16 hours (data not shown). 
After 24 hours in Epo, Gadd45a was induced 30-fold in Ter119+ cells expressing 
the non-silencing control hairpin (Figure 3.10A). In contrast, Gadd45a remained 
unchanged, or was even further suppressed, during differentiation in cells expressing 
shRNAs directed against Gadd45a (Figure 3.10A). Similarly, Mbd4 shRNA prevented 
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the mild 2-fold induction of Mbd4 upon differentiation and further reduced Mbd4 mRNA 
to only 2% of its S0 expression level (Figure 3.10A). Preventing Gadd45a or Mbd4 
expression had no obvious effect on erythroid differentiation as judged by cell surface 
markers Ter119 and CD71 (data not shown). Knockdown of Gadd45a and Mbd4 did not 
prevent 5mC loss at LINE-1 regions or the β-globin LCR (Figure 3.10B). These findings 
suggest that Mbd4 and Gadd45a are not involved in erythroid DNA demethylation.  
The rate of DNA replication and fraction of S-phase cells increases during 
erythropoiesis 
We recently found that the onset of erythroid differentiation at the transition from 
S0 to S1 occurs during S-phase of a developmentally-specific cell cycle, and that 
essentially all S1 cells are in S-phase (Figure 3.11A, B) [105]. Further, when subjecting 
fetal livers to a brief pulse of the nucleotide analogue bromodeoxyuridine (BrdU) in vivo, 
S-phase cells at the onset of differentiation in S1 and S2 incorporate 50% more BrdU 
than S-phase cells in previous cycles in S0 (Figure 3.11A, C) [105]. Importantly, this 
increased BrdU incorporation is indicative of a higher rate of DNA synthesis [361, 362]. 
DNA replication rate remains slightly elevated in S3 cells relative to S0, and by S4/5 
cells have exited the cell cycle just prior to enucleation (Figure 3.11). These alterations in 
DNA replication rate and proportion of S-phase cells during the S0 to S1 transition 
coincide with the initiation of DNA demethylation, suggesting a potential role for DNA 
replication in the global and gene-specific loss of 5mC observed during erythropoiesis. 
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DNA demethylation is prevented by arresting the cell cycle with mimosine 
To investigate the potential role of DNA replication in demethylation, we sorted 
fresh S0 cells and incubated them in the presence of mimosine, a plant amino acid that 
blocks cell cycle progression in late G1 [305]. S0 cells cultured in Epo undergo gradual 
demethylation at the β-globin LCR and LINE-1 regions (Figure 3.12A, black circles, t=0 
to 24 h). The addition of 1 mM mimosine for 10 hours prevented methylation loss at 
these loci (Figure 3.12A, red circles, t=4 to 14 h). Demethylation resumed once mimosine 
was removed (Figure 3.12A, red circles, t=14 to 24 h). We performed additional 
experiments with sorted S0 cells cultured in Epo only or Epo plus mimosine for 16 hours, 
allowing more time for demethylation. The presence of mimosine, and subsequent G1 
arrest (Figure 3.12B), prevented methylation loss at the β-globin LCR, LINE-1, PU.1, 
and H19 DMR loci (Figure 3.12C). We previously have shown that the erythroid 
differentiation program also requires DNA replication at the S0 to S1 transition [105]. 
Therefore, while these results suggest a DNA replication-dependent, passive 
demethylation mechanism, the possibility remains that blocking DNA replication in S0 
cells is simply preventing the initiation of an active demethylation mechanism linked to 
the erythroid differentiation program. 
DNA demethylation requires rapid DNA replication 
We examined the potential role of DNA replication in demethylation using 
aphidicolin, an inhibitor of DNA polymerase α that arrests S-phase progression [304]. 
Freshly sorted S0 cells cultured in Epo undergo gradual demethylation at the β-globin 
LCR and LINE-1 regions (Figure 3.13A, black circles, t=0 to 46 h). The addition of 3 μM 
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aphidicolin prevented methylation loss at these loci (Figure 3.13A, red circles, t=0 to 10 
h) and demethylation resumed once aphidicolin was removed (Figure 3.13A, red circles, 
t=10 to 46 h). These results were consistent with similar experiments using mimosine, 
suggesting that DNA replication is a prerequisite for 5mC loss. 
We tested this possibility further by slowing down the rate of DNA replication 
with aphidicolin in different erythroid subsets. We incubated sorted S0, S1, or S2 cells in 
Epo or Epo plus a range of aphidicolin concentrations for 16 hours. DNA replication rate 
was assessed by the amount of BrdU incorporated into cells during a brief, 30 minute 
pulse at the end of the incubation period (Figure 3.13B). The presence of „high‟ dose (1 
μM) aphidicolin dramatically reduced the DNA replication rate (i.e. BrdU MFI of S-
phase cells) in cultured S0 and S1 cells, and completely blocked DNA replication in S2 
cells cultured for 16 hours (Figure 3.13B). High dose aphidicolin fully prevented 
methylation loss at the β-globin LCR, LINE-1, PU.1, and H19 DMR loci in all cultured 
subsets (Figure 3.13C), demonstrating that demethylation is dependent on DNA 
replication throughout erythroid differentiation.  
We also noted that blocking DNA replication for 16 hours in each subset not only 
prevented global demethylation, but actually led to a higher methylation level than found 
in the freshly sorted (t=0 h) controls (Figure 3.13C). For example, S1 cells cultured with 
high dose aphidicolin for 16 hours have a LINE-1 methylation level that is not only 
greater than freshly sorted S1 cells, but also reach a 5mC level almost equivalent to 
freshly sorted S0 cells (Figure 3.13C). In contrast to global regions, demethylation at the 
β-globin LCR appeared to be irreversible (Figure 3.13C), possibly the result of 
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transcription factor binding and exclusion of Dnmt1. Therefore, blocking DNA 
replication allowed cells to recover global methylation that was lost during earlier stages 
of differentiation. This finding suggests that Dnmt1 is capable of restoring lost DNA 
methylation when DNA synthesis is blocked and, because Dnmt1 has limited de novo 
methylation activity, also suggests that methylation loss proceeds through a hemi-
methylated intermediate. 
In contrast, the presence of „low‟ dose (0.1 μM) aphidicolin did not substantially 
change the number of cells in S-phase, but it did slow down their rate of S-phase BrdU 
incorporation (Figure 3.13B). For example, in cultured S1 cells the proportion of S-phase 
cells was 74% both in the absence or presence of low dose aphidicolin, yet the DNA 
synthesis rate, as determined by S-phase BrdU MFI, was reduced from 3000 to 1800 
relative fluorescence units (RFU) (Figure 3.13B). This slower DNA synthesis rate was 
sufficient to completely eliminate demethylation at the LINE-1, PU.1, and H19 DMR loci 
and partially reduce the loss of methylation at the β-globin LCR in all cultured subsets 
(Figure 3.13C).  
The sensitivity of the demethylation process to DNA synthesis rate was also seen 
by genomic-scale RRBS, where freshly sorted S1 cells that were allowed to differentiate 
in 0.1 μM aphidicolin for 24 hours were protected from genome-wide demethylation 
(Figure 3.14A). Low dose aphidicolin prevented demethylation at various types of 
genomic regions, including the retroviral SINEs and LINEs, CpG islands, enhancers and 
imprinted genes (Figure 3.14D). Treatment of S1 cells with low dose aphidicolin for 24 
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hours does not alter the number of cells in S-phase, but does reduce the DNA synthesis 
rate, as measured by BrdU incorporation by roughly 50% (Figure 3.17A).  
The observed delay in DNA demethylation resulting from aphidicolin treatment 
might simply be a reflection of higher methylation levels in regions that had not 
replicated in the 24 h culture period. In other words, many regions may not have had an 
opportunity to demethylate because aphidicolin delayed the replication fork passage 
through these regions. If this were the case, then we would expect to see a reduction in 
methylation within the regions that had replicated, even in the presence of low dose 
aphidicolin. Instead, the RRBS of 5 kb windows, which contain regions replicating at all 
different times throughout S-phase, argues against this possibility since low dose 
aphidicolin was able to block the vast majority of methylation loss (Figure 3.14A, B). 
Collectively, these results demonstrate that DNA replication is required for global 
and gene-specific methylation loss at all stages of erythropoiesis. Furthermore, the lack of 
demethylation in S-phase arrested subsets strongly suggests that an active demethylation 
mechanism is not involved. Therefore, we conclude that demethylation is the result of a 
passive mechanism. Importantly, slowing the rate of DNA synthesis is sufficient to 
prevent global demethylation. This observation suggests that the elevated rate of DNA 
replication induced during the transition from S0 to S1 contributes to inadequate 
maintenance methylation. 
Demethylation is accelerated by inefficient knockdown of Dnmt1 
We attempted to prevent demethylation by retroviral overexpression of Dnmt1 
(courtesy of En Li, Novartis), using an experimental design identical to that described for 
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Dnmt3 (Figure 3.9). Viral supernatant containing Dnmt1-IRES-GFP was used to infect 
sorted S0 cells for 16 hours prior to Epo-induced differentiation for 24 hours. Preliminary 
experiments showed virtually no GFP expression at 40 hours. We attributed this to the 
large, 4.9 kb, size of the Dnmt1 coding region, which when subcloned into the expression 
construct yields a transcript that is 8.5 kb. Since the packaging limit of this virus is 8.3 
kb, poor infectivity is likely due to inefficient viral packaging of our Dnmt1 construct. 
We were able to marginally improve infectivity by concentrating the viral supernatant, 
resulting in differentiated S3 cells expressing low levels of GFP. However, Dnmt1 
mRNA was not increased in these cells compared to control.  
  Next we attempted to knockdown (KD) Dnmt1 using retrovirally expressed 
shRNA linked by IRES to a GFP reporter. We transduced fresh S0 cells with a non-
silencing control shRNA or shRNA directed at Dnmt1 for 16 hours in the presence of 
SCF and IL-3 to allow time for shRNA expression. The infection rate was nearly 100% at 
16 hours (data not shown). Cells were shifted to differentiation media containing Epo for 
24 hours and then harvested, without sorting, for subsequent mRNA and protein analysis. 
Dnmt1 mRNA was reduced 50% after 16 hours of culture and at 40 hours an 80% 
reduction was observed (Figure 3.15A, left panel). Surprisingly, Dnmt1 protein was 
lowered only 27% after 16 hours of culture and by 40 hours this knockdown was 
neutralized (Figure 3.15A, right panel). This result suggests that Dnmt1 protein in 
erythroid cells is only partially controlled by mRNA abundance and post-transcriptional 
mechanisms act to keep Dnmt1 protein levels constant.  
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 If Dnmt1 is in excess in the nucleus, then the incomplete and transient knockdown 
observed above would be expected to have no impact on methylation levels. Therefore, 
we examined the effect of Dnmt1 KD on DNA methylation levels in sorted cells. As 
above, S0 cells were cultured with shRNA viral supernatants for 16 hours in IL-3 and 
SCF. Cells were then shifted to differentiation media containing Epo or Epo plus low 
dose aphidicolin for an additional 24 hours. After differentiation, GFP positive cells from 
S1 and S3 gates were sorted and analyzed. Dnmt1 mRNA showed a 70% reduction after 
16 hours of culture and by 40 hours an 85% reduction was observed in differentiated S1 
and S3 subsets (Figure 3.15B, upper panel), consistent with our previous results in 
unsorted cells (Figure 3.15A, left panel). Dnmt1 KD did not lead to substantial 
methylation loss in non-differentiating S0 cells at 16 hours (Figure 3.15B, lower panel), 
even though Dnmt1 protein abundance is reduced at this time (Figure 3.15A, left panel). 
This finding suggests that prior to differentiation, a time when DNA replication rate is 
comparatively low (Figure 3.11A), Dnmt1 protein is present in relative excess (Figure 
3.15A). 
 In contrast, KD of Dnmt1 in differentiated S1 and S3 cells, which have an 
elevated DNA synthesis rate (Figure 3.11A), caused accelerated demethylation at the β-
globin LCR and LINE-1 regions (Figure 3.15B, lower panel). This finding suggests that 
Dnmt1 availability during differentiation is limited, since even a slight deficiency (<27% 
reduction, Figure 3.15A) negatively affected DNA methylation levels. The addition of 
low dose aphidicolin to slow the rate of DNA replication caused a modest but discernable 
methylation increase in Dnmt1 KD and control cells, consistent with previous results 
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showing that demethylation is replication-dependent. These data support a model where 
the very high rate of DNA replication triggered in cells as they transition into S1 (Figure 
3.11A) generates a quantitative deficit in maintenance methylation by Dnmt1, leading to 
passive, genome-wide demethylation.  
Global methylation loss does not induce genome-wide transcriptional activation 
DNA methylation is associated with gene silencing. Therefore, we investigated 
the possibility that global DNA hypomethylation leads to genome-wide transcriptional 
activation. First, we looked for LINE-1 activation. These regions are normally highly 
methylated in order to silence retrotransposon activity [8] and lose approximately 30% of 
their DNA methylation during erythropoiesis (Figure 3.3A and Figure 3.6A). However, 
the LINE-1 transcript showed only a modest, 1.7-fold induction that did not reach 
statistical significance (Figure 3.16A) (p>0.2, Student‟s two-tailed, paired t-test). This 
result was consistent with our earlier finding of methylation loss in genes whose 
expression decreases in erythropoiesis, such as PU.1 and Fas (Figure 3.1C, D). 
Interestingly, the methyl-CpG-binding protein 2 (MeCP2) has been shown to repress 
LINE-1 transcription in transformed cell lines and in neurons [363, 364]. We found that 
MeCP2 mRNA was up-regulated by approximately 2-fold during differentiation from S0 
to S3 using Affymetrix GeneChips (data not shown). This finding raises the possibility 
that a compensatory mechanism involving MeCP2 may be activated during 
differentiation to keep LINE-1 retrotransposons silenced. 
We examined whether global demethylation affected global mRNA levels using 
the Affymetrix GeneChip gene expression platform, comparing early erythroblasts in S1 
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with later, more mature erythroblasts in S3 (Figure 3.16B, C). We analyzed this data 
using two different approaches. In our first analysis, prior to obtaining RRBS results, 
gene expression data was normalized based on a group of three housekeepers, a method 
traditionally followed in qRT-PCR experiments. We found that 761 transcripts were 
down-regulated during differentiation, while only 146 were up-regulated (Figure 3.16B). 
A similar result was obtained by applying a genome-wide normalization approach to the 
data, with 5862 down-regulated genes and 2268 up-regulated genes during differentiation 
(Figure 3.16C). These results show that the erythroid gene expression profile becomes 
increasingly restricted during differentiation, consistent with the cellular and functional 
specification that occurs during this time. Additionally, these findings suggest that global 
methylation loss is not leading to global transcript induction.  
We tested this directly by combining gene expression profiling with the RRBS 
results. In this analysis, each 5 kb genomic region was assigned to an Affymetrix gene 
based on the closest upstream or downstream Ensembl-annotated transcription start site. 
We observed that up-regulated genes had a median methylation level in S0 cells that was 
lower than that of down-regulated genes, pointing to a correlation between genes poised 
for induction and their levels of DNA methylation. However, both up-regulated and 
down-regulated genes lost 30% of their S0 methylation levels during differentiation into 
S4/5 cells (Figure 3.16C), consistent with the magnitude of methylation loss observed 
genome-wide (Figure 3.6). Therefore, demethylation appears just as likely to be 
associated with gene induction as it is with gene repression during erythroid 
differentiation, suggesting that hypomethylation is not leading to transcript induction on a 
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genome-wide scale. However, this analysis utilized a rather simple approach in 
assimilating RRBS and GeneChip data. Additional, and more complex, analysis methods 
still hold the potential to reveal a correlation between DNA methylation and gene 
expression in our system. Importantly, our preliminary finding, that global demethylation 
is not leading to global gene activation, does not eliminate a potential role for loci-
specific demethylation in gene activation.  
Demethylation is required for activation of erythroid-specific GATA-1 target genes  
We next asked whether inhibiting genome-wide demethylation would affect the 
erythroid differentiation process. We examined expression of several erythroblast-
specific GATA-1 target genes: β-globin (Hbb-b1); aminolevulinic acid synthase 2 
(Alas2), required for the first step of the heme synthesis pathway [365]; and solute carrier 
family 4, anion exchanger, member 1 (Slc4a1, formally known as Band3), a membrane 
protein that functions as both a chloride/bicarbonate exchanger and a binding site for 
cytoskeletal proteins [308, 366, 367]. These genes show a modest increase in their 
expression at the S0 to S1 transition, followed by a 30- to 100-fold induction during 
subsequent differentiation in S2 and S3 (Figure 2.3A and Figure 3.1B). Furthermore, 
GeneChip analysis of S0 and S3 subsets reveals these genes are within the top 25 most 
highly induced genes during differentiation (data not shown). 
We cultured freshly sorted S0 cells with Epo or Epo plus low dose, 0.1 μM, 
aphidicolin for 24 hours followed by sorting of the differentiated Ter119+ population 
(Ter119+ =combined S1, S2, and S3 sorting gate). Aphidicolin did not change the number 
of cells in S-phase, but it did lower the rate of DNA replication, as determined by a 30-
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minute pulse of BrdU at the end of the culture period (Figure 3.17A). Low dose 
aphidicolin prevented global demethylation, and reduced the extent of methylation loss at 
the β-globin LCR (Figure 3.17B). Delayed demethylation was associated with 
compromised expression of erythroid genes; transcript levels for β-globin, Alas2, and 
Band3, were all significantly lower, by 25-40% (Figure 3.17C). We were able to rescue 
the aphidicolin-induced delay in DNA demethylation by adding 50 nM of 5-aza-2‟-
deoxycytidine (5-aza), an inhibitor of DNA methyltransferases (Figure 3.17B) [368]. 5-
aza did not alter the number of cells in S-phase or the DNA synthesis rate (Figure 3.17A). 
Importantly, the addition of 5-aza to aphidicolin-treated cells restored normal levels of 
expression for β-globin, Alas2, and Band3 (Figure 3.17C). These findings suggest that 
the slower induction of erythroid genes in the aphidicolin-treated cells was a result of a 
failure to demethylate DNA. 
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Discussion 
Location and extent of erythroid global demethylation 
We have discovered that erythropoiesis is associated with progressive genome-
wide DNA demethylation. Global demethylation is initiated with the onset of 
erythropoiesis, as cells transition from S0 to S1 (Figure 3.4), and is temporally 
coordinated with extensive demethylation at the β-globin LCR (Figure 3.7). 
Demethylation was truly global, with 67% of 5 kb genomic regions undergoing 
statistically significant methylation loss (Figure 3.5). Demethylation was spread across a 
wide-variety of genomic elements including CCpGG and CpG repeats (3.3B, C); genes 
down-regulated in erythropoiesis (Figure 3.1C, D and 3.16C), endogenous retroviruses 
(Figure 3.3A and 3.7); imprinted genes (Figure 3.2 and 3.6B); and CpG islands, island 
shores, promoters, and enhancers (Figure 3.6B, C). On average, most genomic regions 
lost 30% of initial S0 methylation levels during differentiation into S4/5 cells, with 
notable exceptions at the β-globin LCR which lost 65-80% and imprinted regions that 
lost only 14% (Figure 3.6D). Furthermore, global hypomethylation appears to be a 
general feature of erythropoiesis, neither limited to the definitive lineage nor the fetal 
liver (Figure 3.4).  
Our findings are consistent with a previous study showing reduced levels of total 
methylation in murine placenta and yolk sac tissues [369]. However, their data was not 
sufficient to conclude that hypomethylation was the result of a demethylation process. 
Furthermore, due to the cellular heterogeneity of these tissues, it was unclear as to which 
cell types were hypomethylated. Our data suggests that hypomethylation in the placenta 
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and yolk sac is due to the large number of primitive erythrocytes present in these two 
tissues.  
Erythropoiesis is the first example of global DNA demethylation in somatic cells, 
which until now, were thought to possess similar levels of total methylation with 
differences occurring at a relatively small number of gene-specific loci [36, 40, 47]. 
Instead, physiological examples of global demethylation have been limited to the pre-
implantation embryo and primordial germ cells [203]. In disease, DNA hypomethylation 
is a hallmark of a large number of cancers [237, 238].  
The assays employed to measure DNA methylation in the pre-implantation 
embryo have been largely qualitative, relying on immunofluorescence using an anti-5mC 
antibody or DNA hybridization-based methods. Furthermore, genome-scale methylation 
analysis, such as the RRBS used in our study, has not been performed in the early 
embryo. Therefore, it is difficult to directly compare the genomic locations affected by 
demethylation in the pre-implantation embryo with our data. However, quantitative 
methods have been used, mostly measuring methylation loss at repetitive retroviral 
elements [157, 183-185]. These studies show that the total methylation loss is 
approximately 50%, as compared to the 30% loss observed in our system. Notably, unlike 
in erythropoiesis and PGCs, imprinted regions are spared from demethylation in the pre-
implantation embryo [123, 188-190].  
In PGCs genome-scale methylation analysis has recently been performed [175]. 
Similar to erythropoiesis, PGCs undergo demethylation at a wide-variety of genomic 
elements, including exons, introns, promoters, intergenic regions, and retroviral LINE, 
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SINE and LTR regions. In contrast to erythropoiesis, total methylation loss in PGCs is 
much more dramatic, reaching levels of only 16% and 7.8% in male and female PGCs, 
respectively [156, 157, 175, 185]. This is roughly a 75% reduction in total 5mC, vastly 
exceeding the methylation loss observed in erythropoiesis. In PGCs, DNA methylation at 
imprinted regions is completely removed [214, 215, 219]. This is a notable difference 
compared to the relatively minor 15-30% of 5mC removed at imprinted regions during 
erythropoiesis (Figure 3.2 and 3.6). 
The magnitude of total 5mC loss during oncogenesis differs by the type of cancer, 
but generally ranges between 10-50% [237, 238]. In addition, it is well known that the 
majority of cancers lose methylation at repetitive elements, including retrotransposons 
[244]. However, the precise locations of demethylation in cancer remain largely 
unknown. For example, methylation loss can occur at imprinted regions, but it is not 
known if this is a common feature of all cancers that exhibit global hypomethylation 
[265]. The absence of this information in the literature is mainly due to the large number 
of cancers, their molecular diversity, and a lack of unbiased genome-scale studies. 
Mechanism of erythroid global demethylation  
Demethylation, both globally and at the β-globin LCR, is completely dependent 
on DNA replication at all stages of differentiation (Figure 3.12 and 3.13), and therefore 
proceeds through a passive mechanism. Furthermore, knockdown of proteins with a 
proposed role in active demethylation, Mbd4 and Gadd45a, did not prevent DNA 
demethylation (Figure 3.8 and 3.10). Demethylation coincides with a dramatic increase in 
the rate of DNA replication during the S0 to S1 transition, which remains elevated 
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through the S3 differentiation stage (Figure 3.11A). Slowing the rate of DNA replication, 
without perturbing the number of cells in S-phase, was sufficient to prevent global 
demethylation and limit the extent of β-globin LCR methylation loss (Figure 3.13B, C 
and 3.14). We found that Dnmt3a and Dnmt3b are down-regulated during erythropoiesis, 
but their loss does not appear to be contributing to demethylation, since their exogenous 
expression failed to rescue demethylation (Figure 3.9). Therefore, Dnmt1 seems to be 
solely responsible for maintenance of methylation in erythroid cells. Consistent with this 
finding, transient and inefficient knockdown of Dnmt1 led to an acceleration of 
methylation loss, suggesting that Dnmt1 is present in limiting amounts during 
differentiation (Figure 3.15). Collectively, these results support a model where the very 
high rate of DNA replication triggered in cells as they transition into S1 generates a 
quantitative deficit in maintenance methylation by Dnmt1, leading to passive, genome-
wide demethylation. To our knowledge the finding that increased replication rate is 
sufficient to induce global demethylation has not been described. 
Like erythropoiesis, demethylation of maternal DNA in the pre-implantation 
embryo occurs gradually over several cell divisions [186, 191]. During these divisions the 
highly abundant and oocyte-specific Dnmt1 isoform, Dnmt1o, is localized to the 
cytoplasm, leaving only low levels of somatic Dnmt1 in the nucleus [123, 192, 193]. We 
have not yet investigated the subcellular localization of Dnmt1 during erythropoiesis, but 
Dnmt1 has been found by others to reside almost exclusively in the nucleus of somatic 
cells [193, 370]. Therefore, the mechanism driving passive demethylation in 
erythropoiesis is potentially quite different from that in the pre-implantation embryo; in 
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erythropoiesis the methylation enzyme remains relatively constant, but the DNA 
substrate increases, while in the pre-implantation embryo, presumably normal levels of 
substrate are present, but the enzyme decreases.  
The mechanism of 5mC loss in PGCs is largely unknown. Correlative evidence, 
such as activation of the BER pathway, suggests that demethylation is through an active 
mechanism [197]. Also, Dnmt1 is highly expressed at the mRNA and protein levels in the 
nucleus from E8.5 to E12.5, a period of time during which 5mC is erased [214, 218]. 
This finding has been cited as supporting an active mechanism, since it is not consistent 
with known examples of passive demethylation [153], i.e. nuclear exclusion of Dnmt1 
during replication in the pre-implantation embryo. However, experiments utilizing cell 
cycle inhibitors during PGC development have not been performed, so a DNA 
replication-dependent mechanism has not formally been ruled out. Furthermore, it is not 
known if PGCs have an elevated rate of intra-S-phase DNA synthesis of the kind we have 
described in erythropoiesis.  
Could reduced maintenance methylation, on the order of magnitude described in 
our system, account for the methylation loss observed in PGCs? The „efficiency‟ of 
maintenance has been calculated by others as the fraction of 5mC retained per cell cycle 
[371]. By this metric, even in the absence of any methyltransferase activity, efficiency 
would still be 50% per cycle. We propose that a more appropriate calculation for 
maintenance efficiency is the fraction of 5mC retained on the nascent strand per cell 
cycle. Differentiating erythroblasts undergo 3 cell divisions and lose 30% of their initial 
methylation during this time, resulting in a maintenance efficiency of 76% per cell cycle. 
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PGCs undergo 10 divisions over 5 days during which time the median genome-wide 
methylation level is reduced from approximately 70% in ES or whole embryo to 16% in 
the male PGC [175]. Methylation loss of this magnitude, if it were due to passive 
demethylation only, would require a maintenance efficiency of 73% per cycle. This result 
is in close agreement with the observed maintenance efficiency in erythropoiesis of 76% 
per cycle. Therefore, passive DNA demethylation of the kind described for erythropoiesis 
could account for global methylation loss in PGCs. 
The mechanism of demethylation in cancer is largely unknown, but indirect 
evidence suggests a passive mechanism. First, DNA demethylation is known to be an 
early event during carcinogenesis that often escalates with disease progression [113, 239, 
240, 248, 273-275]. This slow progression, and incomplete loss of methylation, suggests 
a passive mechanism requiring many rounds of cell division. Second, hypomethylation in 
cancer has been correlated with an increased number of proliferating cells, determined by 
markers such as Pcna, Ki-67, histone H4, BrdU immunohistochemistry, or total DNA 
content [239, 243, 248, 276, 372, 373]. Transitional cell carcinomas of the urinary 
bladder have been associated with reduced Dnmt1 abundance relative to the proliferative 
marker Pcna [372]. In glioma, decreased methyltransferase activity resulted from 
decreased recruitment of Dnmt1 to DNA, even though protein levels remained constant 
[113]. Together, these findings suggest that an imbalance between maintenance 
methylation and proliferation likely leads to hypomethylation in cancer. Like cancer, 
demethylation in erythropoiesis occurs progressively over several cell divisions and is 
associated with an increase in the number of proliferating cells (Figure 3.11B). 
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Importantly, our data demonstrate that the rate of intra-S-phase DNA synthesis is a 
contributing factor to passive demethylation and raises the possibility that a similar 
mechanism could be responsible for global hypomethylation in cancer. 
Functional significance of erythroid global demethylation  
We have started to study the functional significance of global DNA demethylation 
during erythropoiesis. Given the known association of 5mC with transcriptional 
repression, we thought that global methylation loss might be linked to global up-
regulation of mRNA. This does not appear to be the case, as demethylation was just as 
likely to be associated with gene repression as it was with gene induction during 
differentiation (Figure 3.16). However, this analysis utilized a rather simple approach that 
potentially lacks the sensitivity necessary to reveal a correlation. For example, in some 
cases the closest 5 kb region to a transcription start site might reside within the gene-
body. This could confound results, since in contrast to the majority of genomic regions, 
gene-body methylation is associated within highly expressed genes [46]. Our analysis 
might be improved by only utilizing 5 kb regions upstream of, or at, the gene 
transcription start site. Alternatively, CpG island shore regions, in which a lack of 5mC is 
strongly correlated with gene expression, could be employed in lieu of 5 kb regions [43, 
47]. More complex methods for associating putative regulatory regions to genes have 
also been recently proposed [374]. 
Nevertheless, our finding is in agreement with other systems, where global loss of 
methylation is not sufficient to generate global gene induction [31, 375-377]. In addition 
to DNA demethylation there are several enzyme classes required for gene activation, 
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including chromatin modifiers and tissue-specific transcription factors. Since 
erythroblasts become increasingly specialized during the differentiation process, it is 
likely that the factors necessary for global gene activation are restricted. Alternatively, 
nuclear condensation and enucleation of mature erythroblasts may protect these cells 
from excessive transcription and other unwanted effects that might otherwise result from 
global demethylation. Interestingly, we observed that up-regulated genes had lower initial 
methylation levels in S0 cells compared to down-regulated genes, pointing to a 
correlation between genes poised for induction and their levels of DNA methylation.  
Global demethylation in the pre-implantation embryo, PGCs, and cancer has been 
shown to affect single copy gene regions. In fact, activation of specific genes important 
for cellular identity is one of the major proposed functions for global demethylation in 
these systems. Global demethylation in the pre-implantation embryo is believed to be part 
of a mechanism required to activate genes leading to pluripotency, such as Nanog and 
Oct4 [42, 174, 204, 205, 209-212]. Similarly, a critical function of methylation loss in 
PGCs is the removal of parental imprints [213-215, 219, 224] and activation of germ-line 
specific genes [228-230]. The functional consequence of global demethylation in cancer 
is more diverse, but single copy gene loci have been shown to exhibit hypomethylation-
linked expression [237, 238, 262, 265]. Importantly, in PGCs, pre-implantation embryo, 
and cancer this function was deduced by a temporal correlation with genome-wide 
demethylation, due to an inability to modulate the rate of demethylation in these systems. 
We have also demonstrated strong temporal correlations between global 
demethylation and gene specific demethylation at the β-globin LCR (Figure 3.7). 
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Furthermore, we have demonstrated that the β-globin LCR and global demethylation are 
linked through a DNA replication-dependent mechanism (Figure 3.12, 3.13, and 3.14). 
The ability to slow the rate of demethylation, using DNA synthesis inhibitors, and 
accelerate demethylation, through addition of 5-aza, has allowed us to dissect the 
functional significance of global demethylation even further. In initial experiments using 
these tools, we provided evidence that demethylation is required for full transcriptional 
activation of the erythroid-specific GATA-1 target genes β-globin, Alas2, and Band3 
(Figure 3.17). These genes are massively up-regulated in normal erythroblast 
differentiation and critically important to red cell function. For example, hemoglobin, of 
which β-globin is a major component, eventually comprises >95% of red cell mass and 
even a 10% reduction has clinical manifestations and is considered anemia [378]. We 
propose that genome-wide demethylation is part of a mechanism required for rapid 
demethylation, and activation, of specific erythroid gene loci. This model is also 
supported by a recent study which showed de-repression of myeloerythroid genes in 
hematopoietic stem cells that lose DNA methylation as a result of expressing 
hypomorphic Dnmt1 [32].  
Accelerated demethylation at the β-globin LCR 
Demethylation during erythropoiesis has a hierarchical structure, with the highest 
demethylation rate found at the erythroid-specific β-globin LCR (65-80% loss), slower 
demethylation in most other genomic sites (30% loss), and the lowest rate at imprinted 
loci (15% loss) (Figure 3.6D). Correlation data (Figure 3.7) and response to cell cycle 
inhibitors (Figure 3.12, 3.13, and 3.14) suggest that demethylation in each of these 
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regions is driven by a single, DNA-replication dependent mechanism. Despite this 
common mechanism, the efficiency of maintenance methylation at the β-globin LCR is 
only 20-40% per cell cycle as compared to 76% per cycle genome-wide. One explanation 
for this dramatically reduced maintenance fidelity could be the binding of erythroid-
specific transcription factors at the β-globin LCR. DNA replication-dependent 
demethylation is known to be induced by the binding of protein factors to DNA [16, 126-
128]. For example, DNA replication and EBNA-1 binding was required for 
demethylation of an episomal oriP sequence in PC-3 prostate cancer cell line [127]. 
Similarly, episomal lacO sites become demethylated upon binding of LacI in the human 
embryonic kidney 293 cell line, and a decrease in LacI binding affinity, caused by 
increasing amounts of IPTG, resulted in a slower loss of methylation. [128]. 
Gata-1 and Eklf are transcription factors essential for erythrocyte differentiation 
[379-381]. These factors directly bind DNA within the hypersensitivity sites of the β-
globin LCR to activate the β-globin gene [103, 382-384]. NF-E2, another transcription 
important for β-globin activation, specifically targets HS2 of the LCR [103, 382-384]. 
We found that Gata-1, Eklf, and NF-E2 mRNAs were present in S0 cells at 200-fold 
higher levels than in fetal brain (Figure 2.3A). They increased a further 2-fold with the 
transition from S0 into S1 and continued to increase in S2 and S3. 
We propose that the increase in DNA replication rate during the S0 to S1 
transition results in an increase in the number of hemi-methylated sites genome-wide and 
at the β-globin LCR. Within genome-wide regions, these sites have the potential to 
become fully methylated by the delayed action of Dnmt1 [370]. In contrast, binding of 
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erythroid-specific transcription factors at the β-globin LCR protects hemi-methylated 
CpGs from the maintenance activity of Dnmt1. This model is supported by data from S-
phase arrest of partially differentiated cells in culture, where non-erythroid loci regained 
methylation lost at previous stages of differentiation, while the β-globin LCR did not 
(Figure 3.13C). This mechanism has recently been proposed in neural precursor cell 
differentiation; where NFI plays a critical regulator role in the epigenetic switch towards 
astrocytogenesis by binding to astrocytic gene promoters and protecting them from 
Dnmt1 activity [129].  
 
  
140 
 
Materials and Methods 
Isolation of erythroid progenitors by flow cytometry 
Single cell suspensions were prepared by mechanically dissociating whole fetal 
livers, obtained from E12.5 to E13.5 Balb/C mouse embryos as described [105]. Cells 
were stained for CD71, Ter119, and a cocktail containing lineage-specific antibodies 
directed at CD3, Gr-1, B220, CD41 and Mac-1 (CD11b). Cells positive for lineage-
cocktail markers were excluded from analysis. Isotype-matched antibodies were used to 
set up background staining in each channel. Erythroid subsets were sorted using gates 
illustrated in Figure 3.1A, on a BD FACSAria (BD Biosciences) using a 100 μm nozzle. 
Dead cells were excluded from analysis using DAPI (Roche). Alternatively, to isolate S0 
cells only, fetal liver cells were labeled with biotin-conjugated anti-CD71 at 1:250 and 
anti-Ter119 at 1:100 and subjected to magnetic separation using EasySep (StemCell 
Technologies). The LSRII (BD Biosciences) cytometer was used for analysis in 
experiments where cell sorting was not required. All FACS data was analyzed using the 
FlowJo software (Tree Star Inc., CA). Antibodies used in flow cytometry analysis: PE or 
biotin rat anti-mouse CD71 (C2 clone), APC or biotin rat anti-mouse Ter119, FITC rat 
anti-mouse CD41 (MWReg30), FITC rat anti-mouse CD45R/B220 (RA3-6B2), FITC 
hamster anti-mouse CD3e (145-2C11), FITC rat anti-mouse CD11b (M1/70), FITC rat 
anti-mouse Ly-6G and Ly-6C (RB6-8C5) (BD Biosciences). 
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Measurement of DNA methylation by pyrosequencing 
Genomic DNA (gDNA) was isolated from flow-cytometrically sorted fetal liver 
subsets S0 to S4/5 using the All Prep DNA/RNA Micro Kit (Qiagen). For sodium 
bisulfite conversion, between 50 and 150 ng of gDNA were treated using the EZ DNA 
Methylation-Direct Kit (Zymo Research). Alternatively, for samples containing small cell 
numbers (≈10,000), cells were treated with proteinase-K and used directly for bisulfite 
conversion. For each genomic locus, the region of interest was amplified by PCR using 
primers specific to the bisulfite-converted gDNA. DNA methylation assays for β-globin 
LCR HS1 (ADS937), β-globin LCR HS2 (ADS938), H19 DMR (ADS438), PEG3 
(ADS183), Kcnq1ot1 (ADS912), PU.1 (ADS1090), and LINE-1 (ADS685) were 
designed by EpigenDx (Worcester, MA). Assay design reports, which include the target 
region sequence, linearity/validation data and primer sequences, are available from 
EpigenDx. As a control, the efficiency of bisulfite conversion was assessed using primers 
to the non-converted DNA sequence. In this case, there was no amplification, indicating 
that the DNA was fully converted. The PCR product was visualized on a 1% agarose gel 
to verify amplification specificity, followed by pyrosequencing (EpigenDx) using 
sequencing primers internal to the amplification primers. Cytosine dispensation in non-
CpG positions was used to verify that the PCR product amplified genomic DNA that was 
fully converted. The methylation status of each locus was analyzed individually as a T/C 
SNP using QCpG software (Qiagen) by EpigenDx. 
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Measurement of DNA methylation levels by cloning 
Genomic DNA was isolated and bisulfite converted as described above. 
Converted DNA was amplified by PCR using primers specific for the H19 DMR (FW, 
aggaaagaaaaaggttggtgagaaaatagag; RV, aaataacccacaacattaccatttataaattcc). PCR product 
was cloned into pCR2.1-TOPO vector using the TA Cloning kit (Invitrogen) and used to 
transform DH5α E.coli (Invitrogen). Plasmid DNA was prepared from individual 
colonies, sequenced using M13 forward or reverse primers, and analyzed using the 
Bisulfite Sequencing DNA Methylation Analysis (BISMA) toolkit [385]. DNA 
methylation levels of individual CpGs obtained by this strategy strongly correlated with 
those of the pyrosequencing assay described above (R2 = 0.85).  
Measurement of DNA methylation levels using LUMA 
Genome-wide methylation of CCpGG sites was detected using the LUminometric 
Methylation Assay (LUMA) [355]. In parallel reactions, 100 ng of gDNA was digested 
with either methylation sensitive HpaII or methylation insensitive MspI. EcoRI was 
included in both reactions as an internal control for the amount of template DNA. MspI 
and HpaII leave 5‟CG overhangs, while EcoRI produces 5‟AATT overhangs. The 
quantity of overhangs present in each enzymatic reaction was measured using 
pyrosequencing by EpigenDx. 
Measurement of DNA methylation levels by ELISA with an anti-meCpG antibody 
Purified gDNA was first quantified using the DNA Quant-iT™ dsDNA HS Assay 
Kit (Invitrogen), followed by methyl-cytosine quantification using the Methylamp™ 
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Global DNA Methylation Quantification Ultra Kit (Epigentek). gDNA (100 ng) for each 
sorted subset was immobilized to the bottom of a 96-well plate. Binding of an antibody 
raised against 5-methylcytosine was quantified by ELISA and compared to binding of a 
fully methylated control DNA. 
Measurement of DNA methylation by reduced representation bisulfite sequencing  
RRBS was performed as previously described [42]. Genomic DNA (gDNA) was 
isolated using the All Prep DNA/RNA Micro Kit (Qiagen). For all RRBS experiments, 
two independent biological replicate pools were investigated. Genomic DNA from 4 or 7 
sorting experiments was pooled to yield each biological replicate for the S0, S1, S3 and 
S4/5 populations (Figure 3.5 and 3.6). Genomic DNA from 2 sorting experiments was 
pooled to yield each biological replicate in experiments utilizing aphidicolin treated S1 
cells in culture (Figure 3.14). RRBS data for these samples are available at 
http://erythrocyte-demethylation.computational-epigenetics.org/ 
GeneChip analysis 
Experiment-matched S1 (n=3) and S3 (n=3) cells were isolated by sorting E12.5 
fetal liver cells on three different days. Total RNA (20 ng per sample) was converted to 
cDNA, linearly amplified and biotinylated using Ovation reagents (Nugen, San Carlos, 
CA). Samples were hybridized to Mouse Genome 430 2.0 Arrays (Affymetrix, Santa 
Clara, CA). For the analysis presented in Figure 3.16B, microarray suite 5 (MAS5) 
processed sample data were normalized to the average of 18SRNA (AFFX-
18SRNAMur/X00686_M_at), GAPDH (AFFX-GapdhMur/M32599_3_at) and β-actin 
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(1419734_at) expression values using BRB-ArrayTools developed by Dr. Richard Simon 
and BRB-ArrayTools Development Team [386]. Genes were identified as differentially 
expressed if their random variance t-test p-value was less than 0.005 and absolute fold 
change value larger than 2. The analysis presented in Figure 3.16C used R/Bioconductor 
and the limma library, with FDR<0.05 and log2(fold-change)<-1 for down-regulated 
genes and log2(fold change) >1 for up-regulated genes. Data was normalized using 
gcRMA and expression values were subsequently scaled into the interval from 0 to 10, 
with 0 corresponding to genes expressed at or below the 0.5% quantile and 10 
corresponding to gene expressed at or above the 99.5% quantile.  
Cell cycle analysis 
For determination of DNA replication in vivo (Figure 3.11), mice pregnant with 
E13.5 or E14.5 embryos were injected intraperitoneally 30 min prior to harvesting of 
fetal livers with 100 μl of 10 mg/ml BrdU; erythroid subsets were fixed, permeabilized 
and analyzed using the BrdU flow kit (BD Bioscience). Simultaneously, CD71 and 
Ter119 antibodies were used to identify differentiation subsets and 7AAD (BD 
Biosciences) was used as a marker of total DNA content. For determination of DNA 
replication in vitro, cells in culture were pulsed with 10 μM BrdU for 30 min. BrdU 
incorporation was detected as described above. 
Culture of primary fetal liver cells in vitro 
Freshly sorted fetal liver subsets were incubated for up to 48 hours in IMDM (L-
glutamine, 25mM HEPES) (Gibco) supplemented with 20% fetal calf serum, 1% 
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penicillin/streptomycin and 10-4 M β-mercapthoethanol, in the presence of 2 U/ml Epo. 
Aphidicolin (Sigma), L-mimosine (Sigma), 5-Aza-2'-deoxycytidine (Sigma) were added 
to the cells at 0.1-1.0 μM, 1 mM, or 0.05 μM respectively. 
Retroviral transduction of Dnmt3 
cDNAs for Dnmt3a, Dnmt3b1 and Dnmt3b1:PC were kindly provided by Dr. En 
Li (Novartis Institutes for BioMedical Research) and subcloned into the MSCV-IRES-
GFP retroviral vector MSIG [387]. Viral supernatants were prepared by co-transfecting 
the desired plasmid and the pCL-Eco packaging vector [388] into 293T cells using 
FuGENE6 (Roche). One milliliter of viral supernatant, supplemented with 5 μg of 
polybrene (Sigma), was used to infect 5x105 S0 cells by spinning at 2000 rpm at 30ºC for 
1 hr in fibronectin-coated dishes. Cells were then incubated overnight (16 h) in the 
presence of 100 ng/ml SCF (Peprotech, Rocky Hill, NJ), and 10 ng/ml IL-3 (Peprotech) 
to allow expression of retrovirus. Expression was examined 16 hours and 40 hours post 
infection by flow-cytometry for GFP, and at 40 hours by QRT-PCR for DNMT mRNA. 
Knockdown experiments 
Short hairpin RNA targeting Gadd45a (clone1= V2MM_13565, ID SM2169-e-9; 
clone 2= VSHS_151136, ID SH2954-H-4), MBD4 (V2MM_16858, ID SM2374-d-10) or 
Dnmt1 (V2MM_46797, SM2437-d-12) were subcloned into LMP microRNA-adapted 
retroviral vector containing an “IRES-GFP” reporter (Open Biosystems, Huntsville, AL). 
Similarly, a nonsilencing negative control shRNA (RHS4971, Open Biosystems) that is 
processed by the endogenous RNAi pathway but will not target any mRNA sequence in 
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mammals, was subcloned into LMP. Viral supernatants were generated as described 
above. Sorted S0 cells were transduced with retroviral vectors as described above. 
Quantitative RT-PCR 
Total RNA was prepared from cells sorted from each fetal liver subset, using the 
All Prep DNA/RNA Micro Kit (Qiagen) with on column DNase treatment. Reverse-
transcription was conducted using Superscript II (Invitrogen) with random hexamer 
primers. The ABI 7300 sequence detection system, TaqMan reagents and TagMan MGB 
probes (Applied Biosystems) were used and several dilutions of each template were used 
to ensure detection in the linear range of the assay. A „no template‟ and „no reverse-
transcriptase‟ controls were included. The threshold cycle (Ct) for housekeeping genes 
GAPDH or β-actin was subtracted from the Ct for genes of interest to yield a relative 
expression value. QRT-PCR probes used: Gapdh (Mm99999915_g1), β-actin 
(Mm02619580_g1), β-globin (Mm01611268_g1), PU.1 (Mm00488140_m1), Dnmt1 
(Mm00599784_m1), Uhrf1 (Mm00477873_g1), Dnmt3a (Mm00432870_m1), Dnmt3b 
(Mm01240113_m1), Mbd4 (Mm00521972_m1), Gadd45a (Mm00432802_m1), Tdg 
(Mm00834243_g1), Aidca (Mm00507774_m1), Apobec1 (Mm00482894_m1), Alas2 
(Mm01260713_m1), Band3 (Mm00441492_m1), LINE-1 5‟ Region 
(FW,GCTACCTTGCCAGCAGAGTCTT; RV, AGTTCCGCGCGATTGGATT; probe, 
ACCCTAAGACCTCTGGTGAGT), LINE-1 3‟ Region (FW, 
TTCCACCTCACACCAGTCAGA; RV, CACCAACAATGGAGGAGTGTTC; probe, 
TTCAGGTGACAGCAGATG). 
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Western blot analysis 
Sorted cells from each fetal liver subset were lysed by rocking for 15 min at 4°C 
in 1% NP40, 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% glycerol 
supplemented with protease inhibitors (Roche); following centrifugation for 15 min at 
4°C, supernatant was quantified by the BCA Protein Assay Kit (Pierce). Phoenix cells, a 
293T-derived cell line, transiently transduced with retroviral vectors encoding either 
Dnmt3a or Dnmt3b were used as positive controls. Lysates (10 μg protein per lane) were 
analyzed on a 3-8% Tris-acetate gradient polyacrylamide gel (Invitrogen), transferred to a 
nitrocellulose membrane, and probed with mouse anti-Dnmt3a (ab13888) (Abcam, 
Cambridge, MA), mouse anti-Dnmt3b (ab13604) (Abcam), or mouse anti-Dnmt1 
(ab92453) (Abcam) overnight at 4ºC. Following washing, membranes were probed with 
peroxidase donkey anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA) 
followed by washing, then detection with Lumi-LightPLUS western blotting substrate 
(Roche) (Figure 3.8B, left panel). Membranes were then re-probed with rabbit anti-beta 
actin (ab8227) (Abcam) and mouse anti-DNMT antibodies, followed by detection with 
anti-Mouse-IRDye 800CW (green channel) (LI-COR Biosciences) and anti-Rabbit 
IRDye 680 (red channel) (LI-COR). Membranes were simultaneously analyzed for β-
actin and either Dnmt1, Dnmt3a, or Dnmt3b using the Odyssey infrared imaging system 
(LICOR). Target protein bands were quantified using the Odyssey software (Figure 3.8B, 
right panel). 
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Statistical analysis 
Methylation levels on multiple CpGs (in Figure 3.1, 3.2, and 3.3) were analyzed 
using a general linear mixed model with CpG and/or subset as fixed effects and 
individual experiments as the random effect. Normal distribution of model error was 
confirmed by Kolmogorov-Smirnov test on residuals. „P‟ values were adjusted using 
Sidak multiple comparison correction. Other statistical tests are described directly in the 
main text. 
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Figure 3.1. DNA methylation loss at the β-globin LCR and at loci of genes down-
regulated with erythroid differentiation.  
A. Erythroid maturation subsets in fetal liver. CD71/Ter119 flow cytometric 
profile of freshly isolated fetal liver (left panel), and examples of cells from each of 
subsets S0 to S4/5 (right panel). Erythroid maturation is associated with decreasing cell 
size, nuclear condensation and positive staining for hemoglobin with diaminobenzidine 
(brown-orange). Cell density in the flow-cytometric profile is represented by color, from 
highest (red) to lowest (blue).  
 
B. DNA methylation (in black) and β-globin mRNA expression (in red) in 
erythroid subsets S0 to S4/5 sorted from fresh fetal liver. DNA methylation is shown for 
3 CpGs labeled A to C within hypersensitivity site 2 (HS2) of the β-globin LCR (see 
map, not to scale). Results are mean ± s.e.m. of independent replicate sorting 
experiments; number of experiments (n) for each subset is n=11 (S0, S1), n=5 (S2), n=7 
(S3) and n=3 (S4/5). β-globin mRNA data is the mean of four replicates, expressed 
relative to the Gapdh mRNA and normalized to expression in S0. As expected, DNA 
methylation loss at the β-globin LCR precedes β-globin gene activation. 
 
C. DNA methylation of a region upstream of the PU.1 gene transcription start site 
(marked in red and expanded, see locus map). Upper panel shows methylation level at 
each of four CpGs for each of subsets S0, S1, S3 and S4/5 by pyrosequencing of PCR 
products generated from bisulfite converted gDNA; each symbol represents a single 
sorting experiment. Lower panel shows a summary of the data in upper panel: the mean 
methylation level of all four CpGs for all experiments at each subset (black symbols, 
mean ± s.e.m.), and the mean methylation level for all experiments at CpG4 (which 
shows the largest loss in methylation) and CpG1 (showing the smallest loss in 
methylation). Statistics for each erythroblast subset are based on a comparison to S0. 
***P<0.001, **P<0.01, *P<0.05 by linear mixed model analysis of variance with Sidak 
correction for multiple tests.  
 
D. DNA methylation of a regulatory region upstream of the Fas gene transcription 
start site (marked in red and expanded, see locus map). Data and statistics represented as 
described in „C‟. 
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Figure 3.2. DNA methylation loss at imprinted regions. 
A. DNA methylation at the imprinted H19 DMR locus in erythroid subsets. Left 
panel shows individual clones (rows, n=34 and 36) were sequenced from S0 and S4/5, 
respectively (left panel). Columns represent the position of individual CpGs (see locus 
map). The red line divides the clones into two halves. Black boxes represent methylated 
cytosines, white boxes represent unmethylated cytosines. Average methylation level for 
all clones is 61% for S0, and 42% for S4/5 (p=0.007, two-tailed Mann-Whitney test). 
Right panel shows methylation levels at each individual CpG for each of subsets S0, S1, 
S3 and S4/5 by pyrosequencing of PCR products generated from bisulfite converted 
gDNA. Data and statistics as described in Figure 3.1C. 
 
B. DNA methylation at the imprinted PEG3 locus. Data and statistics as described 
in Figure 3.1C.  
 
C. DNA methylation at the imprinted Kcnq1ot1 locus. Data and statistics as 
described in Figure 3.1C. 
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Figure 3.3. DNA methylation loss in global methylation assays. 
A. Methylation of LINE-1 retrotransposons (marked in red and expanded, see 
locus map). LINE-1 retrotransposons are present at approximately 100,000 copies 
throughout the mouse genome. Data and statistics as described in Figure 3.1C. 
 
B. Global DNA methylation level of CCpGG motifs. Methylation levels of 
CCpGG motifs, present at 2.5 x 106 copies in the mouse genome, were evaluated by 
digestion of genomic DNA with the isoschizomers HpaII and MspI restriction enzymes 
which are methylation sensitive and insensitive, respectively. Results are mean ± s.e.m. 
of n=3 (S0, S1, S3) and n=2 (S4/5). Statistics for each erythroblast subset are based on a 
comparison to S0. **P<0.01, and ***P<0.001 by linear mixed model analysis of 
variance. 
 
C. Measurement of global DNA methylation level by ELISA with an antibody 
directed at 5-methylcytosine. Results are mean ± s.e.m. of n=3. Statistics for each 
erythroblast subset are based on a comparison to S0. *P<0.05, **P<0.01 by linear mixed 
model analysis of variance.  
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Figure 3.4. Global methylation levels in erythroid and non-erythroid subsets. 
A. DNA methylation at LINE-1 retrotransposons in a variety of cell lineages of 
the early embryo. All cell types were isolated from E12.5 or E13.5 embryos. „LSK‟ (Lin-
Sca1+Kit+) cells contain early hematopoietic progenitors (short and long-term 
hematopoietic stem cells, and hematopoietic progenitor cells) and the common myeloid 
and lymphoid progenitors (CMP and LMP). „Mac1+‟ cells are granulocytes and 
macrophages. „CD41+‟ are mostly megakaryocytes. „EpoR-/-‟ are Lin- cells from EpoR-/- 
fetal liver at E12.5. Cells from EpoR-/- fetal livers do not differentiate into red cells and 
resemble the S0 subset in their CD71/Ter119 profile. Nuclei, also known as pyrenocytes, 
are extruded nuclei from definitive erythrocytes. Yolk sac red cells are the differentiated 
progeny of the primitive erythropoietic lineage and were isolated from the circulation of 
E13.5 embryos. Results are mean of n≥5 (S0, S1, S2, S3, S4/5), n=2 (Brain, LSK, Mac1+, 
CD41+, Nuclei), n=3 (EpoR-/-), n=4 (yolk sac); error bars are s.e.m. 
 
B. LINE-1 DNA methylation levels for erythropoiesis in adult bone marrow. ProE 
and EryB/C subsets of adult bone marrow are equivalent to S2 and S4/5 cells, 
respectively. Results are means of n=2 (ProE, EryA, EryB, EryC), n=8 (S2), or n=5 
(S4/5). 
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Figure 3.5. Genome-wide reduced representation bisulfite sequencing reveals global 
loss of DNA methylation during erythropoiesis. 
A. Scatterplots of the DNA methylation level of 5 kb, non-overlapping, sliding 
windows of S0 progenitors (x-axis) vs. increasingly mature S1, S3 and S4/5 erythroblasts 
(y-axis). Each data point (n=62,844) represents the average CpG methylation in each 5 kb 
window. Only 5 kb windows that included at least 5 CpGs with at least 5 sequencing 
reads each for each sample were included in the analysis. Red line represents a constant 
methylation level between each subset comparison. Data shown is for a single, 
representative sample. 
 
B. Box plots of replicate averaged RRBS data from „A‟. Replicate data (n=2) for 
each sample in „A‟ were averaged. Box plots, representing n=62,844 unique 5 kb tiles per 
sample, display the median (black line) and mean (cross) ± central quartiles (boxes); 
whiskers show the 2.5 to 97.5 percentiles. Median DNA methylation level for each subset 
is indicated at the top of each box plot. 
 
C. Statistical analysis of 5 kb RRBS data. The methylation level of each 5 kb 
window in the S0 subset was compared to S1, S3, or S4/5 subset and categorized as 
hypomethylated, hypermethylated, or no change. Utilizing sample replicate (n=2) and the 
individual CpG data within each window (n>5), a false discovery rate (FDR) and p-value 
for each 5 kb window was generated by t-test. A 5 kb window was designated “no 
change” if the FDR>0.1; „hypomethylated‟ if FDR<0.1, P<0.001, and methylation 
change >20%; and „hypomethylated (weak)‟ if FDR<0.1, methylation change >0% and 
not „hypomethylated‟ as defined above. „Hypermethylation‟ criteria were defined 
similarly, but with the methylation change in the opposite direction. Percentages are 
based on n=62,844 unique 5 kb windows per sample comparison. 
 
D. Absolute number of 5 kb windows in each category described in „C‟ 
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Figure 3.6. DNA methylation loss at various sequence motifs using RRBS. 
 A. Genome-wide RRBS data for each subset S0 to S4/5 was analyzed at repeat 
elements; LINE (n=5680 individual genomic sites), SINE (n=163), and LTR (n=3305). 
Each data point is the mean of duplicate samples from independent sorting experiments. 
Data points are shown only for genomic regions with sufficient RRBS coverage (≥5 
covered CpGs with at least 5 valid sequencing reads per CpG). Box plots display the 
median (black line) and mean (cross) ± central quartiles (boxes); whiskers show the 2.5 
to 97.5 percentiles. Median DNA methylation level for each subset is indicated at the top 
of each box plot. 
 
B. Genome-wide RRBS data for each subset S0 to S4/5 was analyzed at 
functional genomic elements; CpG islands (n=34,558 individual genomic sites), CpG 
island shores (n=4,302), putative enhancer elements (n=2070), and imprinting-associated 
regulatory elements (n=72). CpG islands were mapped using the Gardiner-Garden criteria 
[41], CpG island shores were defined as 2-kb genomic regions that are directly adjacent 
to bona fide CpG islands [358, 359], enhancers are based on histone H3K4me2 peaks 
[42, 358], and imprinting-associated regulatory elements were manually curated from the 
literature [358]. Data points and box plots as in „A‟. 
 
C. Genome-wide RRBS data for each subset S0 to S4/5 was analyzed at promoter 
regions. Promoter regions are defined as regions -5kb to +1kb surrounding Ensembl-
annotated transcription start sites. Promoter regions were analyzed based on CpG 
frequency; <1% (n=753), 1%< CpG <2% (n=8217), and >2% (n=13,878). Data points as 
in „A‟. Boxes correspond to center quartiles with the median marked by a black bar, and 
whiskers extend to the most extreme data point which is no more than 1.5 times the 
interquartile range from the box. 
 
D. Fraction of S0 methylation lost during erythroid differentiation. Methylation 
level in S4/5 cells was compared to the initial level of methylation in S0 cells for various 
assays. Upper grouping, proportion of methylation lost at β-globin LCR regions assayed 
by bisulfite sequencing in Figure 3.1B. Middle grouping, proportion of methylation lost 
at various sequence motifs using RRBS data in „A‟, „B‟, and Figure 3.5B. Lower 
grouping, proportion of methylation lost using LUMA assay from Figure 3.3B. 
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Figure 3.7. Linear correlation between DNA methylation levels at the β-globin LCR 
and at various genomic regions. 
For each of subsets S0 to S4/5 the DNA methylation levels at the β-globin LCR 
(x-axis) were compared to DNA methylation levels at various genomic regions (y-axis) 
measured by LUMA, pyrosequencing (P), or RRBS (R). Data for each assay is pooled 
from Figures 3.1-3.6. In the case of pyrosequencing comparisons to β-globin LCR, data 
from matched samples were used. The slope of this correlation suggests that 
demethylation at β-globin LCR is 2- to 3-fold greater than global demethylation. Data is 
mean (LUMA, pyrosequencing) or median (RRBS) of 2 to 12 replicates. 
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Figure 3.8. Decreased expression of Dnmt3 and increased expression of Gadd45a 
and Mbd4 with erythroid differentiation.  
A. mRNA expression of genes involved in maintaining and establishing DNA 
methylation (left panel) and in active DNA demethylation (right panel). Activation-
induced cytidine deaminase (Aicda) was undetectable in any erythroid subset. Dnmt3a 
and 3b were undetectable in S4/5. Data (qRT-PCR) is mean ± s.e.m relative to β-actin 
mRNA and normalized to expression in S0. n=4 replicate experiments. Similar results 
were obtained when expression was measured relative to Gapdh (not shown). 
***P<0.001, and **P<0.01 by 2-tailed Student‟s t-test with unequal variance in a 
comparison of S0 and S3 subset data. 
  
B. Western blotting for DNA methyltransferases in freshly sorted erythroid 
subsets (left panels) and corresponding quantitation of the same membranes using near-
infrared fluorescence detection (right panels), expressed as an absolute value (top) or 
normalized to β-actin (bottom). An equal mass of cell lysate was loaded in each lane. 
Control Phoenix cells were used either untransfected (Ctrl) or were transfected with 
vectors encoding Dnmt3a1, Dnmt3a2, Dnmt3b1, or Dnmt3b3 as indicated.  
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Figure 3.9. Exogenous expression of Dnmt3a or Dnmt3b does not prevent DNA 
demethylation. 
A. Exogenous expression of DNA methyltransferases in freshly sorted S0 cells. 
S0 cells were transduced with retroviral constructs expressing DNMT-IRES-GFP or 
'empty' vector expressing GFP only (MSIG) and cultured in interleukin 3 (IL-3) and stem 
cell factor (SCF) for 16 hours to allow time for Dnmt and GFP expression. Cells were 
then transferred to Epo for 24 hours to allow for differentiation into the S1 and S3 
subsets. Total GFP expression at the end of the incubation period is shown for each of the 
retroviral supernatants used (upper-right panel). GFP+ cells in each of S0, S1, and S3 
gates (lower panel) at the end of the incubation period were isolated by sorting and used 
for mRNA or DNA methylation analysis described in „B‟ and „C‟. Sorting and analysis 
experiments in „B-E‟ were performed using supernatant dilutions of 1:200 for the empty 
vector and 1:25 for Dnmt3a in order to obtain equivalent GFP expression to cells 
transduced with Dnmt3b1 and Dnmt3b1:PC. Flow cytometry profiles are representative 
of 3 to 6 replicate experiments for each viral supernatant.  
 
B. Dnmt3 expression is maintained throughout differentiation in retrovirally 
infected cells. Expression of Dnmt3a (left panel) and Dnmt3b (right panel) mRNAs in 
GFP+ cells sorted from each of gates S0, S1 and S3, at the end of a 24 hr culture in Epo in 
an experiment as illustrated in 'A'.  
 
C. DNA methylation is unchanged by exogenous expression of Dnmt3. 
Methylation levels of LINE-1 elements and of the β-globin LCR in GFP+ cells sorted 
from each of gates S0, S1 and S3, at the end of a 24 h culture period in Epo, in the 
experimental strategy illustrated in 'A'. Results are mean ± s.e.m. n=3 for infection with 
the MSIG, Dnmt3a, or the Dnmt3b1 supernatants or n=2 for infection with the 
Dnmt3b1:PC supernatant. Statistical significance was determined by comparing Dnmt3 
infection to MSIG within each sorting gate. ***P<0.001, **P<0.01 by 2-tailed Student‟s 
t-test with unequal variance. 
 
D. Exogenous expression of Dnmt3b1 or Dnmt3b1:PC prevents erythroid 
differentiation. The percent of cells was calculated in each of gates S0, S1 and S3, at the 
end of a 24 h culture period in Epo, in an experimental strategy illustrated in 'A' above. 
Results are mean ± s.e.m. n=6 (MSIG), n=5 (Dnmt3a), n=6 (Dnmt3b1), and n= 3 
(Dnmt3b1:PC). Statistics as described in „C‟. 
 
E. Dnmt3b expression induces cell death in S3 cells. GFP+ cells in each of gates 
S0, S1 and S3, at the end of a 24 h culture period in Epo as illustrated in 'A' above, were 
analyzed for DAPI staining. Results are mean ± s.e.m. n=2. Statistics as described in „C‟. 
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Figure 3.10. Knockdown of Gadd45a or Mbd4 does not prevent DNA 
demethylation. 
A. Efficiency of shRNA-mediated knockdown. Freshly sorted S0 cells were 
transduced with a retroviral construct expressing shRNA (linked by IRES to GFP) 
directed against either Mbd4 (shMbd4) or Gadd45a (two different hairpins, shG45a-1 or 
shG45a-2), or a non-silencing shRNA control (shCtrl). Cells were cultured with viral 
supernatant in IL-3 and SCF for 16 hours to allow time for shRNA and GFP expression. 
Cells were then transferred to Epo for 24 hours to allow for differentiation into „CD71+‟ 
cells (CD71+ = combined S1, S2, and S3 subsets). GFP+CD71+ cells were sorted and 
evaluated for mRNA levels of Gadd45a (left panel) or Mbd4 (right panel). Data (qRT-
PCR) is expressed relative to Gapdh mRNA and normalized to expression in S0 t=0. 
 
B. DNA methylation levels. Samples, as described in „A‟ were assayed for DNA 
methylation at LINE-1 regions or the β-globin LCR. 
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Figure 3.11. Cell cycle status of erythroid subsets S0 to S4/5. 
A. Fetal livers were labeled in vivo with BrdU by injecting pregnant mice 30 
minutes prior to harvest of embryos. Cells were fixed and then stained for CD71, Ter119, 
BrdU, or total DNA content (7-AAD). BrdU and 7-AAD staining is shown for each of S0 
to S4/5 subsets. Red gates show cells in the G1 (bottom left), S (top), or G2/M (bottom 
right) phases of the cycle. For each subset, both the fraction of cells in S-phase, and the 
median fluorescent intensity (MFI) of the BrdU signal within the S-phase gates, are 
indicated. MFI is an indicator of DNA replication rate. Representative of 8 to 15 replicate 
experiments. Color mapping represents the highest to lowest cell frequency as spectrum 
from red to blue, respectively. 
  
B. Percent of cells in S-phase in each subset. Data is mean ± s.e.m of 8 to 15 
replicate experiments per subset. 
 
C. Median fluorescent intensity of S-phase cells. Data is mean ± s.e.m of 8 to 15 
replicate experiments per subset. 
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Figure 3.12. Mimosine treatment prevents DNA methylation loss at LINE-1 regions, 
and at the β-globin LCR, PU.1 and H19 DMR loci.  
A. Cell cycle block with 1mM mimosine (Mim) reversibly arrests DNA 
demethylation at LINE-1 elements and at the β-globin LCR during erythroid 
differentiation in vitro. Sorted S0 cells were cultured in Epo for 24 hr (black line); Mim 
was added at t=4 and removed at t=14 hr (red line). Data is mean ± s.e.m from three 
independent experiments.  
 
B. Mimosine prevents DNA replication in cultured S0 cells. Sorted S0 cells were 
cultured in Epo for 16 hr in the presence or absence of 1 mM mimosine. BrdU was added 
in the last 30 minutes of culture. BrdU incorporation and total DNA content (7-AAD) 
were measured by flow cytometry. Upper red gate contains cells in S-phase that are 
actively synthesizing DNA at 16 hr. Lower left and right gates contain G1 and G2/M 
phase cells, respectively, or cells not actively synthesizing DNA at 16 hr. Contour density 
indicates relative cell frequency. 
 
C. Methylation level at the LINE-1, β-globin LCR, PU.1, and H19 DMR loci for 
the experiment described in „B‟. Red dotted line is the mean methylation level of freshly 
sorted S0 cells at t=0. Formatting and y-axis scaling of plots was chosen to be equivalent 
to that of Figure 3.13C. Exp, experiment. Ave, average of replicate experiments. 
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Figure 3.13. DNA methylation loss at LINE-1 regions, and at the β-globin LCR, 
PU.1 and H19 DMR loci, is dependent on DNA replication.  
A. DNA replication arrest with aphidicolin reversibly prevents demethylation. 
Sorted S0 cells were cultured with Epo (black line) or Epo plus 1 μM aphidicolin (red 
line) for 10 h. Aphidicolin was removed and culture continued for an additional 36 hr in 
Epo. DNA methylation was determined at the β-globin LCR and global LINE-1 regions. 
Exp, experiment. Ave, average of replicate experiments. Aphi, aphidicolin. 
 
B. Decreasing DNA replication rate with increasing amounts of aphidicolin. 
Freshly sorted S0, S1, or S2 cells were incubated in Epo or Epo plus 0.1, 0.5, or 1.0 M 
aphidicolin for 16 h. BrdU was added in the last 30 min of culture. BrdU incorporation 
and total DNA content (7-AAD) were measured by flow cytometry. MFI of BrdU in S-
phase cells is shown, as is the fraction of cells in S-phase (%). Contour density indicates 
relative cell frequency.  
 
C. Demethylation is inhibited by decreasing the DNA replication rate. For the 
experiment described in „B‟, a portion of cells were removed just prior to BrdU addition. 
Bisulfite pyrosequencing was used to determine methylation levels at the β-globin LCR, 
LINE1, PU.1, and H19 DMR. Red dotted line is the mean methylation level of freshly 
sorted S0, S1, or S2 cells at t=0. 
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Figure 3.14. Treatment of differentiating S1 cells with low dose aphidicolin prevents 
genome-wide demethylation. 
A. Freshly sorted S1 cells were cultured in the absence (left panel) or presence 
(right panel) of low dose aphidicolin (0.1 μM) for 24 hours (y-axis) and compared with 
their methylation levels at the time of sorting (t=0, x-axis) using RRBS. Scatterplots 
show the average CpG methylation level of 5 kb, non-overlapping, sliding windows 
(n=62,844). Data points are shown only for genomic regions with sufficient RRBS 
coverage (≥5 covered CpGs with at least 5 valid sequencing reads per CpG). Red line 
represents a constant methylation level between each comparison. Data shown is for a 
single, representative sample. 
 
B. Box plots of replicate averaged RRBS data from „A‟. Replicate data (n=2) for 
each sample in „A‟ were averaged. Box plots, representing n=62,844 unique 5 kb tiles per 
sample, display the median (black line) and mean (cross) ± central quartiles (boxes); 
whiskers show the 2.5 to 97.5 percentiles. Median DNA methylation level for each subset 
is indicated at the top of each box plot. 
 
C. Genome-wide RRBS data for each sample in „A‟ was analyzed at repeat 
elements; LINE (n=5680 individual genomic sites) and SINE (n=163). Data points and 
box plots as in „B‟. 
 
D. Genome-wide RRBS data for each sample in „A‟ was analyzed at functional 
genomic elements; CpG islands (n=34,558 individual genomic sites), putative enhancer 
elements (n=2070), and imprinting-associated regulatory elements (n=72). Data points 
and box plots as in „B‟. 
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Figure 3.15. Accelerated demethylation induced by inefficient knockdown of Dnmt1. 
A. Efficiency of shRNA-mediated knockdown. Freshly sorted S0 cells were 
transduced with retroviral constructs containing shRNAs (linked by IRES to GFP) 
against Dnmt1 (D1) or a non-silencing shRNA control (Ctrl). Cells were cultured in IL-3 
and SCF for 16 hours to allow time for shRNA and GFP expression. Cells were then 
transferred to Epo for 24 hours to allow for differentiation. Cells (not sorted) were 
evaluated for Dnmt1 mRNA by qRT-PCR (left panel) or for Dnmt1 protein by western 
(right panel). For western blot, an equal mass of cell lysate was loaded in each lane. 
Dnmt1 and β-actin was quantified using near-infrared fluorescence detection. For both 
mRNA and protein, Dnmt1 levels have been expressed relative to β-actin and normalized 
to the non-silencing control at t=16 h. 
 
B. Effect of Dnmt1 knockdown on LINE-1 methylation. S0 cells were cultured 
with shRNA viral supernatants described in „A‟ for 16 hours in IL-3 and SCF. Cells were 
then shifted to differentiation media containing Epo or Epo plus low dose aphidicolin 
(Aphi) for an additional 24 hours. After differentiation, GFP positive cells from S1 or S3 
gates (as defined in Figure 3.9A) were sorted and analyzed for Dnmt1 mRNA by qRT-
PCR (top panel) or LINE-1 methylation (bottom panel). Dnmt1 mRNA has been 
expressed relative to Gapdh and normalized to the non-silencing control at t=16 h. 
Results are representative of 2 or 3 experiments for data points with or without 
aphidicolin, respectively. 
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Figure 3.16. Global methylation loss does not induce genome-wide transcriptional 
activation. 
A. Expression of LINE-1 RNA during erythroid differentiation. QRT-PCR for 
LINE-1 RNA in freshly sorted erythroid subset. Probes were designed to the 5‟ and 3‟ 
ends of the full length LINE-1 RNA (GenBank: M13002.1). Results were normalized to 
the indicated housekeeping gene and then expressed relative to the S0 subset. Data are 
mean ± s.e.m. of 5‟ and 3‟ probes for 4 biological replicates. 
 
B. No global increase in gene expression as a result of global demethylation. 
Gene expression in S1 (x-axis) and S3 (y-axis) subsets was measured using Affymetrix 
GeneChips. Data was processed using microarray suite 5 (MAS5) algorithm and then 
normalized to the average housekeeper gene expression (see methods).Transcripts 
displayed have a random variance t-test of p< 0.005 and absolute fold change >2; n=3. 
Genes up-regulated (n=146) or down-regulated (n=761) in S3 relative to S1 are in green 
and red respectively. 
 
C. DNA methylation (5 kb tiling regions) for genes that exhibit increased vs. 
decreased expression between erythroblast stages S1 and S3. GeneChip data described in 
„B‟ was re-analyzed using the gcRMA algorithm (see methods). Differentially regulated 
transcripts were selected based on FDR <0.05 and absolute fold change >2; n=3. The 
methylation levels for up-regulated (n=2268) or down-regulated (n=5862) transcripts are 
represented as box plots. Boxes correspond to center quartiles with the median marked by 
a black bar, and whiskers extend to the most extreme data point which is no more than 
1.5 times the interquartile range from the box. 
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Figure 3.17. Rapid demethylation is required for rapid erythroid gene induction. 
A. Cell cycle status of aphidicolin and 5-aza-2-deoxycytidine treated cells. 
Freshly sorted S0 cells were allowed to differentiate for 24 hour in Epo into CD71+ cells 
(CD71+= combined S1, S2, and S3 cells), in the presence or absence of low dose (0.1 
μM) aphidicolin (Aphi) and/or 0.05 μM 5-aza-2‟-deoycytidine (5-aza), as indicated. Cell 
cycle status was assessed by pulsing with BrdU for 30 minutes at the end of incubation. 
BrdU incorporation and total DNA content (7-AAD) for CD71+ cells were measured by 
flow cytometry. MFI of BrdU in S-phase cells is shown, as is the fraction of cells in S 
phase (%). Low dose aphidicolin did not alter the percent of cells in S-phase but did slow 
down the rate of DNA synthesis. 5-aza had no significant cell cycle effect. 
 
B. DNA methylation levels in CD71+ cells treated in panel „A‟. At 24 h, CD71+ 
cells were sorted by flow cytometry and DNA methylation determined by bisulfite 
pyrosequencing. Treatment of S0 cells with aphidicolin prevents methylation loss at 
LINE-1 elements and delays methylation loss at the β-globin LCR. 5-aza is able to 
reverse the effect of aphidicolin on DNA methylation. Results are mean ± s.e.m of 2 
independent experiments. 
 
C. Expression of erythroid genes in CD71+ cells treated as in panels „A‟. QRT-
PCR of β-globin, Alas2, and Band3 for CD71+ cells isolated at 24 hr (same samples as in 
„B‟) was normalized to housekeeper genes (mean of Gapdh and β-actin mRNAs) and 
expressed relative to each aphidicolin negative control. Results are the mean value ± 
s.e.m. of 2 independent experiments. The aphidicolin-induced delay in erythroid gene 
expression is reversed in the presence of 5-aza. 
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CHAPTER IV 
Concluding Remarks and Future Directions 
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Concluding Remarks 
We have utilized a recently developed flow cytometry method to classify fetal 
liver cells into 6 distinct subsets, each at an increasingly mature stage of erythroid 
differentiation. We found that up-regulation of CD71 identifies cells that are 
synchronized in S-phase of a single cell cycle and is associated with a number of 
differentiation milestones, whose precise timing in erythroid development was previously 
unknown. These include the onset of Epo dependence, activation of GATA-1 function, 
and the opening up of chromatin at the β-globin locus. Specifically, our work identified 
the timing of, and provided mechanistic insight into, DNA demethylation at the β-globin 
LCR in vivo; demonstrating that it is initiated with up-regulation of CD71, continues in 
subsequent maturation stages, precedes up-regulation of β-globin, and is dependent on S-
phase progression (Chapter II). Prior to this work, little was known about β-globin LCR 
demethylation during progressive erythroid progenitor maturation in primary cells. 
Furthermore, the mechanism by which β-globin LCR demethylation occurred was 
completely unknown.  
Successful characterization of DNA methylation at the β-globin LCR encouraged 
us to investigate DNA methylation at other loci that are important for erythropoiesis. This 
pursuit eventually led us to a completely unexpected discovery: Global DNA methylation 
is progressively and irreversibly lost during red cell differentiation. This finding is 
significant because in somatic cells global methylation levels were previously thought to 
remain constant. In normal development, only primordial germ cells and the pre-
implantation embryo have been identified as undergoing waves of genome-wide 
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demethylation. In disease, global hypomethylation has long been known to be associated 
with cancer. Despite decades of research, fundamental aspects of global demethylation in 
these model systems are still poorly understood. Unfortunately, these are especially 
difficult systems in which to investigate global methylation loss, due to severe limitations 
in the accessibility of cells at various developmental stages and the small number of cells 
that can be obtained for study.  
Documentation and characterization of global demethylation in erythropoiesis 
comprise the major components of my dissertation research (Chapter III). We used many 
orthogonal approaches, including genome-scale reduced representation bisulfite 
sequencing, to map the extent and magnitude of DNA methylation loss in four 
progressive stages of erythropoiesis. We also identified two important components of the 
mechanism responsible for erythroblast demethylation. First, that it is dependent on DNA 
replication at all stages of differentiation. Therefore, methylation loss is passive, resulting 
simply from inefficient maintenance methylation, as opposed to resulting from active 
enzymatic removal. Second, we discovered that loss of methylation requires the 
accelerated rate of intra-S-phase DNA synthesis that is coincident with erythroid lineage 
commitment. This requirement has not previously been identified as a contributor to 
methylation loss in any system, but could be relevant to the hypomethylation that is 
observed in cancer, where the mechanism remains largely unknown. Functionally, we 
show that inhibition of genome-wide demethylation results in slower demethylation at the 
β-globin LCR and slower erythroid gene induction, an effect that could be reversed by 
the addition of the demethylation agent 5-aza. This last finding strengthens existing 
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evidence in PGCs and the pre-implantation embryo for a functional link between global 
demethylation and a requirement for demethylation at specific loci for gene activation. 
Our progress in elucidating the mechanism and functional significance of global 
demethylation in erythropoiesis is largely due to our model system, which offers 
significant advantages over other models of global demethylation. First, using in vivo 
tissues, we can reproducibly identify and isolate pure cell populations with discrete levels 
of methylation. The number and purity of these cells allows for greater experimental 
flexibility. Second, isolated erythroid subsets undergo comparable demethylation when 
placed in ex vivo culture. These traits allow us the ability to genetically or chemically 
manipulate these cells in vivo and ex vivo.  
In conclusion, our work demonstrates that global hypomethylation can occur in 
somatic cells, overturning previous held dogma. Furthermore, we demonstrate that 
elevated rates of DNA replication can lead to DNA methylation loss required for 
erythroid-specific gene activation. Finally, our work establishes fetal liver erythropoiesis 
as a new experimental model that will facilitate the study of genome-wide methylation 
loss associated with development and disease. 
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Future Experiments 
Understanding the mechanism of demethylation 
Direct detection of methylation loss on the nascent DNA strand. Passive 
demethylation is defined as DNA replication-dependent loss of methylation on the newly 
synthesized DNA strand. We have demonstrated that the methylation loss we observe is 
dependent on DNA replication. Additionally, partially differentiated cells in which the 
DNA replication has been inhibited are able to recover methylation lost during earlier 
stages of differentiation, suggesting the presence of a hemi-methylated intermediate. 
However, we have yet to directly demonstrate the presence of a hemi-methylated 
intermediate or lower methylation on nascent DNA. The addition of these data would 
strengthen the finding of passive demethylation.  
Hemi-methylation can be detected by two slightly different methods. One method 
uses a hairpin linker, targeted and ligated to restriction-enzyme-cleaved genomic DNA, 
to maintain attachment of complementary strands during subsequent bisulfite conversion 
and PCR amplification [389]. Another method takes advantage of the fact that HpaII will 
not cut the sequence CCpGG in either the fully- or hemi- methylated state [389]. Cut 
DNA is bisulfite converted and amplified by PCR using primers designed to flank the 
cutting site. Molecules without any methylation will not be amplified, allowing for the 
calculation of fully-, hemi-, and un- methylated fractions. We would expect to find an 
increase in hemi-methylated DNA in later stages of differentiation as compared to freshly 
sorted S0 cells. 
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 Nascent DNA can be isolated by incorporation of BrdU, followed by purification 
using an anti-BrdU antibody [390, 391]. Methylation of precipitated and bulk DNA can 
then be determined by bisulfite conversion, PCR, and pyrosequencing. To isolate nascent 
DNA in erythropoiesis, BrdU would first be injected into adult mice pregnant with E12.5 
to E14.5 embryos, and shortly thereafter developmentally-staged erythroid populations 
would be isolated by flow cytometry. If demethylation is passive, then it is expected that 
within each subpopulation (S1 to S4/5), the nascent BrdU-precipitated DNA should have 
a lower methylation level than the bulk DNA. As a control, nascent DNA in the S0 
population should have an equal amount of 5mC compared to bulk DNA.  
Dnmt1 overexpression. The maintenance methylation deficiency we observed in 
erythropoiesis could be due to inadequate levels of Dnmt1. Therefore, successful 
overexpression of Dnmt1 is critical to our understanding of the mechanism of 5mC loss. 
We have attempted to prevent demethylation by retroviral over expression of Dnmt1. 
However, due to the packaging limit of this virus and the large size of Dnmt1, poor 
infectivity was observed. We were able to marginally improve infectivity by 
concentrating the viral supernatant, resulting in differentiated S3 cells expressing low 
levels of GFP. However, Dnmt1 mRNA was not increased in these cells compared to 
control, possibly the result of a high level of endogenous Dnmt1 mRNA and inadequate 
time to express the exogenous transcript above endogenous levels. Delivery of Dnmt1 
could be improved by utilizing an alternative viral delivery system with a greater 
packaging size limit, such as an erythroid-specific lentiviral system described previously 
[392, 393].  
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Alternatively, we have initiated experiments in which we enrich for infected cells 
using culture conditions that allow for erythroblast expansion without differentiation. 
This system uses the glucocorticoid steroid dexamethasone to maintain freshly isolated 
fetal liver cells in an „S1-like‟ state (data not shown) in culture for up to 8 days [394]. 
Differentiation is induced by dexamethasone withdrawal. We have completed 
experiments that confirm global and β-globin LCR methylation levels are maintained in 
cells expanded in dexamethasone-containing media, and that demethylation is induced 
upon differentiation. We have also infected these S1-like cells with Dnmt1-IRES-GFP 
retrovirus and, through sequential rounds of sorting for GFP positive cells, obtained a 
population of cells expressing Dnmt1 mRNA at a level 5-fold greater than controls. 
Additional experiments using this system need to be performed to determine if Dnmt1 
protein is also overexpressed and the effect of elevated Dnmt1 expression on global 
demethylation.  
Dnmt1 localization, activity, and co-factor association. Total protein levels of the 
maintenance methyltransferase Dnmt1 were slightly increased during erythroid 
differentiation, consistent with increased numbers of cells in S-phase. In the pre-
implantation embryo, Dnmt1 is shuttled to the cytoplasm, leading to passive 
demethylation during subsequent cell cycles. We have not yet investigated the subcellular 
localization of Dnmt1 during erythropoiesis. The subcellular localization of Dnmt1 
should be determined by nuclear and cytoplasmic protein fractionation of erythroid 
subsets S0 to S4/5 followed by western blotting. Alternatively, anti-Dnmt1 
immunofluorescence microscopy of erythroid subsets could be utilized.  
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Post-translational modifications, such as phosphorylation and SUMOylation, have 
the potential to affect Dnmt1 enzymatic activity [120, 121]. Additionally, the possibility 
exists that there is a direct inhibitor of Dnmt1 that is induced during erythroid 
differentiation. To test if diminished Dnmt1 enzymatic activity plays a role in passive 
methylation loss during erythropoiesis, the methyltransferase activity of nuclear lysates 
from S0, S1 and S3 subsets should be determined. 
Dnmt1 is targeted to replication foci and hemi-methylated DNA by direct 
interactions with Pcna and Uhrf1, respectively. All three factors are up-regulated during 
S-phase and co-localize at replication foci [111, 112]. Depletion of Uhrf1 or preventing 
Dnmt1-Pcna binding reduces Dnmt1 association with chromatin and leads to a reduction 
in DNA methylation levels [109-112]. Similarly, phosphorylation of Dnmt1 leads to a 
disruption of Dnmt1-Uhrf1-Pcna interactions and hypomethylation in gliomagenesis 
[113]. Therefore, an imbalance in the ratios of these proteins [372] or a disruption in their 
interactions could contribute to the reduced maintenance methylation observed in 
erythropoiesis. To investigate the former possibility, nuclear protein levels of Pcna and 
Uhrf1 should be determined in each erythroid subset and then compared directly to one 
another and to Dnmt1. The latter possibility could be tested by monitoring 
phosphorylation of Dnmt1 during differentiation or by immunoprecipitation of Dnmt1 
followed by western blotting with Dnmt1, Uhrf1, and Pcna.  
The mechanism driving increased intra-S-phase DNA synthesis rate. The 
increased DNA replication rate observed in S1 to S3 cells is a contributing factor in 
genome-wide demethylation during erythropoiesis. This rapid DNA synthesis rate may 
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result from an increase in the number of origins firing simultaneously, or alternatively, 
may represent accelerated replication fork progression. A better understanding of the 
mechanism driving increased intra-S-phase DNA synthesis rate is critical to our general 
goals of characterizing the S0 to S1 transition. More specifically, this line of research will 
aid our understanding of the mechanism of global DNA methylation loss. Since our data 
suggest that Dnmt1 abundance is limiting, if the number of origins firing is found to 
increase, then it would raise the possibility that the quantitative defect in maintenance 
methylation results from lowered occupancy of Dnmt1 at origins. Inter-origin distance 
and replication fork velocity can be determined by sequential pulse labeling of replicating 
DNA using two nucleotide analogues, followed by dynamic molecular DNA combing 
and fluorescent detection of the nucleotide analogues [395-397]. 
SAM, SAH, and dcSAM abundance. SAM is the methyl donor utilized by DNA 
methyltransferases in a reaction that forms 5mC and S-adenosyl homocysteine (SAH). 
SAM is also decarboxylated (dcSAM) and then used as an aminopropyl group donor for 
the synthesis of polyamines. Both SAH [139, 140] and dcSAM [141] act as competitive 
inhibitors of DNA methyltransferases. Disruption in the balance of SAM relative to its 
by-products SAH and dcSAM is linked to hypomethylation [142-147]. Therefore, it is 
possible that a contributing factor to passive global demethylation in erythropoiesis is an 
alteration in SAM, SAH, and dcSAM ratios. Intracellular levels of these metabolites in 
S0, S1 and S3 subsets can be measured by high performance liquid chromatography 
[398]. 
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Gata-1 and Eklf occupancy at the β-globin LCR. Demethylation during 
erythropoiesis has a hierarchical structure, with the highest demethylation rate found at 
the erythroid-specific β-globin LCR (65-80% loss) and slower demethylation in most 
other genomic sites (30% loss). One explanation for this dramatically reduced 
maintenance fidelity at the β-globin LCR could be the binding of erythroid-specific 
transcription factors, such as Eklf and Gata-1, leading to protection of hemi-methylated 
CpGs from the maintenance activity of Dnmt1. These factors are present in S0 cells and 
their expression increases in differentiating erythroblasts, but it is unknown at which 
developmental stage they bind to the β-globin LCR. If transcription factor binding is 
found to be correlated with genome-wide demethylation, this would suggest that the two 
processes are linked. Additionally, immunoprecipitation of genomic DNA using Gata-1 
antibodies, in conjunction with DNA methylation analysis at the β-globin LCR, could 
determine if Gata-1 binding is enriched at demethylated DNA. 
Understanding the functional significance of demethylation 
Demethylation in nuclear condensation and enucleation. Maturing erythroblasts 
undergo extensive chromatin condensation leading to a 10-fold reduction in the nuclear 
volume [399]. Extrusion of the pycnotic nucleus occurs by an asymmetric cell division 
following terminal cell cycle exit. [400]. Global levels of several acetylated histones are 
reduced during culture of primary fetal liver erythroblasts, and ectopic expression of the 
histone acetyltransferase Gcn5, whose level gradually decreases during erythropoiesis, 
blocks condensation and enucleation [401]. Consistent with this finding, histone 
deacetylase 2, whose level gradually increases during erythropoiesis, is required for 
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chromatin condensation and enucleation [393] and chemical inhibition of histone 
deacetylases blocks enucleation [393, 402]. These studies establish a critical role for 
global histone deacetylation in chromatin condensation and enucleation in erythroid cells. 
Importantly, they raise the possibility that other global epigenetic alterations, such as 
DNA methylation loss, might also be required for condensation and enucleation during 
erythropoiesis. 
We have begun to investigate this possibility by utilizing „ImageStream‟ flow 
cytometry (Amnis Corporation, Seattle WA). This technology combines the single cell 
resolution of traditional multicolor flow cytometry with a CCD camera, allowing us to 
quickly capture and analyze the morphological features of tens of thousands of individual 
cells [403]. By using CD71, Ter119, and a cell permeable nuclear stain, Draq5, we have 
been able to accurately quantify the nuclear volume of distinct erythroid subsets in 
suspension. Using this method, we found that blocking global demethylation in S1 cells 
using low dose aphidicolin prevents the decrease in nuclear size associated with 
differentiation (data not shown). However, addition of 5-aza, and subsequent methylation 
loss, was unable to reverse this effect. Additionally, acceleration of demethylation by 
using 5-aza alone did not accelerate nuclear condensation. However, in this experiment, 
aphidicolin might also be preventing other events that are required for condensation. 
Therefore, a potential role for DNA demethylation in nuclear condensation and 
enucleation is still unclear and warrants additional investigation. 
Demethylation requirement for activation of erythroid-specific target genes. We 
have shown that slowing DNA replication prevents global demethylation and reduces the 
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extent of methylation loss at the β-globin LCR. Delayed demethylation was associated 
with delayed expression of the erythroid genes β-globin, Alas2, and Band3. This effect 
was reversed by adding 5-aza, an inhibitor of DNA methyltransferases. This result 
suggested that the slower induction of erythroid genes was a result of a failure to 
demethylate DNA, providing a functional link between global demethylation and a 
requirement for demethylation at a subset of specific loci. This result could be 
strengthened by the following additional experiments. 
First, the experiment above used 5-aza, which has known cytotoxic effects. We 
used nanomolar concentrations of 5-aza, well below the micromolar range that causes 
genotoxic damage [404], and as a result we observed minimal effects on cell viability. 
Nonetheless, the possibility exists that 5-aza may have indirect effects that influenced our 
experimental results. Therefore, a similar experiment should be performed utilizing 
shRNA knockdown of Dnmt1, in place of 5-aza, to reverse the demethylation delay 
caused by slowing the cell cycle. Second, Affymetrix GeneChip mRNA profiling of the 
samples described above would reveal the exact set of genes affected by global 
methylation levels. Once identified, a detailed methylation analysis at selected loci can be 
performed. 
New lines of research 
Differentiation block resulting from Dnmt3b expression. Dnmt3a and Dnmt3b 
were both dramatically down-regulated at the onset of erythropoiesis. Surprisingly, 
ectopic expression of Dnmt3b1, but not Dnmt3a, had an inhibitory effect on erythroid 
differentiation. This effect was not dependent on DNA methylation activity, as it was also 
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observed in cells expressing the catalytically inactive mutant Dnmt3b1:PC. This 
inhibitory effect was reminiscent of the PU.1-mediated arrest of erythroid differentiation 
described in Chapter II. In this case, PU.1 was shown to simultaneously prevent the 
transition from S0 to S1 and S-phase progression. 
A role for Dnmt3b1 in restricting proliferation has been described previously; 
Dnmt3b1-deficient murine embryonic fibroblasts undergo spontaneous immortalization, 
and reintroduction of Dnmt3b1 results in reduced proliferation [137]. Interestingly, 
Dnmt3b and PU.1 have been shown to directly associate with one another in 
hematopoietic progenitor cells [405]. Furthermore, Dnmt3b associates with the PU.1-
Sin3a-Hdac1-MeCP2 repressor complex in vitro and is able to repress PU.1 mediated 
transcriptional activation [405]. Therefore, the effect of Dnmt3b on erythropoiesis could 
be the result of inhibited proliferation, possibly through an interaction with PU.1. 
Therefore, further investigation into the cell cycle characteristics of Dnmt3b-expressing 
erythroblasts, as well as the potential association between Dnmt3b and PU.1 in S0 cells 
and erythroblasts expressing exogenous Dnmt3b, is required. 
5-hydroxymethylcytosine in erythroid cells. 5-hydroxymethylcytosine was first 
identified in bacteriophage a half a century ago and has recently been discovered in 
relatively high abundance in ES and brain cells [130, 406, 407]. 5hmC is formed directly 
from 5mC through the action of the Tet family of 5mC hydroxylases [130]. This 
epigenetic modification is the subject of intensive investigation because it might reflect 
an intermediate step in the process of 5mC demethylation. Alternatively, 5hmC could 
influence chromatin structure and local transcriptional activity by recruiting selective 
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5hmC binding proteins or excluding methyl-binding domain proteins that normally 
recognize 5mC [179, 408]. 
The bisulfite sequencing assays employed in our work cannot distinguish between 
5mC and 5hmC. Therefore, we currently do not know if 5hmC is present during 
erythropoiesis. GeneChip analysis detects Tet2 and Tet3 transcripts in S0, S1, and S3 
subsets (data not shown), suggesting that 5hmC might be found in these cells. 
Importantly, DNA sequences containing 5hmC are not substrates for the maintenance 
methyltransferase Dnmt1 [134]. If 5hmC were to be found in erythroid cells, its presence 
could provide new mechanistic insight into the DNA replication dependent methylation 
loss that we have observed. Additionally, the finding in and of itself would be novel, 
since 5hmC has not been reported for the erythroid lineage. There are a number of 
techniques that detect both 5mC and 5hmC including thin-layer chromatography, high 
performance liquid chromatography, mass spectrometry and single-molecule real-time 
sequencing [130, 406, 409]. 
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